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7SUMMARY
The coding region of the apolipoprotein B (apoB) gene was
screened for previously unknown mutations in hyperlipidemic
Finnish patients, using single-strand conformation analysis as
the detection method. ApoB gene exons 2 to 25, 27 and 28 were
amplified as a whole, and exons 26 and 29 in six and three
overlapping segments, respectively. Altogether, twelve new
variants of apoB were detected. Four of them were silent
variants, and three other were considered not likely to affect
lipid levels. Possible lipid effects of the other five apoB
variants were assessed in hyperlipidemic families and patients,
in the normal population and patiens undergoing coronary
angiography, and during diet or drug intervention. In addition,
effects of earlier known apoB variants, the apoB ins/del,
Thr71SIle and Ala591SVal, on serum lipid levels were studied.
The newly detected Val703SIle polymorphism seemed to affect
triglyceride levels in healthy subjects, and the Ala591SVal
polymorphism serum apoB levels in hypertriglyceridemic subjects.
The His1896SArg polymorphism was shown to affect serum total and
LDL cholesterol concentrations in healthy men during low-fat,
low-cholesterol diet. No statistically significant lipid effects
of three other apoB polymorphisms, the Asn1887SSer, Arg4243SThr,
and Ala4454SThr, could be detected in the subjects studied. A
new immunogenetic apoB polymorphism, detectable by monoclonal
antibody D7.2 and associated with both Asn1887SSer and
His1896SArg variations was characterized.
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1. INTRODUCTION
The risk of coronary artery disease (CAD) is correlated with
elevated serum levels of total cholesterol, low density
lipoprotein (LDL) cholesterol, apolipoprotein B (apoB) and
triglycerides, as well as with low levels of high density
lipoprotein (HDL) cholesterol (1-5). Although heritability
estimates, genetic models and modes of transmission vary between
different study settings, a considerable portion of the
variability of serum levels of these lipids and lipoproteins is
believed to be genetically determined (6-8). One of the
candidate genes possibly involved in this variation is the apoB
gene.
The apoB gene encodes for two protein isoforms, apoB-100 and
apoB-48, of which apoB-48 is composed of the first 2552
(approximately 48 percent) amino acids of apoB-100. ApoB-100 is
the major lipid-binding protein constituent of very low density
(VLDL), intermediate density (IDL) and low density (LDL)
lipoproteins and functions in LDL also as a ligand for the LDL
receptor (LDLR) (9,10). The main role of apoB-48 is to bind
lipids in chylomicrons (CM) (9,10). The enormous size of apoB
and its gene, and the variability of lipid phenotypes have made
studying the pathogenetic role of apoB in dyslipidemias
difficult. The most common approach has been the use of
population association studies. Several genetic polymorphic
variants of apoB have been described, many of which have been
associated with elevated serum cholesterol, triglyceride, LDL-
cholesterol or apoB levels in different populations (9,11,12).
Among the most studied is the silent XbaI restriction fragment
length polymorphism (RFLP), which has been associated with serum
lipid levels and CAD in several populations, especially the
Finns (12). To date, three mutations of apoB with major effects
on serum lipid levels have been characterized, the apoB
Arg3500SGln (13,14), Arg3531SCys (15), and Arg3500STrp mutations
(16). All have been shown to elevate serum total and LDL
cholesterol levels (17-21). None of these mutations have so far
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been detected in the Finnish population.
For decades, the Finns have belonged to populations with a high
incidence of dyslipidemias, especially hypercholesterolemia, and
thus increased risk of CAD (22,23). Although primary preventive
measures have lead to major declines in both coronary risk
factors and the incidence of CAD (24-26), CAD mortality in the
Finns is still among the highest in the world (27,28). As a
nationally and regionally isolated population, the Finns are
genetically exceptionally homogeneous (29,30), a fact reflected
in the existence of four common unique LDLR mutations causing
familial hypercholesterolemia (FH) (31), and in the apparent
absence of the apoB Arg3500SGln mutation in the Finnish
population (32). With these facts in mind, the series of studies
presented in this thesis were designed to search for previously
unknown apoB genetic variants characteristic to Finns which
could explain part of the commonly occurring dyslipidemias in
this country.
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2. REVIEW OF THE LITERATURE
2.1. General outline of lipoprotein metabolism
2.1.1. Plasma lipids and lipoproteins
The major lipids in the body are triglycerides (Tg), cholesterol
(free cholesterol, FC, and cholesterol esters, CE), and
phospholipids (Pl) (10,33). Triglycerides serve as a source of
energy and are stored in adipose tissue. Cholesterol serves as
a component of cell membranes and as a precursor for steroid
hormones and bile acids. Phospholipids are major components of
cellular membranes and lipid-transporting lipoproteins. As
hydrophobic compounds, cholesterol and triglycerides cannot
dissolve directly in plasma but are carried in the circulation
together with the amphipathic Pl as water-soluble lipoproteins.
Basically, all lipoproteins are organized into a hydrophobic
core of neutral lipids (Tg and CE), and a hydrophilic surface
coat of polar lipids (FC and Pl) and apolipoproteins. Although
lipoprotein particles, differing in their relative lipid and
apolipoprotein composition, size, density and function actually
form a heterogenous continuum, major classes of lipoproteins
have been defined. A traditional classification, based on the
density at which lipoproteins float during ultracentrifugation,
divides them into chylomicrons (CM), very low density
lipoproteins (VLDL), intermediate density lipoproteins (IDL),
low density lipoproteins (LDL), and high density lipoproteins
(HDL) (10,33). Additionally, lipoproteins can be classified on
the basis of particle size, electrophoretic mobility, or
apolipoprotein content. Within the classical lipoprotein
fractions, especially the LDL and HDL fractions have been shown
to be comprised of several distinct subclasses differing in
their density, particle size or apolipoprotein composition
(34-36), reflecting steps in lipoprotein metabolism. In addition
to the classic five lipoprotein classes, a heterogeneous class
of LDL-like lipoprotein particles termed lipoprotein(a)
containing apolipoprotein(a) and apoB-100 as protein moiety has
13
been characterized (37,38). The major characteristics of these
lipoprotein classes are presented in Table 1.
2.1.2. Apolipoproteins
Apolipoproteins are specific protein components of lipoproteins.
They act as structural lipid binding components of lipoproteins
(apoA-I, apo A-II, apoB-48, apoB-100), as ligands for
lipoprotein receptors (apoA-I, apoB-100, and apoE), as
inhibitors for lipoprotein-receptor interactions (apoC-I and
apoC-III), as modulators of the activity of enzymes involved in
lipoprotein metabolism (apoA family, apoC family), and as
cofactors in lipid transport between lipoproteins (apoA-IV)
(10,39). Characteristics and physiological functions of ten of
the best known apoliporoteins are summarized in Table 2.
Additionally five minor apolipoproteins, termed apoD, apoF,
apoG, apoH (A2-glycoprotein), apoI (serum amyloid A), and apoJ
(clusterin), have been characterized (39,40). Their
physiological roles are still largely unknown.
2.1.3. Lipoprotein metabolism
Lipid and lipoprotein metabolism can be divided into two
pathways, the exogenous pathway involved in the transport of
dietary lipids, and the endogenous pathway, both schematically
illustrated in Figure 1. In the intestine, absorbed and re-
esterified Tg, CE and Pl are packed into apoB-48-containing CM,
and secreted via the lymph to the circulation (10,41).
Thereafter, CM Tg are rapidly hydrolyzed by lipoprotein lipase
(LPL) and to some extent also by hepatic lipase (HL), which
process, together with other changes in the lipid and
apolipoprotein content of the particles, results in the
formation of smaller, cholesterol-enriched CM remnants. CM
remnants are removed from the plasma mainly by the liver through
the LDLR and to a smaller extent through the LDL receptor-
related protein (LRP-1), or cell surface proteoglycans (PG)
(10,42). Under normal conditions, most of the absorbed Tg
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carried by the CM is used in the extrahepatic tissues whereas
nearly all cholesterol is delivered to the liver. A small
portion of CM remnants seems to be cleared by peripheral tissues
as well (43).
The endogenous lipid transport system can be divided into two
subsystems: the apoB-100 lipoprotein system (VLDL, IDL and LDL)
and the apoA-I lipoprotein system (HDL). The apoB-100 system
begins with the hepatic assembly and secretion of apoB-100-
containing VLDL particles (10). Thereafter, VLDL Tg are
hydrolyzed in peripheral tissues by LPL, and the particles
converted to smaller Tg-depleted remnant particles. A part of
VLDL remnants are directly cleared from the plasma by hepatic
and possibly also peripheral receptor-mediated mechanisms
(10,42,43). The remaining particles enter into the VLDL-IDL-LDL
cascade, where most of the core Tg in the particles are
hydrolyzed by LPL and HL, leading to the formation of IDL and
LDL particles. Some of the IDL particles are conceivably removed
by the liver via LDLR or LRP-1. The rest are converted to LDL
particles. Most of the LDL particles are cleared by the liver
through the LDLR, other receptors and non-receptor-mediated,
still poorly defined pathways playing a smaller role in LDL
clearance (10,44).
The metabolism of the apoAI-containing HDL-particles is
intimately connected with both the exogenous and endogenous
lipid transport pathways. HDL particles are derived from
precursor complexes secreted by the liver and intestine. They
are the main mediators of the reverse cholesterol transport
system whereby cholesterol synthesized or deposited in
peripheral cells is returned to the liver (4,10,45). This
process begins with the removal of FC from cell membranes to
nascent HDL particles (35,46) and esterification of FC by
lecithin cholesterol acyl transferase (LCAT), after which the CE
is transferred to the hydrophobic core of the HDL particle. In
this process, nascent HDLs are converted to spherical lipid-rich
HDL. Part of the HDL core CE is then transferred to apoB-48- or
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apoB-100-containing lipoproteins in exhange for Tg by the
cholesteryl ester transfer protein (CETP), whereafter these
transferred CEs can either be removed from the circulation by
the liver or redistributed to peripheral cells. The CEs
remaining in the HDL particles are taken up by hepatocytes
either via receptor-mediated endocytosis by of apoE-containing
HDL particles by the LDLR, LRP-1, or the putative HDL
holoparticle receptor, or through selective removal of HDL CE by
the hepatic scavenger receptor BI (4,5,10). At the same time, Tg
transferred from other lipoproteins to HDL are hydrolyzed by HL,
leading to the conversion of Tg-rich HDL2 to Tg-poor HDL3
particles, and release of free apo-AI and lipid-poor HDL to be
reused in the reverse cholesterol transport cycle (35,45).
Besides the exchange of CE for Tg, the complex interplay of HDL
with other lipoproteins during reverse cholesterol transport
involves exchange of other components as well, such as
apolipoproteins and Pl. Thus, HDL particles can be considered to
serve in plasma as a reservoir of lipids and apolipoproteins for
apoB-100 and apoB-48-containing lipoproteins (10,42).
2.1.4. Factors regulating lipid and lipoprotein levels
2.1.4.1. Diet, other lifestyle factors, age, gender, and obesity
The metabolism and plasma levels of lipids and lipoproteins are
influenced by several non-genetic factors, including both
dietary as well as other lifestyle factors, age, gender and the
degree and distribution of body fat. A summary of the effects of
these factors on plasma lipid and lipoprotein levels is shown in
Table 3.
Of all dietary constituents, the amount and composition of fatty
acids and the amount of cholesterol seem to be the most
important modulators of serum lipid and lipoprotein metabolism,
and therefore have been targeted in dietary recommendations
aimed at reducing lipoprotein levels and CAD risk. Dietary fats
are composed of mixtures of saturated, monounsaturated or
16
polyunsaturated fatty acids. Of these, most saturated fatty
acids raise serum total and LDL cholesterol by impairing the
clearance of LDL, whereas the polyunsaturated and mono-
unsaturated fatty acids, when substituted for saturated fatty
acids, reduce serum cholesterol levels (47,48). Thus, reductions
of total dietary fat to 30% of total calories and dietary
saturated fatty acids to 10% of total calories with a moderate
increase in polyunsaturated and monounsaturated fatty acids in
the diet is considered beneficial (49). The influence of dietary
cholesterol on plasma lipoproteins is variable (48,50,51), but
usually, high levels of cholesterol consumption have been
associated with elevations of cholesterol in all lipoprotein
classes, an effect enhanced when cholesterol is consumed with
saturated fatty acids (47,48,52). Current recommendations
suggest a limitation of dietary cholesterol to 300 mg/day (49).
Compared with the effects of dietary fatty acids and cholesterol
on lipid and lipoprotein levels, the effects of other dietary
components, such as carbohydrates (52,53), soluble fibre (54),
and proteins (55,56) are more subtle and also variable and have
not lead to major dietary recommendations. Dietary alcohol
raises Tg and HDL cholesterol levels, and lowers LDL cholesterol
(57). A high overall caloric intake increases hepatic VLDL
synthesis, resulting in hypertriglyceridemia and hyper-
cholesterolemia (52).
Besides diet, several other lifestyle factors such as tobacco
smoking (58), physical activity (59), and psychological stress
(60), are associated with variations in lipid and lipoprotein
levels. However, knowledge of the relative importance of these
factors on lipid levels and their variability is currently
limited. Instead, the effects of age (61-63), gender (61,62),
menopausal (63,64) and menstrual (65) status in women, and the
degree (66-70) and distribution (66,70) of body fat are more
pronounced and should be taken into account when estimating the
effects of genetic variation on lipid and lipoprotein levels. In
addition, endocrinological, renal and hepatic diseases, diabetes
mellitus, and drugs are known to affect lipid metabolism and
17
have to be considered when lipid effects of other factors such
as genes are estimated (52,71,72).
2.1.4.2. Genes
A considerable portion of the variability in serum levels of
lipids and lipoproteins between individuals as well as the
variability of changes induced in these levels by factors such
as dietary modifications and weight reduction is believed to be
genetically determined. Several polymorphisms in the genes
encoding for various proteins involved in lipid metabolism have
been characterized, some of which have been associated with
serum lipid levels or responses to diet in populations. The most
studied and well characterized genetic variants in this respect
are located in the apoE and apoB genes.
ApoE is a protein constituent of the triglyceride-rich
lipoproteins VLDL, ßVLDL, IDL, CM, their remnants, and apoE-rich
HDL (39,73-76). It mediates the interaction of these particles
with cell surface receptors, and occupies a central role in
determining the metabolic fate of lipoproteins. A role in the
reverse cholesterol transport for apoE has also been postulated
(39). The apoE gene exhibits a common polymorphism with three
alleles coding for three protein isoforms of apoE (E2, E3, and
E4). In population studies, the apoE4 isoform has been
associated with higher and apoE2 with lower serum total and LDL
cholesterol and apoB levels (39,75,77). Compared with apoE3,
apoE2 is defective in receptor binding, leading to reduced
cholesterol delivery to the liver and up-regulation of LDLR,
whereby LDL clearance is increased (39,75). ApoE4, while binding
to receptors equally well as apoE3, seems to be metabolized more
rapidly, leading to cholesterol accumulation in hepatic cells
and down-regulation of LDLR (39,75). In addition, subjects with
the apoE4 isoform absorb cholesterol more efficiently than
carriers of the other two isoforms (75). Carriers of the E4
allele have also been shown to be more responsive to dietary
modifications (75,76).
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In addition to the apoE gene, polymorphisms in several other
genes have been associated with variations in lipid and
lipoprotein levels. To date, such associations have been
reported from genetic variants in the LDLR gene (74,78,79), the
LRP-1 gene (80), the VLDL receptor gene (79), the scavenger
receptor BI gene (81), genes in the apoAI-CIII-AIV cluster
(39,76,82), the apoCI gene (83), the LPL gene (79,84-86), the HL
gene (87), the CETP gene (88,89), the MTP gene (90), the fatty
acid binding protein-2 gene (91,92), the paraoxonase gene
(91,93-95), and the haptoglobin gene (96). The magnitude of the
effect of each of these polymorphisms on plasma lipid levels is
probably small for the individual. Since the sequences causing
these polymorphisms are common, most individuals are likely to
carry several such lipid-affecting genetic variants, which, when
combined, may lead to major changes in lipid levels. Similarly,
if common enough, they can also have an impact on serum lipid
levels at the population level as well.
Besides gene polymorphisms affecting lipid and lipoprotein
levels in the population, occasionally a single mutation is
capable of producing an abnormal lipoprotein phenotype
genetically transmitted as a familial dyslipoproteinemia. The
underlying genetic change of some forms of familial dyslipo-
proteinemias is known (97). Among these are mutations in the
LDLR gene leading to the production of missing or defective LDLR
and causing FH (44), and mutations in the apoB gene producing a
LDLR-binding defective apoB-100, termed familial defective apoB-
100 (FDB) (15-17). Hypobetalipoproteinemia and abetalipo-
proteinemia have been linked to mutations in the apoB and MTP
gene, respectively (98,99). On the other hand, the exact
underlying genetic defect of some other common syndromes such as
familial hypertriglyceridemia or familial combined hyper-
lipidemia is still unknown. Of the possible candidate genes, the
apoB, apoCIII and LPL genes have been excluded as causative
factors for familial hyper-triglyceridemia (100), and the LPL,
HL, hormone-sensitive lipase and several other candidate genes
as causative for familial combined hyperlipidemia (101,102).
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Recently, linkage of familial combined hyperlipidemia to two
novel loci on chromosomes 1 and 11 has been reported (102,103).
2.2. Genetic approaches to study heritability of plasma lipid
traits and hyperlipidemias
The classical approach to estimate the relative contribution of
genetic and environmental factors for a particular trait has
been to use biometrical methods comparing individuals who are
likely to share genes and environment to different extents, such
as identical and non-identical twins, sibling pairs, and parents
and children. These methods have demonstrated a significant
impact of genetic variation in determining the plasma levels of
total, LDL, and HDL cholesterol, apoB and apoAI, with reported
heritabilities in the range of 0.4-0.6 (6,7). For Tg, reported
estimates of heritability are more variable, ranging from 0.2 to
0.8 (104,105), and for Lp(a), higher, over 0.9 (6,106). Family
studies and complex segregation analyses have found evidence for
a major gene determining levels of total, LDL and HDL
cholesterol, apoB and apoAI, with both environmental factors and
genes of small or intermediate effect making a contribution (6).
After establishing evidence for the existence of a major gene
affecting lipid metabolism, the next problem is to identify this
gene. To accomplish this, two approaches can be used (107). In
the candidate gene approach, an association between lipid and
lipoprotein levels and a genetic marker of a known gene whose
product is believed to be important in lipid metabolism is
looked for. In the random search strategy, novel genes involved
in lipid metabolism are searched for by screening the whole
human genome with hundreds or more of random markers distributed
across the genome and associating them with lipid parameters.
While the majority of studies of genetic determinants of lipid
metabolism published so far have been based on the study of
candidate genes, recent developments in molecular genetics and
automatization of genotyping have made the random search
approach more feasible.
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Depending on the material studied, differing strategies in
searching for genes involved in lipid metabolism can be adapted
(107,108). Of these strategies, classical linkage analysis is
one of the most powerful methods to find the chromosomal
localization and to identify major disease causing genes. It is
based on calculation of the genetic distance between a genetic
marker and the supposed disease locus in families where the
inheritance of these two loci can be followed. If the loci
cosegregate more often than expected by chance, they are said to
be linked; the more tightly the loci are linked, the more close
they are in the genome (108). Linkage analysis and its
modifications such as the affected-pedigree-member and the sib-
pair analysis have been used to identify disease loci in
dyslipidemias. However, besides the need for informative
families of sufficiently large size, the need to know the mode
of inheritance of the disease or trait in question, and the fact
that low penetrance of the trait, the multiple loci involved,
and phenocopies (i.e. the same phenotype produced by different
loci) weaken the strength of the analysis, the use of linkage
analysis in lipoprotein genetics is further hampered by
difficulties in estimating the cutoff levels for normal and
abnormal lipid and lipoprotein concentrations (107).
Population association studies take advantage of the same
principle of genetic closeness of a candidate locus and a
supposed disease locus leading to linkage disequilibrium between
these two loci. If a genetic marker and a disease or trait occur
in the same individual more often than expected by chance, they
are said to be associated (108). Analysis of the association of
a genetic marker with a specific trait in populations has been
the most widely used approach to study the effects of candidate
genes on lipoprotein traits (6,107). In contrast to linkage
analysis, knowledge of the mode of inheritance is not needed in
association studies, neither do the latter suffer from
incomplete penetrance, and families are not necessary for the
study. However, large samples are needed, and the populations
studied should be well stratified in terms of factors such as
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age, sex, and ethnic composition (6,12,107). This approach has
been most successful in genetically homogeneous populations
where the effects of variation in genes other than those being
studied are expected to be lower than in genetically more
heterogeneous groups (30). In the case of highly polymorphic
genes, such as the apoB gene, powerful association studies have
also been performed using combinations of polymorphic markers
lying in the same chromosome, termed haplotypes, as markers
instead of single diallelic markers (12,107).
2.3. Apolipoprotein B: structure and function
In humans, apoB exists in two isoforms, apoB-100 and apoB-48,
both always attached to lipids. ApoB-48 is normally found in
fasting plasma in very low concentrations, in the range of only
a few cg/ml, whereas apoB-100 concentrations range normally from
60 to 120 mg/dl (9). More than 90% of apoB-100 is found in the
LDL fraction. Due to the large size of apoB, its extreme
hydrophobicity and thus poor solubility in aqueous buffers after
delipidation, its tendency to aggregate, and its sensitivity to
degradation, direct studies of apoB structure have been
difficult (109). Only after the cloning of the apoB gene and
uncovering of the nucleotide and amino acid sequence of the
protein have details of its structure and functional domains
been elucidated.
2.3.1. Structure of the apoB gene
The apoB gene is located on the short arm of chromosome 2
(110-112). The complementary DNA (cDNA) and part of intronic
nucleotide sequences, the deduced amino acid sequence as well as
molecular organization of the apoB gene are known (113-118). In
humans, the apoB gene is expressed mainly in liver hepatocytes
and intestinal epithelial cells (111); to a small extent,
expression of the human gene has been found also in the heart
(119), aortic endothelial cells (120), fibroblasts (121) as well
as kidney, colon and stomach (122). The apoB gene, with over 43
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kilobases (kb), is organized into 29 exons and 28 introns, shown
schematically in Figure 2. Two of the exons, exon 26 (7572 bp)
and exon 29 (1906 bp), are exceptionally large. The apoB cDNA is
composed of 14121 nucleotides, with 5´ and 3´ untranslated
regions of 128 and 304 bp, respectively (116). Outside the apoB
gene, two 5´ and one 3´ nuclear matrix attachment regions
ranging from J5.2 kb upstream of the gene to a few hundred bp 3´
to the gene have been identified (123). This 47.5 kb domain has
been suggested to represent a topologically sequestered
functional unit containing both the regulatory elements and
coding region of the gene (123). However, recent studies in
transgenic mice expressing the human apoB gene have shown that
while this 47.5 kb domain is sufficient for expression of the
apoB gene in the liver (124,125) as well as in the heart (126),
intestinal expression is dependent on an enhancer element
located outside this matrix attachment domain and situated
between 54 and 62 kb 5´ to the structural gene (127). In the 5´
part of the 47.5 kb domain, the apoB gene contains classical
promotor structures such as a TATA box and a CAAT box within 60
bp upstream from the transcriptional start site (113). In
addition, several other regulatory elements have been identified
extending from a negative regulatory element -2738 to -1802 bp
upstream from the transcription start site (128) through a
promoter region between nucleotides +1 to -898 (129) to the
first untranslated exon containing both positive and negative
regulatory elements (130), and enhancer elements located in the
second (131) and third (132) introns of the gene. The 3´ end of
the apoB gene also contains two sites possibly involved in gene
expression regulation: the first is localized in the 3´
untranslated region of the gene about 80 bases beyond the
translational stop codon in exon 29, and the second in the
middle of the AT-rich hypervariable region (133). The exon 29
site has been postulated to have a role in transcription
termination, whereas the site located inside the 3´ VNTR region
may provide an accessible region of DNA for the action of
topoisomerase II, an enzyme that alters the topological state of
DNA during transcription (133). Besides the identification of
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these regulatory regions and motifs and some of the nuclear
proteins binding to these regulatory elements (134-136), not
much is known about the mechanisms and factors regulating the
level of gene expression in apoB expressing tissues. In adult
humans, the apoB gene seems to be constitutively expressed, with
relatively constant steady state levels of messenger RNA (mRNA)
even under conditions in which the level of apoB production
changes significantly (9,137,138).
2.3.2. ApoB mRNA editing
ApoB-48 is produced by the same gene as apoB-100 through a
mechanism termed mRNA editing. In this process, the apoB mRNA is
posttranscriptionally deaminated at nucleotide 6666,
substituting a uracil for a normal cytosine, changing codon 2153
from CAA to UAA, and replacing the normal glutamine with a
termination codon (139-143). Thus, an apoB protein with 2152
amino acids and about 48% of the size of full length apoB is
produced. The mRNA editing process involves a specific RNA
binding cytidine deaminase (143-147), termed the apoB mRNA
editing enzyme catalytic complex-1 (APOBEC-1), and auxiliary
factors that complement APOBEC-1 in apoB mRNA editing in the so
called 'editosome' complex (143,146,148). The gene for human
APOBEC-1, located in chromosome 12, has been cloned (149-153).
In adult humans and rabbits, APOBEC-1 expression is restricted
almost exclusively to gastrointestinal epithelial cells, whereas
in the rat and mouse, the gene is more widely expressed (143).
The auxiliary protein factors required for apoB mRNA editing are
widely distributed in mammalian tissues, including many that do
not synthesize apoB (143,146-148,154). To date, one APOBEC-1
binding protein suggested to be involved in apoB mRNA editing
has been cloned (155), and some others have been partly
characterized (148,154). Under physiological conditions, apoB
mRNA editing is a very specific process leading to the
deamination of only cytidine 6666 of apoB mRNA. Several sequence
elements in apoB mRNA needed for efficient editing have been
identified (143,156,157). Computer modelling and ribonuclease
24
probing of wild type and mutant apoB mRNA substrates suggest
that the secondary structure required for proper editing
involves a stem loop which contains the cytidine 6666 to be
edited within the loop (157). To date, it is not known whether
defective apoB mRNA editing in human intestine leads to a
specific disease or not. One polymorphism in the human APOBEC-1
gene has been described, but this polymorphisms seems to bd
functionally silent (152). Likewise, no genetic variant of the
apoB gene located close to the editing site and affecting
efficient editing has been identified so far.
2.3.3. Structure of the apo B protein
In the liver and intestine, the mRNA of apoB codes for a 4560 to
4565 amino acid and a 2176 to 2181 amino acid protein,
respectively. Before either of these peptides are translocated
to the endoplasmic reticulum, an amino-terminal 24 to 29 amino
acid signal peptide is cotranslationally cleaved from the
growing nascent peptide. Thus, a full-length mature apoB-100
protein comprised of 4536 amino acids and with a calculated
amino acid molecular weight of approximately than 550 kDaltons
(kDa), and a 2152 amino acid apoB-48 with a molecular weight of
264 kDA are produced (115,117,158,159). The sequence of the
apoB-100 polypeptide chain is unique, although homology with
other apolipoproteins, the microsomal triglyceride transfer
protein (MTP) and vitellogenin has been found (160-164). In
addition, the apoB polypeptide sequence contains several long
internal repeats (160). In lipoproteins, apoB is glycosylated:
4-9% of its mass is carbohydrate linked to asparagine residues
(165). Of the 19 potential N-linked glycosylation sites of apoB,
at least 16 have been found to be glycosylated (166). The
distribution of the glycosylated asparagines is asymmetric,
clustering in the vicinity of the putative LDLR binding site,
but whether this clustering has any role in LDLR binding is not
known (167). During apoB synthesis, glucose trimming of
asparagine residues seems to be important for proper association
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of apoB with endoplasmic reticulum-resident proteins such as
calnexin and calreticulin (168). ApoB contains 25 cysteine
residues, 16 of which are known to exist in disulfide form,
forming cysteine bridges in the molecule (169,170). The
distribution of the cysteines is uneven, 12 occurring within the
first 500 amino acids of the protein and all of them being
involved in cysteine bridge formation (170). The amino-terminal
cysteine bridges are believed to stabilize the amino-terminal
end of apoB into a globular domain (170). Proper folding of this
domain is believed to be essential for lipoprotein assembly and
secretion (171,172). Furthermore, the disulfide bond between
cysteines 218 and 234 seems to have an important functional role
in lipoprotein assembly separate from a structural role in apoB
folding (173). A cysteine bridge between residues 3167 and 3297
takes part in the conformational organization of the LDLR
binding site of apoB (158). In addition, a disulfide bond
between apoB cysteine 4326 and apo(a) cysteine 4057 is involved
in Lp(a) assembly (174-177).
The tertiary structure and conformation of apoB-100 in
lipoprotein particles has been explored by a number of methods.
Original analyses of the accessibility of apoB-100 to
proteolytic enzymes such as trypsin suggested apoB-100 to have
five broad domains (166). Based on combined data from trypsin
accessibility studies (166), studies with monoclonal antibodies
(mAb) against native and delipidated apoB-100 (178-180) and
electron microscopic studies with negatively stained lipid
extracted LDL (181), the following model has been put forward,
with the apoB-100 suggested to have a globular amino terminal
end extending away from the lipoprotein particle and a belt-like
structure with apoB sequences partly inside the particle and
partly on the surface of the particle (166,181). Further support
for this model has come from immunoelectron (182) and cryo-
electron microscopic studies (183,184). A recent cryo-electron
microscopic study (185) suggests that the first 89% of apoB
wraps like a ribbon once around the LDL particle, while the
carboxyl-terminal 11% constitutes a bow that crosses the ribbon
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and brings this part of apoB near the putative LDLR binding
site. A schematic illustration of this ribbon-and-bow model is
shown in Figure 3a. Based on the primary sequence of apoB,
circular dichroism spectra and infrared spectroscopy analyses,
LDL apoB is known to present both ?-helixes and A-structure
(158,186). Studies using computer-assisted methods searching for
amino acid sequences in the apoB protein capable of forming
amphipathic ?-helixes and A-sheets to identify lipid-associating
domains of apoB-100 have also suggested a pentapartite structure
(Figure 3b) for apoB in LDL: NH2-?1-A1-?2-A2-?3-COOH, with ?1
representing the globular amino-terminal domain (187,188). CM
apoB-48 would thus be comprised of only two domains, the
globular amino-terminal ?1 domain and a second domain of a
cluster of amphipathic A-sheets. When compared, the trypsin-
accessible and computer-identified domains and domains
accessible or not accessible to mAbs seem to be closely
correlated (189) and agree also with experimental thermodynamic
data indicating a five-domain, folding organization for apoB-100
(190).
2.3.4. ApoB functions and functional domains
2.3.4.1. Lipid binding domains
The main function of both isoforms of apoB relate to their
ability to bind lipids: in the absence of apoB-48 or apoB-100,
no CM or VLDL particles are formed and lipid absorption and
transport is severely hampered as can be seen in homozygous
abetalipoproteinemia and some forms of homozygous hypobeta-
lipoproteinemia (98,191). The ability of apoB to bind lipids
resides in the multiple hydrophobic domains present throughout
the length of the protein (114,158). Cell cultures expressing
truncated apoB proteins of varying size seem to confirm this:
the smaller the apoB protein, the smaller the quantity of core
lipids in the secreted lipoprotein (192). Both the amphipathic
?-helices 2 and 3 and the amphipathic A-sheet clusters have high
lipid binding potential, of which the ?-clusters are claimed to
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bind lipids reversibly and the A-clusters irreversibly (187).
Analyses of the effects of progressive lipidation of apoB-100 on
its immunoreactivity suggest that the A-domains represent
inflexible regions of apoB structure that could act as a
backbone during lipoprotein assembly, whereas the amphipathic ?-
helical domains would represent flexible lipid-binding regions
that allow the particles to accommodate varying amounts of lipid
during lipoprotein assembly and intravascular metabolism (189).
The wide dispersion of lipid-binding sequences has been assumed
to explain the fact that apoB is never exchanged between
lipoprotein particles, in contrast to other apolipoproteins,
which have only one or two putative lipid binding domains and
are readily exchangable (9,10). ApoB-48 has been suggested to
contain only one lipid-binding domain, a cluster of A-sheets
(187). A recent study with cells expressing recombinant
truncated human apoB-48 showed that these A-strands are critical
determinants of lipoprotein assembly, with very short
hydrophobic sequences from 152 to 237 amino acids mediating the
recruitment of large quantities of Tg into the lipoprotein
particle (193).
2.3.4.2. Receptor binding domains
In LDL particles, apoB-100 functions as a ligand for the LDLR
(44). Much interest has been focussed on the putative receptor
binding region of apoB. Several kinds of observations point
towards the carboxyl-terminal portion of the apoB molecule as
the receptor binding region. Among these are studies with
carboxyl-terminally truncated natural apoB variants (194),
studies with apoB mutations causing defective binding of LDL
with LDLR (14-16), studies using mAbs with epitopes in the
carboxyl-terminal region of apoB blocking LDLR binding (179),
apoB sequence analyses identifying positively charged regions
assumed to interact with the negatively charged regions in the
ligand-binding domain of the LDLR (158), indentification of
sequence homology with the receptor binding region of the other
LDLR ligand, apoE (158), and chemical modification of the
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positively charged amino acid residues arginine and lysine of
apoB leading to abolishment of LDLR binding (195,196). The LDLR
binding domain of apoB has been suggested to lie somewhere
between two regions enriched with arginine and lysine residues,
amino acids 3147-3157 (Site A) and 3359-3367 (Site B), in a
region containing a disulfide bond between cysteines 3167 and
3297 bringing the two short amino acid sequences close to each
other (158). However, studies with mAbs suggest that even a
larger part of the protein, spanning amino acids 2285 and 4081
(179) or 2935 and 4189 (180) could be involved. Recent
observations with transgenic mice expressing mutant forms of
human apoB suggest that Site B is critical for LDLR binding and
forms the actual binding site (197). In favor of this
hypothesis, this region is evolutionally highly conserved (198),
binds heparin (199), is extremely similar to the site on apoE
that binds to the LDLR (158) and seems also in vivo to be needed
for LDLR binding since natural apoB truncations lacking this
region cannot bind to the LDLR (194,200) whereas apoB:s
truncated distally to this site show receptor binding capacity
(201-203). Besides the actual LDLR binding site, the carboxyl-
terminal end of apoB seems also to influence the efficiency of
LDLR binding. Immunoelectron microscopic studies suggest that
the carboxyl terminus of apoB beginning at amino acid residue
4050 constitutes a bow-like structure that stretches back into
one hemisphere of LDL and crosses the linear ribbon-like part of
apoB between residues 3000 and 3500, bringing the carboxyl-
terminal part of apoB-100 near to the actual LDLR binding site
(185). Since apoB truncations lacking the carboxyl-terminal
sequences show increased clearance and binding to LDLR compared
with full-length apoB-100 (202-204), the carboxyl-terminal
sequences have been suggested to act as a negative regulator of
LDLR binding. Studies with gene-targeted mice show that removal
of the carboxyl-terminal 20% of apoB increases the binding
activity of normally receptor-negative VLDL to the LDLR (197).
In addition, this 20% of apoB-100 seems also to be necessary in
order for the apoB Arg3500SGln mutation to disrupt receptor
binding (197). Thus, it has been proposed that the carboxyl-
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terminus of apoB-100 normally functions to inhibit the
interaction of VLDL apoB-100 with the LDLR, but after the
conversion of triglyceride-rich VLDL to smaller cholesterol-rich
LDL, an interaction with a region encompassing Arg 3500
modulates the conformation of the carboxyl tail allowing the
interaction of the actual receptor binding site with the LDLR.
Mutation in this modulator element such as the Arg3500SGln
change would abolish this interaction, resulting in disrupted
LDLR binding of LDL (197).
ApoB-containing lipoproteins have been shown to bind to other
receptors of the LDLR superfamily (42,205-207) as well as to the
scavenger receptors (205,208), the lipolysis-stimulated receptor
(209), and the asialoglycoprotein receptor (210). However, data
on whether the LDLR binding region, other regions or any sites
of lipoprotein apoB have any direct function in these receptor-
ligand interactions is still limited. A mAb against the
receptor-binding region of apoB-100 (mAb 4G3) has been shown to
inhibit the interaction of LDL with and endocytosis by one
member of the LDLR family, LRP-2 (211). Since a natural apoB
variant, B70.5, lacking the LDLR binding site B still binds to
LRP-2, the sites recognized by these two receptors seem to
differ (200). The amino terminus of apoB (amino acids 547-735)
has been proposed to have a specific function in the recognition
of malondialdehyde-modified LDLs by class A scavenger receptors
(212). Also, apoB-100 has been suggested to be one ligand for
the lipolysis-stimulated receptor (213). Finally, an amino-
terminal site of apoB with no heparin binding affinity located
at or near the LPL-binding domain has been suggested to mediate
binding of Tg-rich lipoproteins to a partly characterized
receptor in human monocytes and macrophages (214).
2.3.4.3. Domains involved in lipoprotein(a) assembly
Lipoprotein(a) is a lipoprotein particle similar to LDL in terms
of lipid content and composition containing apoB-100 covalently
linked by a disulfide bond to apo(a) (38,106). After the
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secretion of apo(a) from the liver, Lp(a) particles are
assembled on the hepatocyte cell surface or in the circulation
through processes involving both initial noncovalent and
covalent linkages between apoB-100 and apo(a) (215,216). The
noncovalent association is mediated by amino-terminal apoB
sequences between residues 680 and 781 (217), and apo(a) kringle
IV types 6-8 (218). For the formation of a stable Lp(a)
particle, a covalent disulfide bond between cysteines 4057 and
4326 of the apo(a) and apoB proteins, respectively, is required
(174-177). In addition to these sites, the carboxyl terminus of
apoB, especially amino acid residues 4331-4397, and possibly
also the LDLR binding region of apoB, although not absolutely
required, seem however to be necessary for efficient Lp(a)
assembly (219,220).
2.3.4.4. LPL binding domain
Lipoprotein lipase (LPL) has multiple roles in lipoprotein
metabolism (221-226). It is generally accepted to be the major
enzyme responsible for hydrolysis of lipoprotein Tg molecules at
the luminal surface or capillary endothelium (223,224). In
addition, LPL has been suggested to facilitate cellular uptake
of lipoprotein particles either by acting as a bridge anchoring
the lipoproteins to cells or matrix, or by acting directly as a
ligand for lipoprotein receptors (221,223,226). In vitro,
enhanced receptor binding and cellular uptake of a variety of
lipoproteins via LPL has been demonstrated in conjunction with
essentially all known members of the LDLR superfamily as well as
the scavenger receptors (226), but the biological relevance of
this effect in vivo has so far not been elucidated. Within
arteries, LPL bound to the subendothelial wall PGs has been
shown to increase binding of both native and oxidized LDL
(227-229) as well as other lipoproteins (230,231) to the
arterial wall matrix, leading to entrapment of lipoproteins in
the subendothelial space which is believed to be one of the key
initiating events in the pathogenesis of atherosclerosis (232).
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For long, LPL has been believed to bind to endothelial cells via
electrostatic interactions with heparan sulphate PGs (233,234).
However, studies with cultured endothelial cells suggested that
LPL binding to the endothelium involves both PG and non-PG
binding sites (235). The non-PG binding site was identified as
a 116 kDa heparin-releasable protein (hrp-116) which was shown
to confer specificity to the binding of LPL to the endothelial
cells (235,236). The sequence of hrp-116 is identical with four
different regions in the amino terminus of apoB, and hrp-116 is
also recognized by mAbs against amino-terminal epitopes of apoB
(237). Amino-terminal fragments of apoB and mAbs against the
apoB amino terminus compete with LPL binding to endothelial
cells (237). ApoB is expressed and synthesized in endothelial
cells, and pulse-chase studies suggest initial production of
full-length apoB-100 with further degradation to produce the
116-kDa apoB fragment which is thereafter released from the
cells with heparin and is able to bind LPL (120). Cell-surface
expression studies of the amino-terminal apoB region (apoB-17,
amino acid residues 1-771) demonstrate that this domain of apoB
is not only able to mediate the association of LPL with the
cells but that the LPL-apoB interaction is also more stable than
the LPL-PG association (238). Based on these observations, it
has been suggested that apoB fragments such as the hrp-116,
expressed on the surface of endothelial cells, provide a high-
affinity binding site that stabilizes LPL activity and delays
its release into the bloodstream and eventual catabolism in the
liver (238).
LPL is known to associate with most lipoprotein classes (239),
but whether this binding is mediated through lipoprotein lipids
or apolipoproteins has not been fully clarified. Studies with
mAbs against apoB, thrombin digested fragments of apoB,
delipidated LDL, and a recombinant truncated amino-terminal
fragment of apoB in a solid phase assay free of lipoprotein
receptors and cell surface PGs suggest that LPL association with
LDL involves protein-protein interaction with the amino-terminal
end of apoB (240). The association of LDL with LPL in solution
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is also diminished by antibodies against the amino-terminal
region of apoB (241). These experimets, identifying the amino-
terminal globular region of apoB as a mediator for the LPL-
lipoprotein association, were carried out with LDL. However,
since LPL has been shown to be associated with all classes of
apoB-containing lipoproteins in postheparin plasma (239,242),
since all apoB-containing lipoproteins are able to compete with
the VLDL-LPL-interaction (243) as well as inhibit LPL-induced
VLDL hydrolysis (244), and since binding of LPL with VLDL was
similar to that of LDL (240), it has been suggested that the
amino terminus of apoB acts as a binding site for LPL in all
apoB-containing lipoprotein classes (241). This specific
interaction between LPL and lipoprotein apoB has been proposed
to play a role in facilitating Tg hydrolysis of circulating
triglyceride-rich apoB-containing lipoproteins (240). As to the
biological role for the well-documented LPL association with
LDL, which is not a physiologic substrate for LPL-catalyzed Tg
hydrolysis, another role for this specific protein-protein
interaction has been postulated, suggesting that LDL particles
could act as carriers of LPL molecules dissociated from the
endothelial surface and circulating in the bloodstream,
preventing LPL from readhering to the vessel wall and allowing
its clearance by the liver (241). On the other hand, an
interaction of LDL with LPL in the vessel wall would lead to
accumulation of LDL in the subendothelial matrix (229). Both
hypotheses have to be confirmed by further studies. Also, the
exact LPL binding motif in the amino terminus of apoB needs to
be defined.
2.3.4.5. Hepatic lipase binding domain
Like LPL, hepatic lipase (HL) is a multifunctional protein
exhibiting both enzymatic and other functions in lipoprotein
metabolism (223,245,246). HL acts as an acylhydrolase and as a
phospholipase and is essential for LDL production and
conversions in the HDL fraction during lipoprotein metabolism.
HL may also mediate the unloading of cholesterol from HDL to the
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liver and to steroidogenic tissues such as the ovaries and
adrenal glands (245). In addition, HL has been postulated to
promote apoB-containing lipoprotein, especially CM remnant
uptake by cells either by acting as a bridge between cell
surface PGs and the lipoprotein, or by acting as a direct ligand
for lipoprotein receptors, such as LRP-1 (245-248). Like LPL,
the HL-lipoprotein interaction has been suggested to involve
protein-protein interactions. While the interaction between CM
and VLDL remnants and HL might involve apoE, HL has also been
shown to associate with LDL (242). In vitro, HL enhances LDL
uptake via LDLR (249), and it can also bind to hrp-116 (250).
Thus, direct interaction of HL with apoB seems plausible and has
recently been demonstrated in ligand blot studies which show
that HL binds to apoB but not to apoE or apoAI (251). While the
exact site(s) in apoB mediating these interactions have not yet
been identified, the site of apoB interacting with HL and LPL
seems to differ: both carboxyl-terminal and amino-terminal
regions of apoB seem to be involved in the apoB-HL interaction,
which is futhermore not inhibited by LPL (251).
2.3.4.6. Heparin and proteoglycan binding domains
Proteoglycans (PG) are large molecules consisting of linear
heteropolysaccharide chains termed glycosaminoglycans (GAG)
covalently attached to a core protein through a short
nonpolymeric polysaccharide linker (252-254). PGs are found both
in intracellular granules, at cell surfaces and extracellularly,
with different types of PGs predominating in different sites.
ApoB-containing lipoproteins are known to interact with both
cell surface and matrix PGs (252). Association with cell surface
PGs, either directly or through a bridging action of LPL or HL,
has been suggested to facilitate receptor mediated clearance of
lipoproteins, but some types of heparan sulfate PGs may function
also directly as lipoprotein receptors (254). On the other hand,
matrix PGs have been suggested to be involved in the retention
of cholesterol-rich atherogenic lipoproteins within the intima
of the vessel wall (255). The lipoprotein-PG association of
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apoB-containing lipoproteins is believed to be mediated through
an interaction of apoE and apoB regions rich in positively
charged amino acids, such as arginine and lysine, with the
negatively charged polysaccharides in PGs (252,256,257). Seven
heparin-binding sites evenly distributed throughout the apoB
molecule have been identified (amino acids 5-99, 205-279, 875-
932, 2016-2151, 3134-3209, 3356-3489, and 3659-3719), with the
two sites exhibiting the highest affinity for heparin located in
the putative LDLR binding region of apoB (199). Still other
sites have been suggested to be involved in the binding of apoB
with chondroitin sulphate PGs (amino acids 2106-2121, 3145-3157,
3359-3377, and 4230-4254) (258). The relative role of these
putative sites, identified in delipidated or synthetic apoB-
fragments, in the apoB-PG interaction of lipid-containing
lipoproteins is not precisely known. Separate sites seem to be
used for binding with differing PGs (259). Differences in PG
binding between lipoprotein classes and subclasses suggest that
the lipid composition and conformation of binding sites may also
determine which sites are used (259-261). In addition,
modulating factors such as LPL and apoE, or apoB modifications
such as proteolysis or fusion of lipoproteins may affect the
apoB-PG interaction (262-264). Recently, studies with transgenic
mice expressing recombinant mutated human apoB identified apoB
amino acids 3359-3369 as the principal site for LDL apoB-PG
interaction (265). This same site has also been identified to be
the major LDLR binding site of apoB (197). While an artificial
mutation at this site disrupting the sequence of positive
charges was shown to abolish the affinity of LDL for the PGs
studied (265), no natural apoB mutations at this site
interfering with apoB-PG interactions have been characterized so
far. In addition to the carboxyl-terminal PG-binding region, the
amino-terminal globular region of apoB has also been shown to
mediate binding of both apoB-100 and apoB-48-containing
lipoproteins with PGs (266). To date, no metabolic defects
connected with abnormal apoB-PG interaction are known.
Theoretically, an altered apoB-PG interaction might modulate
both receptor-mediated metabolism and artery wall entrapment of
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several kinds of apoB-containing lipoproteins.
2.3.4.7. Microsomal triglyceride transfer protein binding domain
The assembly of apoB-containing lipoproteins requires the
association of lipid with the nascent apoB polypeptide while the
protein is still being translated. This first step of
lipidation, initiated after the folding of the amino-terminal
disulfide bonded domain of apoB (172), involves a specific
microsomal triglyceride transfer protein (MTP) (99,267). ApoB
and MTP have been shown to associate physically through both
ionic and hydrophobic interactions (268,269). The amino terminal
18% of apoB seems to be essential for optimum MTP binding
capacity, with both increasing length of the apoB polypeptide
and lipidation decreasing this affinity (268). In particular,
lysine and arginine residues in the amino terminus of apoB
differing from those associated with PG of LDLR binding seem to
be critical for the binding of apoB with MTP (269). Recent
studies have delineated two major amino-terminal sites on apoB
for MTP binding: one located between amino acid residues 1-264,
and another, centered on residues 512-592 but including flanking
residues 430-511 and 640-711 (163,270,271). Several mutations of
the MTP gene leading to defective hepatic lipoprotein assembly
and secretion and a disease entity termed abetalipoproteinemia
have been described (99). To date, no apoB mutations in the MTP
binding domain leading to a comparable metabolic defect have
been characterized.
2.3.4.8. Other functions and functional domains of apoB
Besides its roles in lipoprotein metabolism, several other
functions for apoB still waiting for verification and detailed
information concerning their mechanisms and physiological
relevance have been proposed. Based on studies with genetically
engineered mice, a putative role in normal fetal development,
possibly relating to lipid nutrient transport to developing
embryos (272-275), as well as a role in spermatogenesis
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(274,276) has been suggested. ApoB has been proposed to have
domains binding benzo(a)pyrene (277), thyroxin (located at amino
acid residues 471-539, 1438-1481 and 3250-4536) (278), and
nucleolin, a nuclear protein expressed also at the surface of
cultured hepatic cells (279). Other putative apoB functions
include enzymatic activities such as phospholipase A1 and A2
activity (280) and protein tyrosine kinase activity (residues
3788-4006) (281). ApoB-100 seems to inhibit the procoagulant
action of tissue factor (amino acids 3147-3160) (282,283). In
addition, its carboxyl terminus has recently been shown to
mediate binding of the platelet-activating factor acetyl-
hydrolase to LDL particles (283).
2.4. Metabolism of apolipoprotein B
2.4.1. ApoB synthesis and secretion
In humans, apoB-containing lipoproteins are synthesized mainly
in liver hepatocytes and intestinal epithelial cells (143,284).
To a small extent, apoB is produced in other tissues as well,
some of which, such as the heart, have been shown to synthesize
and secrete lipoproteins (285), and some of which, such as
aortic endothelial cells, have not (120). The synthesis and
secretion of apoB-containing lipoproteins is a complex process
requiring the association of lipid with the apoB polypeptide in
an appropriate temporal sequence (41,286-288). ApoB synthesis
takes place in the rough endoplasmic reticulum (RER), where,
while still being translated, the nascent polypeptide enters the
RER lumen through a proteinaceous channel, the translocon,
directed by the amino terminal signal peptide sequence, which is
thereafter cleaved from the growing peptide chain (286,289).
Soon after translocation, the amino terminus of apoB is folded
into a globular domain through a process involving several ER
proteins, which act either as catalysts for the formation of
disulfide bonds in this region, or as chaperones protecting the
growing chain from degradation (288,290). Proper folding of the
amino-terminus of apoB, mediated partly through the formation of
37
disulfide bonds in this domain, is required to initiate MTP-
dependent lipid transfer to nascent apoB in the RER (172).
Especially, the bond between cysteines 218 and 234 is of
importance for efficient lipoprotein assembly and secretion
(173). The MTP-binding site of apoB has been located within this
amino-terminal globular domain (163,270,271). During
translation, the translocation of apoB into the RER lumen has
been postulated to pause at certain points in a way not
affecting chain synthesis. This translocational pausing,
dictated by so called pause transfer sequences of apoB, has been
proposed to be important for lipid binding of apoB or to allow
the nascent apoB to interact with other macromolecules involved
in the regulation of lipoprotein synthesis and degradation
(286,291). While studies with cell-free systems have suggested
that translocational pausing does occur (286,291,292), it is not
known, whether this phenomenon can regulate apoB synthesis or
secretion in vivo (289). After translation and translocation,
apoB seems to associate with the inner leaflet of the ER
membrane, but whether this newly synthesized apoB assumes a
transmembrane orientation or is totally translocated into the ER
lumen is not clear (284,293). The transmembrane orientation is
supported by the fact that apoB associates with cytosolic
proteins (294), and that two regions of apoB (amino acids 690-
797 and 3221-3240) seem to be exposed to the cytosol in the
secretory pathway of HepG2 cells (293). This pattern of
transmembrane orientation could help in keeping the apoB protein
close to ER-resident proteins, functioning both as regulators of
lipidation or degradation of apoB (293). After initial apoB
protein synthesis, assembly of apoB-containing lipoproteins
occurs in a putative two-step process in which a primordial
lipoprotein particle is formed in the RER, and expansion of the
lipid core then occurs in a second step in the smooth
endoplasmic reticulum (SER), and, possibly, the Golgi apparatus
(41,99,143,284,295). The first lipidation step seems to be
required for the protection of apoB from degradation (41,288).
After formation of the primordial lipoprotein particle, more
lipids are added to the partilce either sequentially as it moves
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along the secretory pathway, or through a fusion of the
primordial particle with preformed triglyceride-rich lipid
particles in the RER/SER junction (41,287,295-297). MTP is
generally accepted to mediate the co-translational first
lipidation step, but its role in the second step is still a
matter of dispute (41,99,295). After the second lipidation step,
the particles are transported to the Golgi apparatus for further
modulation where they are glycosylated, phosphorylated and
aquire additional phospholipids, whereafter the mature
lipoprotein particles are rapidly secreted (284,298).
Regulation of the secretion of apoB-containing lipoproteins is
a co- and post-translational process. ApoB mRNA has a relatively
long half life, with levels that do not usually change
substantially in situations where apoB secretion is altered
(284,286,287). Instead, apoB secretion is regulated through
intracellular degradation of newly synthesized apoB (286). ApoB
degradation has been shown to occur at every step of lipoprotein
synthesis, ranging from co-translational degradation of
misfolded nascent apoB peptides to degradation of preformed
lipoprotein particles in the ER, Golgi or lysosomes (287,288).
Two major apoB degradation pathways have been characterized. In
the ubiquitin-proteasome pathway, misfolded or poorly lipidated
apoB is tagged by ubiquitin to be degraded by a cytosolic multi-
subunit protease complex termed the proteasome (286,299) in a
process involving other cytosolic chaperone-like proteins such
as the heat shock protein 70 (300). This proteasome-mediated
degradation has been shown to occur both co- and post-
traslationally (301,302). In this degradation pathway, the apoB
chain has to be translocated back to the cytosol from the lumen
of the ER, either through the translocon complex involved in
early apoB chain synthesis, or other not yet characterized
specialized retrotranslocons (288,302). Unassembled or aberrant
apoB retained in the ER are also degraded by proteases inside
the ER lumen. This degradation pathway seems to involve ER
resident molecular chaperones such as calnexin or calreticulin
and ER proteases such as ER 60 (284,286,290). In some species,
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the main site of apoB degradation is in the Golgi or post-Golgi
department; details of apoB degradation in these locations are
still limited (286,287).
The most important factor regulating apoB degradation is
intracellular lipid availability (41,284,287), which seems also
to be the main mediator of other factors affecting lipoprotein
secretion, such as hormones and diet. ApoB in lipoproteins with
inadequate lipids is incorrectly folded and destined to be
degraded (143,286). The major lipids secreted in the newly
formed lipoproteins are Tg, FC, CE, and Pl. Of these, Pl,
especially phosphatidylcholine, though required for the normal
secretion of apoB-containing lipoproteins, are usually found in
cells in quantities exceeding the amounts needed for lipoprotein
assembly and are therefore not likely to be main regulators of
lipoprotein degradation or secretion (284,303,304). However,
phospholipid composition may regulate apoB degradation: in
vitro, enrichment of microsomal membranes with phosphatidyl-
monomethylamine impairs apoB secretion, possibly by inhibiting
the restart of translocation after pausing, and directing apoB
to degradation instead of secretion (292). Availability of the
other main lipid components of apoB-containing lipoproteins, Tg
and cholesterol, plays a major role in the efficient assembly
and secretion of lipoproteins. The relative contribution of Tg
and cholesterol or CE in this regulation is still a matter of
discussion: studies favoring both factors have been published
(41,287,296,305,306). Besides phospholipids, the composition of
other lipids in the assembled lipoproteins seems to be of
importance as well: in vitro, n-3 fatty acids increase apoB
degradation (307), and oxidized fatty acids interfere with the
assembly and secretion of TGRLP particles (308).
Apart from the lipidation-assisted folding of apoB, lipoprotein
maturation involves other post-translational modifications such
as glycosylation and phosphorylaton. While glycosylation appears
not to be crucial in apoB secretion regulation, aberrant
glycosylation has been shown to disrupt the assembly and
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secretion of apoB-containing lipoproteins (286,309,310). To
date, no role for the post-translational phosphorylation of apoB
in lipoprotein secretion or degradation regulation is known
(286,309).
The lipoprotein particles secreted by the liver are
heterogeneous in terms of their lipid composition and size (36).
Mainly, the liver produces lipoproteins of the VLDL class;
these, in turn, can be subdivided into large, buoyant,
triglyceride-rich VLDL1 particles and to small, dense,
cholesterol-enriched VLDL2 particles (36,311,312). In addition,
part of the LDL particles in the circulation are postulated to
be secreted directly from the liver (36,311). The intracellular
mechanisms regulating the lipid composition and thus the
spectrum of lipoproteins secreted from the liver are largely
unknown. Factors affecting apoB degradation during lipoprotein
synthesis affect mainly the number of particles secreted.
However, there seem to be both common elements that regulate the
secretion of lipoproteins in general (such as estrogen,
regulating secretion of both VLDL1 and 2), and factors with
independent effects on the secretion of distinct lipoprotein
subclasses (such as insulin, inhibiting VLDL1 secretion
(36,312).
2.4.2. Intravascular metabolism of apoB-containing lipoproteins
After the secretion of CM particles into intestinal lymph, and
VLDL particles into the space of Disse in the liver, both
triglyceride-rich particles undergo several modifications
affecting both their lipid and apolipoprotein composition before
their final removal from the circulation through lipoprotein
receptors (9,10,36,42,313). These modifications include
hydrolysis of some of their core Tg, removal of surface
components to HDL particles, changes in their apolipoprotein
content, and exchange of non-hydrolyzed Tg for CE derived from
HDL particles. These modifications lead to the formation of
smaller, CE-enriched remnant particles and to the production of
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IDL and LDL particles from VLDL precursors. Despite these
considerable changes in both the lipid and protein composition
of lipoproteins during their intravascular metabolism, the
primary structure of their apoB moiety remains unchanged
throughout the metabolic cascade. However, the tertiary
organization of apoB undergoes modifications during these
processes. This is reflected in differences in immunochemical
reactivity of mAbs against apoB epitopes between lipoprotein
classes (314) and can also be visualized as structural
differences between lipoprotein classes detected by cryo-electon
microscopy (315). Some of these conformational changes may have
effects on apoB functions such as affinity for lipoprotein
receptors (197) or PGs (259).
2.4.3. Receptor mediated and receptor-independent metabolism of
apoB-containing lipoproteins
LDLR-mediated lipoprotein uptake to hepatic and peripheral cells
is the major mechanism for lipoprotein catabolism (44,316). In
this process, apoB-containing particles are specifically bound
to the LDLR in a process facilitated by cell surface GAGs, and,
possibly by LPL and HL (42,317). Receptor-bound lipoproteins are
internalized by endocytosis and transported into lysosomes where
their lipids and apolipoproteins are degraded. The cholesterol
liberated from the lipoprotein particle regulates cell
cholesterol homeostasis by down-regulating LDLR expression,
diminishing cholesterol synthesis and increasing cholesterol
esterification (44). The ligand for the LDLR in LDL is apoB; in
other apoB-containing lipoproteins, apoE molecules, inhibited by
apoC:s, mediate the interaction with the receptor (42). Since
several molecules of apoE associate with a single lipoprotein
particle, apoE-containing lipoproteins are more effectively
bound and catabolized than LDL particles, which contain only one
apoB-100 molecule (44). The removal of LDL particles in plasma
is mediated mainly through hepatic LDLR, whereas peripheral
LDLR, other lipoprotein receptors and non-receptor-mediated
pathways play a less important role (10,44). The LDLR pathway is
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also considered to comprise the main route for hepatic
lipoprotein remnant catabolism (42,313).
In recent years, several other cellular receptors structurally
related to the LDLR have been characterized (206,207). They all
show high affinity for apolipoprotein E and an inhibitory
protein termed the receptor-associated protein (RAP) (318), but
their tissue distribution and preferred ligands vary
considerably, and their physiological contribution to
lipoprotein metabolism in humans has still to be determined. Of
these LDLR family receptors, the LDL receptor-related protein
(LRP-1) (319) may be involved in LDLR-independent lipoprotein
remnant catabolism in the liver (42,320), and the VLDL-receptor
(321,322) has been suggested to function in the clearance of
large CM and VLDL remnants in peripheral tissues (43). The
physiological functions of other LDLR family receptors such as
the apoE receptor 2 (LR7/8B) (323), LR11 (324), and LRP-2
(megalin or glycoprotein 330) (325,326) are largely unknown.
LRP-2 mediates LDL endocytosis in vitro, but its mainly
extravascular expression seems to preclude its role in clearance
of LDL directly from the blood in vivo (211). Two other non-
LDLR-related receptor proteins believed to be involved in
lipoprotein metabolism have been characterized. Of these, the
lipolysis-stimulated receptor has been suggested to mediate the
cellular uptake of large TGRLP in the liver (209). Instead, the
role of the hepatic asialoglycoprotein receptor in lipoprotein
metabolism is still disputable (42,320,327).
Much of the cholesterol that accumulates in atherosclerotic
plaques is found within monocyte-macrophages. Uptake of
lipoproteins in these cells seems to occur through specialized
receptors, two types of which have been characterized. One class
of these receptors mediates apoE-independent uptake of TGRLP
such as CM into macrophages, leading to their conversion into
foam cells (214,328-330). Still another class of macrophage
receptors termed scavenger receptors and recognizing modified,
such as oxidized, lipoproteins may be even more important for
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foam cell formation (208,331). Besides macrophages, these
receptors are expressed in other cells, such as endothelial and
vascular smooth muscle cells. As opposed to the LDLR pathway,
uptake of lipoproteins through scavenger receptors is not
followed by down-regulation of receptor expression: in fact,
some types are upregulated by oxidized LDL (208). Besides
mediating selective cholesterol uptake from HDL particles to
liver and steroidogenic tissues and cholesterol removal from
peripheral cells to HDL, the scavenger receptor BI (SR-BI) binds
also native LDL and VLDL with high affinity in vitro (332). In
transgenic mice overexpressing SR-BI, LDL and apoB levels are
decreased, and in vitro studies show selective uptake of LDL CE
mediated by SR-BI (332). While the exact role of SR-BI in
lipoprotein metabolism in humans is not known, recently, genetic
variation in the human SR-BI gene was associated with both LDL
and HDL cholesterol levels (81). Apart from SR-BI, other
scavenger receptors seem to recognize only modified, mostly
ozidized apoB-containing lipoproteins. Therefore, they are not
likely to be main mediators of normal lipoprotein catabolism.
A minor part of lipoprotein particles have been suggested to be
catabolized through receptor-independent pathways. Among
possible mechanisms are direct internalization and eventual
degradation of LDL through cell-surface heparan sulfate PGs
belonging to the syndecan and perlecan family (254), and
selective CE uptake from LDL bound to hepatic or peripheral
cells mediated by proteins other than the SR-BI (333,334). In
addition, nonspecific low affinity mechanisms such as fluid
endocytosis and adsorptive endocytosis, possibly facilitated by
cell surface proteoglycans, may take part in lipoprotein uptake
(10,335,336). The physiological relevance of all these
mechanisms is still unknown.
2.4.4. Oxidative and other modifications of apoB-containing
lipoproteins and their role in atherogenesis
Besides modifications involved in their lipid-carrier function,
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apoB-containing lipoproteins undergo other changes in vivo, many
of which are commonly regarded to be involved in the patho-
genesis of atherosclerosis. Lipoprotein oxidation is among the
most important of these (337-341). All lipoproteins, especially
LDL, are susceptible to oxidation (337), and although oxidation
mainly involves lipoprotein lipids, apoB protein is also known
to be modified (340,341). Among apoB oxidative modifications are
lipid derivative adduct formation with apoB amino acids such as
lysine, and cross-link generation between lipids and the apoB
protein or within apoB, and, in addition, direct oxidation of
amino acids such as tryptophan, arginine and histidine (337,339,
341). The relative and temporal role of protein modification in
the oxidation process is still a matter of discussion. While
oxidative modification of apoB, leading to protein aggregation
and fragmentation, is usually considered to be a relatively late
phenomenon in lipoprotein oxidation, some apoB changes seem to
occur already at the earliest stages of LDL oxidation (341).
Depending on the extent of oxidative modifications, a hetero-
geneous continuum of oxidized lipoproteins ranging from
minimally modified LDL (mm-LDL) to fully oxidized lipoproteins
is produced. A major difference between mm-LDL and fully
oxidized LDL lies in their receptor-mediated metabolism: the
former are recognized by the LDLR, whereas the latter are taken
up by scavenger receptors (339,341). So far, no apoB domains
especially sensitive to oxidative modification, or apoB genetic
variants associated with changes in lipoprotein oxidazibility
have been identified.
In addition to oxidation, lipoproteins are also known to be
glycated in vivo (342,343). Nonenzymatic protein glycation by
glucose is a physiological process resulting either from direct
interaction of glucose with serum proteins, or a modification of
proteins with low molecular weight, highly reactive advanced
glycation end products (AGE), formed during degradation of other
glycated proteins (344). In lipoproteins, AGE modification may
involve lipids as well. Sugar residues in glycated LDL are
readily auto-oxidized, generating superoxide radicals which
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stimulate further LDL lipid and protein oxidation (343). AGE-LDL
show reduced affinity for the LDLR, but are instead taken up by
vascular cells through both scavenger and specific AGE-
receptors, leading to several cellular injury responses
(344-347). ApoB lysine residues are known to be important in
both the initial glycation and AGE-modification of the protein
(344). While lysine residues within the putative apoB LDLR
binding site seem to be protected from glycation, residues in
close proximity to this site are modified, and may explain the
reduced affinity of AGE-LDL for the LDLR (344). In addition, a
domain of apoB between residues 1388 and 1453, detected by AGE-
specific antibodies seems to be specifically modified (348), and
still other sites, showing changes in their immunoreactivity
after LDL glycation have been identified (344). Elevated amounts
of circulating AGE-LDL, detected in diabetics, patients with
renal insufficiency, and in hyperlipidemia, may partly explain
the increased CAD risk in these subjects. So far, no apoB
genetic variants associated with altered glycation sensitivity
have been identified.
Sialic acid is a terminal residue of the carbohydrate chains of
glycoproteins, such as lipoproteins (349). The high surface
charge associated with sialic acid plays an important role in
the prevention of lipoprotein aggregation (350). Desialylation
of LDL particles leads to several changes in their biological
behaviour, many of which have been suggested to play a role in
the early steps of atherosclerosis (351). Like normal LDL,
desialylated LDL are recognized by the LDLR (352,353), but seem
also to be taken up through scavenger receptors (352), the
hepatic asialoglycoprotein receptor (350), a galactose-specific
macrophage lectin receptor (353), and through direct
phagocytosis of aggregated desialylated LDL particles (351).
Desialylated LDL are smaller, denser, more negatively charged,
more prone to PG binding and aggregation than normal LDL
particles, and more suspectible to oxidation (351). In vitro,
these changes are reflected in increased uptake of desialylated
LDL by fibroblast and smooth muscle cells (354) and in their
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accumulation in aortic intimal cells and macrophages (352,353).
In vivo, the catabolism of desialylated LDL has been shown to be
accelerated (355). LDL desialylation seems to occur in vivo: LDL
particles isolated from healthy subjects is partly desialylated,
and even more desialylated LDL particles are found in the plasma
of diabetics and CAD patients (351). However, the exact
mechanism of LDL desialylation is not known, and no specific
apoB sites have been shown to be involved in LDL desialylation
processes.
Increased levels of plasma homocysteine have been associated
with an increased risk for CAD (356,357). Homocysteine may
modify lipoproteins either by facilitating LDL oxidation
(356,357), or by forming adducts with apoB lysine residues,
leading to particles with foam-cell formation capacity (357).
Whether homocysteine-modified LDL are present in vivo is not
known, and thus, the mechanism of the homocysteine and CAD
association has not yet been uncovered (357). The ethanol
oxidation product acetaldehyde is known to be chemically highly
reactive, forming adducts with proteins in alcoholics.
Modification of LDL apoB by acetaldehyde reduces its binding
affinity to the LDLR (358), and in vivo, acetaldehyde
modification of VLDL apoB has been shown to decrease fractional
catabolic rates for both VLDL, IDL and LDL, and to reduce the
fraction of VLDL converted to LDL (359). Considerable
qualitative heterogeneity in these metabolic changes have
however been observed and thus, the physiological relevance of
lipoprotein modification by acetaldehyde remains to be
determined.
Atherosclerosis is a complex and continuous process. Starting
with modulations of vascular endothelial cell function, it
continues by accumulation of lipids in the subendothelial cell
matrix and recruitment of monocytes into the arterial wall with
their transformation to machrophages, and is later followed by
smooth muscle cell migration and proliferation, and the
formation of a fibrous plaque, the rupture of which eventually
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leads to thrombus formation (232,255,338,339,341,360,361).
Oxidatively or otherwise modified lipoproteins seem to play an
important role in atherogenesis. The initial endothelial changes
are believed to be mediated through actions of native or only
minimally modified lipoprotein particles (232,339,362), or their
remnants (363,364). After their transport and entrapment into
the subendothelial matrix, both normal and modified lipoproteins
undergo further oxidative (339,341) and enzymatic modifications
(365-368), and are thereafter taken up into arterial wall cells
through scavenger and other specific receptors (361), or through
non-receptor-dependent mechanisms (336). Uptake of modified
lipoproteins leads to cellular activation and further lipo-
protein trapping and modification (339,360). Atherosclerotic
lesions contain both lipids and components of apoB. To what
extent specificity of the steps leading to full blown athero-
sclerosis is due to lipoprotein apoB is not known; some role in
the initial lipoprotein attachment to the endothelium (237), in
the subendothelial matrix trapping (232,265), and receptor-
mediated uptake of modified lipoproteins to macrophages (212)
seem to be dependent on their apoB moiety.
2.5. ApoB genetic variants and lipids
2.5.1. Polymorphisms
Among the first polymorphisms of apoB to be characterized were
the antigen group (Ag) polymorphisms detected by the use of
alloantibodies produced in multiply transfused patients (369).
These Ag polymorphisms were based on antigens a1/d, c/g, h/i,
t/z, and x/y, which appeared to be products of five closely
linked allele pairs (370). Later on, DNA changes corresponding
to each of the five Ag epitopes were identified, and all were
found to be detectable at the DNA level by restriction
endonucleases (371). Since the availability of the original
alloantibodies for these Ag epitopes is limited, these
polymorphisms are currently analyzed either at the DNA level as
RFLPs, or at the protein level with mAbs.
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Besides the Ag polymorphisms, several other apoB genetic
variants have been characterized and studied in populations.
Among these, the most important are the three-allele
insertion/deletion polymorphism situated in the signal peptide
of apoB (372), the XbaI polymorphism in exon 26 (113,373,374),
and a multiallelic locus at the 3´ end of the gene termed 3´VNTR
(375,376). In the following, the main characteristics and
effects of the major polymorphisms of apoB, in 5´ to 3´ order,
are discussed. The nucleotide and amino acid sequence and
numbering used in defining apoB variants is based on the
sequence published by Knott et al. (116). Therefore, some
polymorphisms will be presented as a change from the actually
rare allele to the common one. A summary of apoB polymorphisms
as well as hypercholesterolemia-producing and neutral apoB
mutations is shown in Table 4.
The apoB signal peptide insertion/deletion polymorphism was
first characterized as a two-allelic genetic variant leading to
the insertion or deletion of three codons coding for the signal
peptide, which thus contains either 27 or 24 amino acids, the
allele containing 27 amino acids designated as the insertion
(ins), and the allele with 24 amino acids the deletion (del)
allele (372). Later on, a third allele encoding a signal peptide
with 29 amino acids was detected: this third allele seems to be
present at a low frequency (0.03 to 0.08) only in Amerindians
(377,378). In Caucasians, the allele frecuency of the del allele
is approximately 0.30 (379-381); in non-Caucasoid populations,
lower frequencies have been reported (378,380,382-388). Several
studies have addressed the effects of the ins/del polymorphism
on lipid levels in both healthy, hyperlipidemic and CAD patient
populations. Some of these studies have shown an association of
the del allele with higher serum total or LDL cholesterol, Tg or
apoB levels (379-384,389-397), while in the Finns, an
association between the ins allele and higher Tg levels has been
detected (398), and yet some studies have found no effect of the
ins/del polymorphism on lipid levels (378,385-387,399-402).
Three studies have found an association between the del allele
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and the extent or presence of atherosclerosis or myocardial
infarction (380,391,403), two studies an association between CAD
and the ins allele (404,405), while in others, no allele
frequency differences between healthy or CAD populations could
be seen (392,396,406-408). Concerning lipid responses to dietary
change, ins/ins homozygotes have been shown to be more
responsive both to modifications in dietary fat and fibre
compared to del/del homozygotes (78,395). This response is
variable, being more consistent in del/del homozygotes (409).
The ins allele has also been associated with larger lipid
changes after a fat challenge (410-412). The mechanism by which
the ins/del polymorphism affects lipid levels is presently not
known with certanity. The signal peptide is cleaved away from
the growing apoB nascent polypeptide chain early in lipoprotein
synthesis and cannot be involved directly in their metabolism
after particle assembly and secretion. Studies using genetically
modified yeast cells, in which the apoB signal peptide region
was added to yeast invertase, have shown the del allele to be
defective as opposed to the ins allele with respect to invertase
secretion from the cell (413). Molecular modelling suggests that
the del allele is not hydrophobic enough to be effectively
translocated through the ER membrane (414). This could,
hypothetically, lead to reduced lipoprotein secretion in del/del
homozygotes, a hypothesis gaining some support from a recent
apoB turnover study in obese men showing higher hepatic VLDL
apoB secretion in ins/ins homozygotes compared with ins/del
heterozygotes or del/del homozygotes (415). This hypothetical
apoB secretion model contrasts with the documented associations
of the del allele with higher lipid levels in population
studies. One explanation for this apparent discrepancy could be
that these observed associations in population studies reflect
a linkage disequilibrium of the ins/del polymorphism with some
other polymorphic site of the apoB gene.
The Ag(c/g) polymorphism results from a CST change at cDNA
nucleotide 421 leading to a ThrSIle change at amino acid residue
71 of apoB (416,417). It can be detected both with restriction
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endonucleases ApaLI (416) and Bsp12861 (416) and with mAbs MB19
(418,419), BIP45 (420) and D2E1 (421). The frequency of the
Ag(c) (apoB 412 Ile, ApaLI-, restriction site absent) allele in
Caucasian populations is estimated to be approximately 0.30
(420,422-424). In other racial groups, considerably lower
frequencies have been reported (370,425). The Ag(c) allele has
been associated with higher serum apoB and LDL cholesterol
concentrations in Finnish children (426), the Ag(c/g) phenotype
with higher serum apoB concentrations (423) and, the Ag(c)
allele connected with the XbaI+ allele with higher serum total
and LDL cholesterol in Finnish healthy men (427). Several other
studies have not detected significant associations between the
Ag(c/g) polymorphism and lipid levels (424,428-430). In
Congolese blacks, the Ag(c) was associated with lower serum apoB
levels (425). Only two studies have addressed the possible
effects of the Ag(c/g) polymorphism on the risk of CAD, with no
signs of significant association (424,428).
The Ag(a1/d) polymorphism, resulting from a TSC change at cDNA
nucleotide 1981 and producing a AlaSVal change in amino acid 591
of the mature apoB protein (431), can be detected with
restriction endonuclease AluI (431) and with mAb H11G3 (421).
The allele frequency of the apoB 591 Ala (Ag(d), AluI+,
restriction site present) allele in Caucasians is approximately
0.45 (370,432). In Chinese, its frequency is much lower, 0.16
(433), and in Africans, much higher, 0.93 (370). Data on lipid
effects of the Ag(a1/d) variation are so far limited. The 591 Val
allele has been associated with larger postprandial TGRLP
responses after a fat load (410). In patients suffering from
ischemic stroke, serum apoB concentrations have been found to be
higher in the carriers of the 591 Ala allele (434). No studies
addressing the effects of this polymorphism on CAD risk have
been published. According to data from both Finnish and other
studies, the signal peptide del and the Ag(d) (apoB 591 Ala)
allele seem to be closely associated (398,410).
The XbaI polymorphism, a TSC change at nucleotide 7673 with no
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change in the threonine residue 2488 of apoB (113,373,374), is
one of the most studied apoB polymorphisms. In Caucasian healthy
populations, the reported allele frequency of the XbaI+ allele
has ranged from 0.40 to 0.60 (373,435), and a similar frequency
has also been reported in healthy Finns (427,436). In non-
Caucasoid populations, the frequency of the XbaI+ allele is
considerably lower, from 0.01 in the Chinese (433,437) to 0.29
in a population of South Asian descent (382). A summary of XbaI
population studies addressing its effects on serum cholesterol,
Tg or apoB levels or on the risk of CAD is shown in Table 5.
Many, but not all studies show an association of the XbaI+
allele with serum lipid and lipoprotein levels. These effects of
the XbaI site on lipid levels seem to be especially clear in the
Finnish population. In Asian populations, the XbaI+ allele (very
rare in these populations) is associated also with lower serum
HDL cholesterol or apoAI levels (382,384,406,438-440), contra-
dictory to a few studies in Caucasians, including the Finns,
which show an association of the XbaI+ allele with higher serum
HDL cholesterol or apoAI levels (441,442). In addition to
studies listed in Table 5, some studies have suggested an effect
of the XbaI polymorphism on postprandial lipid responses (443),
responses to dietary changes (395,442,444-446) and to lipid
lowering drugs (447), as well as on the intra-individual lipid
variability over time (448). As for CAD, several studies show an
association of the XbaI- allele with the presence of CAD. Being
a silent polymorphism, the XbaI change cannot be the causative
factor in these associations and effects. Rather, this site is
believed to be in linkage disequilibrium with another apoB
genetic variant influencing lipid levels or predisposing to CAD.
Regardless of the actual site of apoB mediating the association
detected with the XbaI polymorphism, it does not seem to act
through changes in the production of apoB-containing lipo-
proteins. In hepatoma-derived liver cell lines, the XbaI poly-
morphism has no detectable effect on cholesterol, Tg or apoB
secretion (449), and kinetic studies show similar LDL production
rates across different XbaI genotypes (450,451). On the other
hand, kinetic studies have shown that LDL particles from XbaI+/+
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homozygotes exhibit lower fractional clearance rates compared
with XbaI-/- LDL particles (402,450-452). In addition, lower
LDLR-dependent degradation rates by mononuclear cells (453) and
fibroblasts (454) of the XbaI+/+ LDL particles have been
detected. These two lines of studies point towards an
association of the XbaI+ allele with a factor affecting LDL
removal from the circulation.
The Ag(x/y) polymorphism has been linked to two different DNA
polymorphisms of apoB: a CST change at nucleotide 8344 (exon
26), leading to a ProSLeu change in amino acid 2712 (455), and
detectable with restriction endonucleases MaeI (371) and BfaI
(456), and an ASG change at cDNA nucleotide 13141 (exon 29) with
an apoB Asn4311SSer change (457), detectable with Eco57I (456).
The Ag(x) epitope represents the allele encoding both 2712 Leu
and 4311 Ser (458). The Ag(x/y) and the XbaI polymorphisms are
closely linked, with the Ag(x) allele associating with the XbaI-
allele (459,460). In Caucasians, including the Finns, Ag(x)
allele frequencies of 0.20 to 0.40 have been reported, whereas
the frequency of the Ag(x) allele in non-Caucasoid populations
is highly variable (422,458,461). In population studies, the
Ag(x) allele has been associated with lower serum total and LDL
cholesterol, apoB and Tg levels and with higher serum HDL
cholesterol and apo AI levels (458,462,463). Of these
associations, the most significant have been detected in the
Finnish population (462). So far, no association between the
Ag(x/y) polymorphism and CAD has been detected (404,463).
The Ag(h/i) polymorphism associates with a GSA change at
nucleotide 11041, and leads to an ArgSGln substitution at amino
acid 3611, detectable with MspI (464,465). With an allele
frequency of the 3611 Gln (MspI-, Ag(h)) allele in the range of
0.02-0.14 in Caucasian as well as non-Caucasian populations, it
is the least frequent of the apoB antigenic polymorphisms
(370,406,465,466). Most population studies reported to date show
no association between this polymorphism and lipid levels
(378,390,393,402,437,465-470) or the presence of CAD (406,407,
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437,471-474). Still, in a few studies, the rare Ag(h) allele has
been associated with higher serum lipid levels (79,475-477). As
for CAD, associations with both the rare MspI- (478) and the
common MspI+ allele (470) have been reported.
The Ag(t/z) polymorphism represents the apoB EcoRI RFLP, which
is the result of an ASG change at nucleotide 12669 (exon 29)
producing a Lys to Glu change at amino acid 4154 (113,479,480).
Reported allele frequencies of the 4154 Lys (Ag(z), EcoRI-)
allele have ranged between 0.10 to 0.20 in most Caucasian as
well as African populations (370,388,404,479,481,482). In Asian
and Amerindian populations, lower 4154 Lys allele frequencies
have been detected (378,384,385,440,466,483). In most population
studies, no effect of this polymorphism on serum lipid and
lipoprotein levels have been detected (78,79,378,382,385,390,
393,400,404,406,432,437,438,440,441,466-469,476,477,484-490).
Some studies show an association between the 4154 Lys allele and
elevated serum cholesterol, Tg or apoB levels (470,491-495) and
still others report an association of lower serum cholesterol
levels with the 4154 Lys allele (402,475,483,496). The Ag(t/z)
polymorphism seems not to have an effect on lipid responses to
changes in diet (444,445,497). Both studies showing an increased
risk for developing CAD in carriers of the 4154 Lys allele
(440,441,478,485,488,491), as well as a neutral role for the
Ag(t/z) polymorphism in the pathogenesis of CAD have been
published (382,400,406,407,435,470,472,476,484,498). In patients
with non-insulin-dependent diabetes mellitus (NIDDM), 4154 Glu
homozygosity associates with an increased risk for CAD (499).
There are also reports on the association of the 4154 Lys allele
with NIDDM (492), with high (500) or low BMI (494), and blood
pressure (501). Two studies have shown age-dependent selection
towards lower prevalence of the 4154 Lys allele in very old
compared with younger subjects (473,502). The biological
mechanisms for all these associations are far from being clear.
No relation between cholesterol, Tg and apoB secretion from
hepatoma derived liver cell lines and the EcoRI genotype has
been detected (449). Studies on the effects of the 4154 Lys
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allele on LDL fractional catabolic rate have shown both
decreased (451), increased (402,500) and invariant rates of
clearance (450); the only LDL binding study reported to date
could not demonstrate an effect of this polymorphism on LDL
binding to fibroblasts (503).
The apoB 3´VNTR polymorphism (variable number of tandem repeats)
or 3´HVR (hypervariable region) consists of a multiallelic locus
with repetitive 11 to 16 bp AT-rich DNA sequences beginning 73
bp 3´ to the second polyadenylation signal (375,376). The 3´VNTR
was originally defined as a simple length polymorphism,
resulting from differing numbers (from 22 to 57) of repeated
sequences, and it is most often genotyped based on this size
variation by polymerase chain reaction-based methods in ordinary
agarose (504) or denaturing acrylamide electrophoresis gels
(505). Before the development of these methods, a crude estimate
of the different-sized alleles was achieved with restriction
endonucleases such as MspI, BamHI, and HindIII with or without
SspI (485,487). The majority of length variation resides in the
5´ end of the repeat array constituting from 4 to 15 copy
numbers of one specific 30 bp repeat unit containing the 15 bp
sequences termed x and y (376,506,507). In addition, the number
and type of other repeats which are considered derivatives of
the basic x and y repeats have been shown to vary between
different alleles (506-509). Usually, apoB 3´ VNTR alleles are
named according to the number of repeats. Depending on whether
an 11 bp sequence in the 3´ boundary of this region is included
as a repeat or not, two nomenclatures with mainly even (repeat
not included) (505) or odd numbers of repeats (504) have been
proposed. To date, 26 different-sized 3´VNTR alleles have been
characterized in humans (504,505,510,511). Despite being widely
used in population association studies, definition of the 3´VNTR
site on the basis of size alone is an oversimplification. The
repetitive core sequences seem to exhibit considerably more
genetic variation than has hitherto been known. According to
careful sequence analyses, alleles with an equal number and type
of repeats, formerly believed to be identical, still differ in
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sequence. Structural analysis of 18 size-characterized alleles
resulted in the detection of altogether 39 alleles with up to 6
alleles bearing the same number of repeats (509). As a
multiallelic locus with a high grade (from 0.70 to 0.90) of
heterozygosity (511), the apoB 3´VNTR is a good genetic marker
to be used, for example, in forensic analyses. In lipid
genetics, the high number of possible alleles leads to
difficulties in associating single alleles with lipid levels or
CAD. Therefore, for practical purposes, most association studies
have divided the 3´VNTR alleles into groups containing large or
small alleles, a definition largely based on the known bimodal
distribution of different-sized alleles in populations. In most
populations, alleles containing 35 and 37 repeats (odd number
nomenclature) form the larger, and alleles 47 and 49 the other
distribution peak (387,397,504,505,512-514). In the Koreans, an
unimodal distribution with a peak on allele 35 (515), and in
African populations, unimodal peaks on alleles 35 or 37 and with
a considerable number of both large and small alleles as well
the presence of unique alleles not detected in Caucasians
(510,511) have been reported. A small number of studies seem to
connect single apoB 3´VNTR alleles with serum lipid levels
(381,397,514,516-519), and one study has shown an association of
apoB 3´VNTR allele 35 with essential hypertension (520).
However, most studies have not detected significant lipid
associations (387,390,393,440,471,478,485,486,493,515,521,522).
While the definition of a large allele has varied in different
studies, large alleles have been associated with an increased
risk of CAD in many (440,471,478,485,522,523), but not all
studies (381,393,493,516,518).
In addition to these common apoB polymorphisms, several other
polymorphic sites in the apoB gene have been detected (Table 4).
Most of them have been reported shortly after the cloning of the
apoB gene and represent classical RFLPs. For some of these, the
exact site of DNA variation has later been identified. Also,
intronic polymorphisms have been detected. Data on the effects
of these polymorphisms on serum lipid levels or CAD risk are
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limited. The apoB 5´VNTR locus has been excluded from causing
familial hypertriglyceridemia (100), and it seems not to
associate with serum lipid levels or CAD (524). Recently, an
association of the -516 T allele located in the promoter area of
the apoB gene with elevated LDL cholesterol levels and acute
myocardial infarction was reported (525). Based on in vitro
transfection experiments, the LDL-cholesterol elevating effect
of this variant was suggested to be due to an increased rate of
apoB transcription. One study has shown the apoB promoter region
-265 T allele to have an LDL cholesterol and apoB lowering
effect in healthy subjects (404). Neither the StyI polymorphism
in intron 2 or the HincII polymorphism in intron 4 have been
associated with serum cholesterol levels (475,515,526). The
intron 4 PvuII polymorphism, while linked with serum apoB levels
in one large kindred (517,527), seems not to be associated with
either lipid levels or CAD in population studies (441,484,515).
With regard to other apoB polymorphisms listed in table 4, no
reported data on their effects are available.
Any attempts to measure the contribution of apoB genetic
variants to hyperlipidemias and CAD have been confounded by the
variable, sometimes even opposing results in association studies
analyzing the effect of apoB polymorphisms on lipid levels.
Several reasons for this can be suggested (12). Sample sizes
have often been too small to adequately show associations
between a genetic variant and lipid levels, when the effect is
small. Genetic heterogeneity of the studied sample and the way
in which the statistical analyses are carried out may have also
affected the results of these association studies. According to
one hypothesis, another explanation for the discrepant results
could be that it is not the single apoB polymorphism per se, but
a combination of DNA and amino acid changes in the whole apoB
protein that is affecting lipid levels (528). Thus, attempts to
associate lipid levels with specific combinations of several
apoB polymorphic alleles, termed haplotypes, could be more
informative. Some studies have analyzed partial haplotypes for
a small number of apoB polymorphisms (441,475,477,488,498). More
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detailed haplotypes, however, are difficult to deduce
unambiguously in unrelated subjects. Therefore, while a few
studies using this approach have been reported (515,528,529),
large scale studies of this kind are not likely to gain wide use
in apoB association analyses.
2.5.2. Mutations
2.5.2.1. ApoB mutations causing hyperlipidemia
The first apoB heritable defect shown to be associated with
hypercholesterolemia was an ASG transition at cDNA nucleotide
10708, leading to an ArgSGln change at apoB amino acid 3500 and
to the production of ligand-defective apoB-100, resulting in a
disease entity termed familial defective apolipoprotein B (FDB)
(13,14). Despite lying outside the putative apoB LDLR binding
site, the mutation has been suggested to change the three-
dimensional structure of the binding area so that LDL particles
possessing mutated apoB have reduced binding affinity to the
receptor (530). Proof favoring this hypothesis has recently been
obtained from studies in transgenic mice expressing the human
FDB mutation (197). In vivo, LDL particles from FDB hetero-
zygotes exhibit plasma clearance rates (531,532) and LDLR
binding affinities (13) of less than 50% and 33% of normal,
respectively. The binding affinity of isolated 3500 Gln LDL
particles is much lower, approximately 9% of normal (533). This
leads to an accumulation of LDL particles carrying mutated apoB
in the circulation (533,534). The receptor-mediated metabolism
of VLDL and IDL particles seems to be normal, possibly because
these particles can be removed by the LDLR pathway through
interactions of the receptor with lipoprotein particle apoE
(532,535-537). This has been suggested to explain the fact that
the few 3500 Gln homozygotes detected so far do not seem to
suffer from a more severe disease than heterozygotes (538-540).
The phenotypic characteristics of FDB carriers range from a
disease indistinguishable from FH (18,541,542) through moderate
hyperlipidemia (17,543) to normal serum lipid levels (534,544-
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546). Considerable variability between lipid levels in FDB
carriers belonging to the same families has also been reported
(544-546). The mutation can, but is not always expressed during
childhood (18,547). An increased risk of CAD, possibly
reflecting live-long blood lipid levels in FDB carriers has been
reported (18,536,544,546,548). The Arg3500SGln mutation has been
detected in several Caucasian populations and, depending on the
type of population studied, has been estimated to occur with a
frequency of 1/71-1/1322 (15,17,20,548-553), with the highest
prevalence reported recently in Germany. In Caucasians, most FDB
carriers have identical apoB haplotypes (526,544,554-557),
suggesting a common founder for the mutation. In the few FDB
carriers detected in other racial groups and one German patient,
haplotype analyses point towards recurrent new mutations
different from the Caucasian ancestor mutation (16,551,558,559).
Despite its frequency in other populations, the FDB mutation
seems to be absent from the Finns (32). Based on the distri-
bution of FDB carriers, the common haplotype of the mutation,
and knowledge of early human migrations, the original FDB
mutation has been suggested to have occurred in a common
ancestor living in Europe about 6750 years ago (560).
Recently, two other apoB mutations have been associated with an
FDB-like clinical disease. The first to be detected was the apoB
Arg3531SCys mutation (15); the second affected the same apoB
3500 codon but now with a substitution of Trp for Arg (16).
These mutations are more rare than the original FDB mutation.
Both have been shown to result in defective binding of LDL to
the LDLR and leading to hypercholesterolemia although it has
been suggested that the clinical disease produced by these
mutations is less severe than that produced by the Arg3500SGln
mutation (20,21,548). So far, the Arg3531SCys mutation has been
detected in 26 families, some of which are of Celtic origin and
share a unique haplotype, while others seem to have occurred
separately and are associated with four separate apoB haplotypes
(15,21,456,548,557,561). The Arg3500STrp mutation has so far
been detected in one Scottish and two German families and twelve
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subjects of Asian descent; haplotype analyses in the latter
point toward a common ancestor whereas the Scottish and the two
German mutations each seem to have occurred independently
(16,20,562,563).
All three hypercholesterolemia-producing apoB mutations are
located in the vicinity of the putative LDLR binding site. Thus
it is not surprising, that their effects on lipid metabolism are
similar and seem to involve the ability of apoB to act as a
ligand for the LDLR. Recently, several reports on methods to
detect all these apoB mutations easily in population samples
have been published (16,20,557,564-566). With these methods, the
relative importance of the new apoB variants in producing
hypercholesterolemia at the population level can be assessed.
2.5.2.2. ApoB mutations causing hypobetalipoproteinemia
In contrast with the few hypercholesterolemia-producing apoB
variants, several unique mutations associated with low
cholesterol levels and a disease entity termed familial
hypobetalipoproteinemia (FHBL) have been characterized (98).
Most of them lead to the production of apoB variants truncated
at different points of the peptide. A summary of mutations
reported to date to be associated with FHBL, distributed
throughout the apoB gene, is shown in Table 6. Usually, the
truncated apoB protein is present in plasma in very small
amounts in varying lipoprotein subclasses. Two mechanisms seem
to lead to this. Firstly, kinetic studies suggest that the
production of the truncated apoB is diminished (202,567-569),
with the secretion rate of truncated apoB directly related to
the size of the protein (567). In vitro studies suggest that the
low production of truncated apoB protein results from an
increased rate of cytoplasmic degradation of the mutant apoB
mRNA (570). Secondly, the clearance of lipoproteins containing
the abnormal apoB may be accelerated (202-204,571). A mouse
model for FHBL with an apoB 83-like truncated apoB suggests that
both mechanisms account for the low plasma levels of the
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abnormal apoB species (572). At the same time, the plasma
concentrations of full-length apoB-100 in FHBL patients is also
often reduced to a level which is less than half of that
expected from normal apoB allele production. This has been
attributed to both diminished production (573,574) and increased
catabolism (574) of apoB-100 in FHBL heterozygotes. Clinically,
heterozygous FHBL carriers manifest as asymptomatic subjects
with low (less than 50% of normal) plasma total and LDL
cholesterol levels. Compound FHBL heterozygotes (201,575,576)
and homozygotes (203,577-581) show varying signs, ranging from
fat malabsorption, liver and neurological abnormalities to
complete absence of symptoms. With a gene frequency of only
0.0001 in the general population, truncated apoB variants are
likely to explain only a minor part of persistent hypobeta-
lipoproteinemia, most cases being related to other causes, such
as the E3/E3 genotype (582). However, in normo- or hypo-
cholesterolemic healthy subjects, FHBL mutations are detected
more often, with reported mutation frequencies from 0.002 to
0.013 (98,583).
2.5.2.3. Neutral apoB mutations
Rare apoB variants not having any effect on lipid levels may be
termed neutral mutations. Many of these represent actual
polymorphisms. Silent mutations producing no amino acid change
are also likely to be neutral in terms of lipid effects
(21,561,562). In addition, for several of them, such as the
Phe1410SLeu, Glu2539SLys, Ala3094SThr, His3292SAsp, Lys3400SThr,
and Arg3480SPro mutations, data on lipid levels are either
totally lacking or otherwise too restricted to assess possible
associations with the DNA variant (565,584,585). Among the first
neutral apoB variants to be detected was the Arg4019STrp
mutation (apoB Hopkins), which did not associate with the
hyperlipidemic phenotype presented in the family in which the
mutation was detected (586). Another more studied neutral apoB
mutation is the Glu3405SGln mutation, which, although showing
changes in LDLR binding studies has not been associated with
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hyperlipidemia in family or population studies (20,561,587,588).
The Val3894SIle mutation, claimed to be associated with
hypocholesterolemia (585), has been described in a single family
including also one hypocholesterolemic non-carrier, pointing
towards a neutral effect of this mutation on serum cholesterol
levels. The Ser3252SGly, Ala3371SVal, Val3396SMet and
Ser3455SArg mutations seem either not to be associated with
hyperlipidemia or to influence the LDLR binding activity of apoB
(561,588).
2.6. Methods to detect DNA variations
2.6.1. Search for new variations
2.6.1.1. Southern blot hybridization
Restriction fragment length polymorphism (RFLP) analysis (589)
with either genomic DNA or cloned DNA from a liver cDNA library
(complementary DNA produced from liver mRNA) as the template,
and the Southern blot hybridization technique as the detection
method (590) was one of the earliest methods to detect apoB
variations. This method is based on digestion of the DNA sample
with a restriction endonuclease cutting the DNA strand at or
near a specific enzyme recognition site, electrophoretic
separation of the digested fragments, and detection of target
sequences by hybridization with sequence-specific probes labeled
with radioisotope, fluorescent, or chemiluminescent tags (591).
If the sequence recognized or the site cut by the enzyme is
altered by a mutation, the abolishment or creation of a new
restriction site results in a change in the length of the
digested fragments. Since most point mutations occur on sites
not harboring restriction sites, the Southern technique is now
rarely used in the search for new mutations. In direct assays of
gene structure, it remains a useful method for detecting large
deletions or gene rearrangements.
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2.6.1.2. Single-strand conformation polymorphism analysis
The polymerase chain reaction-based (592,593) single-strand
conformation polymorphism analysis (SSCP) method (594,595) is
one of the most widely used techniques to search for point
mutations, and it has been used with success in the search for
variants of the apoB gene as well (490,561,584,585). SSCP
analysis is based on the tendency of single-stranded DNA
molecules to adopt a specific three-dimensional conformation
that is uniquely dependent on their nucleotide sequence
composition under non-denaturing conditions. A change in a
single base may affect this conformation, resulting in an
altered electrophoretic migration pattern of the mutant DNA
strand in a non-denaturing polyacrylamide gel. SSCP has been
reported to be most sensitive when used to detect sequence
variation in PCR amplified DNA molecules 300 bp or less in size
(596). Due to constraints on the ability of small DNA fragments
to form stable secondary structures, there appears to be a lower
sizw limit (100 bp) as well (597). Within the optimal size range
of DNA fragments (200 bp), SSCP is sensitive enough to detect up
to 70-90% of single base substitutions (596). However, several
reports show succesful detection of mutations in much larger, up
to 700 bp, fragments, provided several differing electrophoresis
conditions such as temperature, buffer concentrations, gel
composition, running time and power are used (598-600). Besides
the size of the segment to be analyzed and electrophoretic
conditions used, the sensitivity of SSCP seems also to depend on
the sequence composition of the whole DNA fragment, whereas the
position and type of mutation seems to be of less importance
(597). In fact, base substitutions as close as 6 bp to the 3´
end of the amplification primer have been detected by SSCP
(601). As the conformation of RNA molecules is more stable than
that of single-stranded DNA, a modified SSCP procedure based of
the generation of a single-stranded RNA transcript has been
developed (602). In spite of its efficiency, leading to up to
95% detection of variations, this ssRNA-SSCP-method seems to be
too inconvenient for large scale SSCP screening. Most often,
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SSCP analyses are carried out using radioactive nucleotides in
the PCR and detecting the moving pattern of the fragment by
autoradiography. Alternatively, non-isotopic modifications such
as SSCP with silver or ethidium bromide staining (603,604), and
methods using fluorescence labeling and an automated DNA
sequencer (605,606) may be used. Among other modifications to
the classical SSCP protocol are restriction enzyme digestion of
large PCR fragments before SSCP (607,608), the use of multiplex
(609), allele-specific (610) or asymmetric (611) PCR products
for SSCP analysis, or dideoxy chain termination to localize the
approximate position of an SSCP variation in a sequence, a
method termed dideoxy fingerprinting (612). High throuhgput
modifications of SSCP for mutational analyses have also been
developed (596).
2.6.1.3. Denaturing gradient gel electrophoresis and temperature
gradient gel electrophoresis
Double-stranded DNA molecules are typically organized into high-
and low-melting domains. If a DNA molecule in solution is
subjected to an increasing temperature or concentration of
denaturant, such as urea or formamide, the low-temperature
melting domain will eventually become single-stranded. The
denaturing condition at which a domain melts is specific and
sequence-dependent, so that a single base-pair substitution may
alter the point at which the transition to the melted state
occurs. Transition of double-stranded DNA molecules into partly
dissociated strands leads to a decrease of their electrophoretic
mobility. These properties of DNA form the basis of both the
denaturing gradient gel electrophoresis (DGGE) method (613,614)
and the temperature gradient gel electrophoresis (TGGE)
techniques (615,616). Since the behaviour of a DNA fragment in
a denaturing gradient gel can be predicted from the base-pair
sequence (617), the melting characteristics of the fragment can
be altered by addition of a GC-rich sequence termed a GC-clamp
to the fragment (618,619). The sensitivity of DGGE can also be
enhanced with the use of heteroduplex DNA molecules between
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wildtype and mutant sequence, generated either during PCR
cycling of by mixing of PCR products, for the analysis
(620,621). DGGE is a reliable and sensitive method even if
relatively large DNA fragments, up to several hundred bp (621)
are studied, and has the advantage that mostly, non-radioactive
means for the detection of difference in the moving pattern can
be used. Thus, DGGE is being more and more used in screening
studies, either alone or combined with SSCP. DGGE has been
adapted to apoB gene mutation screening as well (16,21,457,562,
565,622,623). TGGE has been used less often: only two studies on
the use of TGGE in apoB gene screening have been published
(20,624).
2.6.1.4. Heteroduplex analysis
In addition to their differentation under denaturing conditions,
heteroduplex DNA molecules containing internal mismatches show
altered migration when compared with correctly matching
homoduplexes also in nondenaturing polyacrylamide gels
(625-627). Reported sensitivities of this heteroduplex analysis
(HA) method lie in the same range as SSCP (627,628). Both
isotopic and non-isotopic detection methods can be used for HA,
and, in addition, both SSCP and HA can be performed
simultaneously (627,629). A HA-based mutation detection protocol
has been described and used in apoB screening (456,542,564), and
has been suggested to be equally sensitive but more simple than
DGGE in the detection of the apoB Arg3500SGln mutation (623).
2.6.1.5. Other methods detecting DNA mismatches
Several mutation detection methods applying either chemical or
enzymatic modification of mismatched base pairs in heteroduplex
DNA strands have been developed. One of these is the chemical
cleavage of mismatch (CCM) method (630,631), which is based on
modification of mismathced bases by chemicals such as osmium
tetroxide or hydroxylamine, cleavage of the DNA at the modified
mismatch by piperidine, and electrophoretic detection of the
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cleavage products. CCM has the andvantage of a relatively low
size constraint in mutation scanning, being effective in
detecting mutations in PCR products up to 1.7 kb in length
(632). Three reports of apoB genetic screening with CCM have
been published (458,633,634), but in spite of its sensitivity,
CCM has not otherwise been used in large scale apoB mutation
screening studies. Among other techniques used in mismatch
detection are modification of mismatches with carbodiimide
(635,636), cleavage of mismatched bases between a wild-type RNA
probe and mutant DNA by RNaseA (637), and mismatch modification
or cleavage with bacterial mismatch repair proteins (638-640) or
bacteriophage resolvases (641,642). Neither of these latter
methods have been used in apoB mutation screening.
2.6.1.6. Direct sequencing
Compared with other mutation detection methods, sequence
analysis of DNA has the advantage of simultaneously detecting
and characterizing the location and nature of the DNA change.
DNA sequencing protocols used in most laboratories apply the
Sanger dideoxy chain termination method (643) and direct
sequencing of PCR products, but cloned templates derived from
genomic or amplified DNA have also been used as sequencing
templates. Several procedures for direct sequencing of double-
stranded PCR amplification products have been described (644).
To overcome problems associated with strand annealing in double-
stranded DNA sequencing, methods to produce single-stranded
templates have been developed. The method used in this thesis is
the solid-phase sequencing technique (645,646). In this method,
one of the amplification primers is biotinylated, leading to the
generation of a double-stranded amplification product with one
strand biotinylated. Taking advantage of the high affinity
between biotin and streptavidin, the PCR product can then be
captured on an avidin-coated solid phase, after which the non-
biotinylated strand can be melted and washed away, leaving the
biotinylated single-strand template immobilized on the solid
phase to be used for sequencing. Other modifications of this
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principle use the non-biotinylated (647) or both strands
(bidirectional solid-phase sequencing) (648) as the sequencing
template. Single-stranded sequence templates can also be
generated by other methods such as the asymmetric PCR technique
(649), the thermal asymmetric PCR technique (650), and by
exonuclease digestion of the PCR-product (651). Originally,
direct sequencing procedures required much manual work and were
therefore considered too labor intensive for large scale
mutation screening. Recent developments in the use of automation
and new fluorescence detection technology has greatly
facilitated the use of direct sequencing in these kinds of
studies (652). A semi-automated DNA mutation screening procedure
to detect genetic variants in the vicinity of the apoB
Arg3500SGln mutation has been presented (653).
2.6.2. Screening methods for known variants
2.6.2.1. Allele-specific oligonucleotide methods
Allele-specific oligonucleotides (ASO) are short nucleotide
probes complementary to a specific allelic sequence. When
hybridized with a DNA sample, they form stable duplexes only
with the allele containing the complementary sequence with no
mismatches. Mutation detection techniques based on ASOs are
particularly useful when the DNA variant in question does not
change restriction endonuclease sites. One of the most widely
used is the ASO hybridization technique (654,655), in which the
region surrounding the target DNA sequence is cloned or
amplified with PCR, the samples applied to a solid support which
is then hybridized with an oligonucleotide probe. Alternatively,
the DNA template can be scanned for several possible sequence
variants by studying its hybridization to an array of
immobilized probes (656). This method has been widely used in
the identification of the apoB Arg3500SGln mutation in both
population and family studies (14,15,17,32,402,534,544,549,
550,555,558,560,561,657-665), and it is still in use in some
research laboratories in the detection of other apoB variants
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(561,584). In addition to ASO hybridization, specific alleles
can also be distinguished through the generation of allele-
specific PCR products by using ASOs differing at their 3´ end as
primers that allow efficient amplification only if no mismatches
exist between the ASO primer and the DNA template. In the
literature, this type of method has been termed as allele-
specific PCR (ASPCR) (666), amplification refractory mutation
system (ARMS) (667), allele-specific amplification (ASA) (668),
or PCR amplification of specific alleles (PASA) (669). To
overcome problems associated with unspecific DNA amplification
in ASPCR, further modifications, such as the competitive oligo-
nucleotide priming (COP) and competitive blocker oligonucleotide
methods (670,671) have been developed. Some of these allele-
specific PCR methods have been adapted to mutation screening of
the apoB gene as well (672-676).
2.6.2.2. Restriction endonuclease recognition of mutant alleles
If a DNA variant changes the cutting or recognition site of a
restriction endonuclease, the presence of this specific
nucleotide change can be easily detected in PCR-amplified DNA
strands surrounding the enzyme cutting site by endonuclease
digestion and electrophoresis of the different-sized digestion
products in ordinary agarose or polyacrylamide gels (592). This
restriction fragment length polymorphism (RFLP) method is now
widely used in the genotyping for apoB RFLPs such as the XbaI
polymorphism (19,378,390,395,443,456,562,677,678), and the
Arg3500STrp (548,566) and Arg3531SCys (15) mutations. As a
modification of RFLP analysis, a method to artificially create
new restriction sites on PCR amplification products using
mutagenic PCR primers has been described (679-681), and has been
used to screen for the apoB Arg3500SGln (557,682-688),
Arg3531SCys (557), and Glu3405SGln (20) mutations.
2.6.2.3. Solid-phase minisequencing
The solid-phase minisequencing technique (689,690) is capable of
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recognizing basically any kind of nucleotide transitions. Like
solid-phase sequencing, this method is based on the generation
of a biotinylated single-stranded DNA template on a solid phase.
Thereafter, a sequence-specific oligonucleotide primer, termed
the detection primer, ending just 3´ to the nucleotide of
interest, is allowed to hybridize to the immobilized DNA strand,
and the detection primer is elongated by one nucleotide using a
DNA polymerase. In order to identify specific alleles, separate
extension reactions are performed so that each reaction contains
only the complementary, either radioactively or non-radio-
actively labeled, nucleotide of the sequence of interest. The
amount of nucleotide incorporation in each reaction reflects the
presence of the complementary nucleotide at the 3´-end of the
detection primer. The solid-phase minisequencing technique is
easy to perform even when large numbers of samples are analyzed,
and it has been succesfully used for mutation detection in
several types of study settings, ranging from hereditary
diseases to the analysis of mutations in solid tumors (690).
Compared with ASO hybridization, minisequencing takes advantage
of the specificity of the DNA polymerase to differentiate
between the mutant and normal nucleotides, whereas ASO
hybridization relies on the specificity of base pairing between
the probe and template. Thus, less stringent reaction conditions
in the minisequencing method are needed. A few reports on the
use of this method in detecting apoB genetic variants have been
published (691), but so far this method has not gained wide use
in lipid gene research.
2.6.2.4. Other methods
In principle, methods used in mutation scanning such as SSCP,
DGGE, TGGE, HA, or CCM, can be used in the screening of DNA
samples for known mutations as well. However, since these are
not capable of identifying specific nucleotide changes,
identical DNA movement patterns from differing mutations can
produce false results, and they are also not particularly
suitable for simultaneous screening of large numbers of samples.
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In spite of this, DGGE analysis has been adapted to
simultaneously screen for the apoB Arg3480SPro, Arg3500SGln,
Arg3500STrp and Arg3531SCys mutations (16,565), TGGE analysis in
the detection of Arg3500SGln, Arg3500STrp and Arg3531SCys
mutations (20), and HA analysis in the detection of the
Arg3500SGln and Arg3531SCys mutations (564). Among other, less
frequently used mutation identification methods are the
oligonucleotide ligation assay (OLA) (692) and the ligation
chain reaction (LCR) method (693,694). Recently, an automated
OLA-based screening procedure for simultaneous screening of
several LDLR mutations and the 3500 ArgSGln mutation has been
described (695).
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3. AIMS OF THE PRESENT STUDY
The general purpose of this series of studies was to search for
new variants in the apoB gene possibly causing moderate to
severe hyperlipidemias in the Finnish population.
The specific aims were:
1) To set up an SSCP-based mutation screening method to cover
the whole coding area of the apoB gene and to look for and
characterize new apoB variants in hyperlipidemic patients.
2) To evaluate the effects of new polymorphisms detected by
screening on serum lipid and lipoprotein levels in
hyperlipidemic families and patients, in the normal population,
in diet and drug intervention studies, and in patients
undergoing coronary angiography.
3) To evaluate the effects of the signal peptide ins/del,
Thr71SIle and Ala591SVal polymorphisms on serum lipid and
lipoprotein metabolism in normo- and hyperlipidemic study
populations.
4) To evaluate effects of an immunogenetic polymorphism of
apoB, detectable with mAb D7.2 and consisting of two apoB
genetic variants, Asn1887SSer and His1896SArg, on lipid and
lipoprotein levels during dietary intervention.
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4. SUBJECTS AND METHODS
4.1. Subjects
ApoB gene screening analyses, allele frequency estimations and
evaluation of lipid effects of detected genetic variants were
carried out in several different study materials summarized in
Table 7.
4.1.1. Kuopio district hypercholesterolemic subjects and
families (Groups 1a and 1)
Screening of the coding region of the apoB gene (exons 2 to 29)
for new variants by SSCP was carried out in twenty-nine
hypercholesterolemic subjects. These subjects were selected from
a group of ninety-two probands with primary non-FH
hypercholesterolemia identified in Kuopio province in connection
with a population-based study on familial aggregation of
hypercholesterolemia originally based on the FINNMONICA 1987
population risk factor survey (696). None of the 92 probands was
a carrier of the apoB Arg3500SGln mutation, but one subject was
a carrier of the FH-Helsinki and two were carriers of the FH-
Pohjois-Karjala mutation. These three subjects were included in
allele frequency estimations of new polymorphisms detected in
this study, but were excluded from final lipid and lipoprotein
calculations. The selection of probands to be screened with SSCP
was based on the lipid data of the families of the remaining 89
probands, leading to the selection of 29 subjects belonging to
families in which inherited hypercholesterolemia appeared most
likely. In addition to lipid data, DNA samples taken from family
members of the probands were used to confirm segregation of new
apoB variants. Besides SSCP screening, allele frequencies and
lipid effects of the apoB Val703SIle, Arg4243SThr, and
Ala4454SThr polymorphisms were analyzed in the whole group of 89
hypercholesterolemic non-FH subjects. In the following chapters,
the Kuopio district 29 probands will be referred to as Group 1a
and the whole group of 92 probands (which contains the subgroup
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1a) as Group 1. (I, II, IV, unpublished).
4.1.2. Non-FH hypercholesterolemic patients (Group 2)
ApoB gene exons 26 to 29 were screened for new variants in a
group of 39 patients with hyperlipidemia resembling classical
FH. In addition to the absence of major LDL-receptor gene
rearrangements and the FH-Helsinki, FH-North Karelia and apoB
Arg3500SGln mutations in the whole group, defects in either the
coding or proximal promoter area of the LDL-receptor gene had
been excluded in 31 of these patients (31). Allele frequencies
of the apoB Asn1887SSer and His1896SArg polymorphisms were also
assessed in this group. (II, unpublished).
4.1.3. Hypertriglyceridemic patients (Group 3)
DNA samples from 76 severely hypertriglyceridemic patients,
originally studied for the effects of LPL variants 291 AsnSSer
and 477 SerSTer on lipid metabolism (697), were subjected to
SSCP-screening for DNA variants in apoB gene exons 2 to 16 and
21. Both persistently (38 patients) and sporadically (38
patients) hypertriglyceridemic patients were studied, and since
the only exclusion criterion used was intravenous alimentation
at the time of the study, this group contained subjects with
secondary causes of hypertriglyceridemia as well. 10 of the
patients were carriers of the LPL 291 Ser, and 14 carriers of
the LPL 447 Ter allele. (IV).
4.1.4. Diet study participants (Group 4)
The identification and characterization of the mAb D7.2
polymorphism, located in the 5´ end of apoB exon 26, was carried
out in a group of 102 apparently healthy subjects who had
participated in three dietary intervention studies in North
Karelia, and belonged to identical intervention groups (442).
Serum and DNA samples were also available from family members of
the two study participants who showed the most marked shifts in
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their mAb D7.2 displacement curves. (III). DNA samples from the
102 diet study participants were also used to analyze allele
frequencies and lipid effects of the apoB Val703SIle (69
subjects), Arg4243SThr and Ala4454SThr polymorphisms (II,IV).
Previously published data from the same group concerning the
effects of the apoB Ag(c/g) and Ag(a1/d) polymorphisms were used
for comparisons in study IV. The dietary interventions carried
out in this group consisted of a 2-week baseline period, a 6- or
12-week intervention period during wich the diet was modified to
provide a low-fat, low-cholesterol content as well as a ratio of
polyunsaturated to saturated fatty acids approximating 1, and a
5- to 6-week switchback period. During the baseline and
switchback periods, the participants were on their normal free-
choice diets.
4.1.5. Random population sample of healthy subjects (Group 5)
Analyses of allele frequencies and lipid effects of apoB
polymorphisms Val703SIle, Arg4243SThr and Ala4454SThr were
carried out in a group of eighty-eight apparently healthy
subjects selected from a random sample of Finnish subjects born
in 1954 (698). (II, IV). Samples from a subgroup of twenty
subjects were analyzed to assess the allele frequency of the
silent polymorphism at the third base of apoB codon 2285 (I).
4.1.6. Drug intervention study participants (Group 6)
Effects of the apoB Arg4243SThr and Ala4454SThr polymorphisms on
serum lipid levels and their responses to antihyperlipidemic
medication were analyzed in 220 hypercholesterolemic patients
participating in two multicenter drug trials carried out at 19
centers in Southern and Eastern Finland (32,699). Both patients
with FH and other primary hypercholesterolemia were included.
The trials compared the effects of gemfibrozil (1200 mg/d) with
different daily doses of lovastatin (20 to 80 mg/d) in a double-
blind parallel study setting (32) and, as an extension, in an
open-label switch study setting with patients originally
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belonging to the gemfibrozil group in the parallel study (699).
(II).
4.1.7. Coronary angiography patients (Group 7)
Allele frequencies of the apoB Asn1887SSer and His1896SArg
polymorphisms and their effects on serum lipid and lipoprotein
levels were assessed in 327 Finnish patients undergoing coronary
angiography because of suspected ischaemic heart disease (700)
(unpublished). Coronary angiography verified CAD in 205 of these
patients, and 122 were free of CAD. In addition, effects of the
earlier known apoB immunogenetic variants, Ag(c/g) and Ag(a1/d)
on lipid levels were assessed in a group of 160 patients
collected from the same population of subjects undergoing
coronary angiography (IV). Of these subjects, 76 had
angiographically normal coronary arteries, and 84 were shown to
have CAD.
4.1.8. Normal voluntary controls (Group 8)
Allele frequencies and lipid effects of the apoB Asn1887SSer and
His1896SArg polymorphisms were assessed in a group of 72
voluntary subjects, who had contacted community health centers
for various reasons not related to CAD and who showed no
symptoms of ischemic heart disease or any ECG changes indicative
of CAD (701) (unpublished).
4.1.9. Subjects used as SSCP homogeneity controls
To verify the homogeneity of SSCP analyses carried out at
different time points, two DNA samples from apparently healthy
Finnish subjects were used as standards in each SSCP-run. For
the apoB polymorphism geno- or phenotypings, samples from
subjects with known geno- or phenotypes were used as controls.
In the case of a new apoB polymorphism, only control samples
perviously genotyped by DNA sequencing were used. In SSCP
analyses flanking the region coding for the apoB Arg3500SGln
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mutation, a DNA sample from a known FDB carrier (a gift from Dr
Stephen Humphries, University College London Medical School,
London, UK) was included.
4.2. Lipids, lipoproteins and apolipoproteins
All blood samples for lipid and lipoprotein analyses were drawn
after an overnight fast. Cholesterol and Tg determinations in
the whole plasma, serum, or lipoprotein fractions were carried
out by enzymatic methods using commercial kits (Boehringer
Mannheim, Germany) (702,703). LDL cholesterol concentrations
were calculated according to the Friedewald formula (704),
except for Groups 3, and 8, and severely hypertriglyceridemic (>
4.0 mmol/l) subjects in Groups 6 and 7, in which LDL cholesterol
concentrations were determined through isolation of the LDL
fraction by sequential ultracentrifugation (705). In Group 1
subjects with Tg > 4.0 mmol/l, the LDL fraction was isolated
using a combined preparative ultracentrifugation and
precipitation method (705,706). HDL cholesterol concentrations
were determined after precipitation of the VLDL and LDL
fractions by dextran sulphate - MgCl2 (706), except for Groups 3
and 8, where HDL concentrations were estimated after isolation
of the corresponding density fraction by sequential
ultracentrifugation, and Group 5, where precipitation with
heparin - MnCl2 was used for HDL isolation (707). ApoB
concentrations were determined by an immunoturbidic method based
on the immunoprecipitation of apoB in liquid phase (Orion
Diagnostica, Espoo, Finland) (Groups 1, 5, 6, 7, and 8) (708,
709), or by the radial immunodiffusion method (Behringwerke,
Marburg, Germany) (Groups 3 and 4) (710).
4.3. DNA analyses
4.3.1. DNA extraction
Genomic DNA was extracted from peripheral blood leukocytes by
phenol and chloroform extraction and ethanol precipitation
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(711), or directly by a rapid cell lysis procedure (Group 3)
(712).
4.3.2. Polymerase chain reactions and enzyme digestions
ApoB exons were amplified either as a whole (exons 2 to 25, 27,
and 28), or in six (exon 26), or three (exon 29) overlapping
fragments using oligonucleotides designed according to published
sequences (118) and presented in Table 8. All oligonucleotides
were synthesized using standard phosphoramidite chemistry (713)
by an Applied Biosystems DNA synthesizer model 392 (Foster City,
CA, USA) at the Institute of Biotechnology, University of
Helsinki, Finland. All amplification reactions were conducted in
an automatic Perkin Elmer/Cetus Thermal Cycler (Norwalk, CT,
USA) in a total volume of 50 µl with 50 ng of genomic DNA (or 5
µl of DNA mixture in samples extracted by rapid cell lysis), 50
pmol of each oligonucleotide used as primer, 0.5 µl of
deoxycytidine 5´-[?-32P]triphosphate (Amersham International,
Amersham, UK), 1.25 U of Taq DNA polymerase (Promega, Madison,
WI, USA) or Dynazyme DNA polymerase (Finnzymes, Espoo, Finland),
and nucleotides, amplification buffer and MgCl2 as specified by
the manufacturer. After an initial denaturation step of 95bC for
5 min, the PCR reaction was carried out using a cycle number,
and temperature and duration of denaturation, annealing and
elongation steps in accordance with the size of the fragment to
be amplified. Usually, 27 to 35 cycles of a denaturation step at
95bC for 30 to 60 s, an annealing step at 52-60bC for 30 to 60 s,
and an elongation step at 72bC for 45 s to 5 min were carried
out. Sometimes, two to three smaller exons were amplified in the
same multiplex PCR reaction in which case, in order to be able
to identify individual exons later in SSCP gels, control
reactions amplified with only one set of primers were included.
Prior to SSCP analysis, the 1190- to 1435-bp fragments of exon
26, and the 632- to 698-bp amplified fragments of exon 29 were
cut into smaller pieces with two (exon 26) or one (exon 29)
restriction enzymes (New England Biolabs, Beverly, ME, USA) in
reactions conducted in a volume of 30 µl at 37bC for 3 hr with 5-
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10 µl of the PCR amplification product, 10-15 U of each enzyme,
and the buffer recommended by the manufacturer. To identify the
different-sized digestion products of exon 26 fragments in the
SSCP gels, one sample was subjected to both simultaneous
digestion with both enzymes and to digestion with each enzyme
alone. Characteristics of the amplification products, the
enzymes used, their cutting sites, and sizes of digestion
products are listed in Table 9.
4.3.3. Single-strand conformation polymorphism analyses of apoB
exons 2 to 29
For the SSCP analysis, the amplification and digestion products
were diluted 1:5 with 10 mM EDTA and 0.1% SDS, and mixed 1:1
with 95% formamide, 0.05% bromphenol blue, and 0.05% xylene
cyanol. The samples were thereafter denatured at 80bC for 4 to 6
min, and 2-5 µl of each sample was applied to a vertical
polyacrylamide gel running apparatus (Bio-Rad Laboratories,
Richmond, CA, USA) for electrophoresis. Depending on the size of
the fragments to be analyzed, SSCP gels for each analysis were
electrophoresed with differing concentrations of polyacrylamide
(5 or 12%, 1:60 bisacrylamide:acrylamide, Bio-Rad Laboratories),
glycerol (0, 5 or 10%), or Tris-borate/EDTA buffer (0.5 or 1 ×),
differing running time (4 to 24 hr), power (10 to 50 W), and
temperature (+8 or +20bC). At least three, usually more differing
sets of electrophoresis conditions were used to achieve
satisfactory resolution of the amplification and digestion
products. Two or three samples with nondenatured DNA (size
control), two standard samples from apparently healthy subjects
(SSCP homogeneity control), as well as samples with individual
exon amplification products (multiplex PCR), or individual
endonuclease digestion products (exon 26 fragments) were
included in each analysis. After the run, gels were dried on
filter paper in a Bio-Rad vacuum gel dryer and exposed X-ray
film at -80bC for 1-5 days with an intensifying screen.
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4.3.4. Solid-phase sequencing
DNA fragments showing mobility shifts in SSCP analysis were
sequenced according to the direct solid-phase sequencing method
(646). DNA segments to be sequenced were amplified with a set of
primers of which one was biotinylated at its 5´ end. The
biotinylation of the primers was carried out using dC-biotin
phosphoramidite directly on the DNA synthesizer (714).
Amplification products were purified by letting 25 µl of the PCR
product bind for 1 hr to avidin-coated polystyrene particles
(Baxter Healthcare Corporation, Mundelein, IL, USA), washing the
particles twice with TENT buffer (40 mM Tris-HCL, 50 mM NaCl, 1
mM EDTA, 0.01% Tween 20), and denaturing the bound DNA strands
with NaOH (50 mM, 5 min). After two final washes, the single-
stranded avidin-bound DNA strand was sequenced by the Sanger
dideoxy termination method (643) using T7 DNA polymerase
(Sequenase version 2.0, United States Biochemical, Cleveland,
OH, USA), [?-35S]dATP (Amersham International), and 50 pmol of
the non-biotinylated PCR primer as the sequencing oligo-
nucleotide. Sequencing reactions were electrophoresed on a 6%
polyacrylamide/7 M urea gel, after which the gels were fixed,
dried, exposed to X-ray film, and manually analyzed. The oligo-
nucleotides used and characteristics of the PCR products for the
sequencing reactions to identify the SSCP shifts seen in apoB
gene exons 15, 18 and 27, in the 422-bp segment cut from the
second fragment of apoB exon 26 by BanI, the 501-bp fragment cut
from the same exon 26 fragment by EcoRI, the 400-bp segment in
the middle of the third fragment of exon 26, in the 5´ 246-bp
segment of fragment 29b, and in the 5´ 403-bp segment of
fragment 29c are shown in Table 10.
4.3.5. Solid-phase minisequencing
DNA changes not easily detectable by use of the PCR-RFLP
analysis were genotyped with the primer guided nuclotide
incorporated assay (689), carried out on streptavidin coated
microtiter wells using the solid-phase minisequencing method
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(690). Biotinylated PCR products were produced in amplification
reactions conducted in a volume of 50 µl with 200 ng of genomic
DNA, 20 pmol of the biotinylated primer, 100 pmol of the non-
biotinylated primer, 1.25 U of Dynazyme DNA polymerase
(Finnzymes), and with nucleotides and amplification buffer as
recommended by the manufacturer. After PCR, a 10 µl aliquot of
the PCR mixture was captured on microtiter wells (Streptavidin
Covalent ScintiStripsTM; Wallac Oy, Turku, Finland) with 40 µl of
buffer (0.15 M NaCl, 20 mM NaHPO4, 0.1% Tween 20 at pH 7.4) and
incubated for 1.5 h at 37bC. The bound PCR products were
thereafer denatured with 100 µl 50 mM NaOH for 5 min at 20bC, and
the wells washed 3-5 times at 20bC with 350 µl of a buffer
containing 40 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl, and 0.1% Tween
20 at pH 8.8. The minisequencing reaction was carried out by
addition of the detection step primer (20 pmol), the appropriate
3H dNTP (2 pmol) (Amersham International), and 0.5 U Dynazyme DNA
polymerase (Finnzymes) in 50 µl of a buffer containing 50mM KCl,
10 mM Tris-HCL, 0.1% Triton X-100, and 4 mM MgCl2 to the micro-
titration plate wells, and allowing the extension reaction to
proceed for 10 min at 50bC with gentle shaking. After this, the
wells were washed three times as described above, treated with
100 µl of 50 mM NaOH, and air-dried for 60 min at 20bC. The
quantity of the the 3H-labeled dNTPs incorporated was determined
thereafter in a Wallac MicroBetaTM scintillation counter. The
oligonucleotides used for the PCR and minisequencing reactions
and the labeled nucleotides for the wild-type and mutant alleles
for the A5869SG (Asn1887SSer), A5896SG (His1896SArg), G12937SC
(Arg4243SThr), and G13569SA (Ala4454SThr) changes are shown in
Table 10.
4.3.6. PCR-RFLP analyses
Several of the newly detected DNA variants as well as the
earlier known polymorphisms of apoB represent restriction
fragment length changes detectable with a specific endonuclease,
enabling rapid genotyping through PCR and enzyme digestion,
followed by ethidium-bromide-stained agarose gel electro-
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phoresis. In this study, genotyping for these RFLPs was carried
out from amplified DNA fragments flanking the DNA variant to be
studied in reactions conducted for 3 hr at 37bC in 30 µl with 10-
20 µl of the PCR mixture, 10-15 U of the enzyme in question, and
the buffers recommended by the manufacturer (New England
Biolabs). The presence or absence of a cutting site was
thereafter visualized in a ethidium bromide-stained 1-3% agarose
gel. Details of the PCR-RFLP analyses used in this study are
shown in Table 11.
4.3.7. Ins/del genotyping
Genotyping for the signal peptide ins/del polymorphism of the
apoB gene was carried out using PCR followed by electrophoresis
in a polyacrylamide gel (372,715). The primers used are shown in
Table 11. The PCR reaction was conducted in a total volume of 50
µl, with primer, DNA, nucleotide, buffer and polymerase
concentrations as described earlier, except for the addition of
10% dimethylsulphoxide, and with 50 cycles of denaturation at
94bC for 1 min and simultaneous annealing and extension at 65bC
for 1.5 min after the initial 6 min denaturation step at 94bC
(372,715). The amplification products were thereafter electro-
phoresed in 8% polyacrylamide gels at 90 V for 5 hr and
visualized by ethidium bromide staining.
4.3.8. Apo B 3´VNTR genotyping
To confirm segregation of newly detected apoB genetic variants
in family members of carriers, apoB 3´VNTR genotyping was
performed using denaturing polyacrylamide gel electrophoresis
(716), with primers as shown in Table 11, and an amplification
mixture identical to that of the SSCP-PCR mixtures. After
initial denaturation, 26 cycles with denaturation at 94bC for 1
min and simultaneous annealing and extension at 55bC for 7 min
followed. The amplified samples were diluted 1:1 with a mixture
containing 95% formamide, 20 mM EDTA, 0.05% bromphenol blue and
0.05% xylene cyanol, incubated at 72bC for 3 min and run on a
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denaturing polyacrylamide/7M urea gel at 75W and 48bC for 3.5 hr,
after which the gels were dried on filter paper and
autoradiographed.
4.4. Antibody binding assays
4.4.1. Ag phenotyping
Phenotyping for the apoB antigen polymorphisms Ag c/g, a1/d, x/y,
h/i and t/z in study Groups 4 and 7 (Study IV) was performed by
the passive hemagglutination inhibition technique (717,718).
This method is based on the inhibition of the anti-Ag serum
-induced hemagglutination of human erythrocytes coated with the
LDL to be studied by normal human sera. The human anti-Ag serum
was extracted from multiply transfused patients having developed
antibodies against epitopes of the foreign LDL particles
contained in the transfused blood preparations.
4.4.2. mAb D7.2 assays
A solid-phase enzyme-linked immunosorbent assay (419) was used
to detect the apoB mAb D7.2 polymorphism (Group 4, Study III).
This method detects the binding affinity of the LDL particles
studied to a specific mAb against LDL-apoB, and it has been used
also to detect the Ag(c/g) polymorphism (mAb 19) (419), and the
apoB Arg3500SGln mutation (mAb 47) (32). Briefly, the wells of
microtiter plates were coated with 150 µl of standard-LDL (1
µg/ml), and extra binding sites were saturated by incubation
with 3% albumin solution for 4 hr at room temperature. The mAb
D7.2 and increasing amounts of sample LDL were loaded to each
LDL-coated well and allowed to incubate for 4 hr at room
temperature, after which the wells were washed three times with
1% BSA-PBS followed by the addition of a second antibody
conjugated to alkaline phosphatase. The amount of antibody bound
was thereafter detected by spectrophotometry. The antibody D7.2
used for these analyses was a generous gift from Dr Gus
Schonfeld and Dr Elaine Krul (Lipid Research Center, Washington
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University, St. Louis, MO, USA.).
4.5. Statistical methods
Allele frequencies of apoB polymorphisms were estimated using
the gene counting method, and differences in the observed allele
frequencies between study populations were tested by m2 analysis
and Fisher's exact test (II, III, IV). These tests were also
used to estimate associations between the apoB Asn1887SSer and
His1896SArg polymorphisms and the mAb D7.2 polymorphism (III).
Other statistical analyses were carried out with the BMDP
statistical software package (BMDP Statistical Software Inc.,
Los Angeles, CA). The mean values of serum lipid and lipoprotein
levels between different genotypes were compared by analysis of
variance (ANOVA), repeated after adjustments for BMI (III), or
BMI and age (II and IV). In case of non-normal distribution,
logarithmically transformed values were used for comparison. If
statistically significant differences in sample variances
according to Levene's test were detected, Welch and Brown-
Forsythe statistics instead of ANOVA were used (IV).
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5. RESULTS
5.1. Screening for and characterization of apoB genetic variants
(I, II, IV, and unpublished)
The SSCP method was used to screen for new apoB variants in the
gene region encoding the apoB protein (exons 2 to 29),
consisting of 13911 nucleotides (Table 9). This was accomplished
through amplification of the small exons 2 to 25, 27 and 28 as
a whole, and the large exons 26 and 29 in six and three
overlapping fragments, respectively. Since the amplified
fragments of exons 26 and 29 were too large for SSCP analysis,
they were cut into smaller segments by restriction endonucleases
prior to the SSCP gel run. With this strategy, SSCP analysis of
altogether 50 amplified and digested segments of the apoB gene
ranging from 80 to 579 bp in size was carried out. Due to the
large size variation of the analyzed segments, several different
electrophoretic conditions were used. All DNA samples showing a
shift in the SSCP moving pattern were subjected to a second SSCP
analysis before further characterization. In some cases,
especially when SSCP shifts in the largest segments were
detected, additional SSCP analyses, using another set of primers
flanking the suspected area, and another restriction
endonuclease were performed. The DNA change behind each shift
was identified by direct sequencing of the segment in question.
After identification, detection of new variants in families and
population samples was carried out either by SSCP, direct
sequencing, PCR-RFLP, or solid-phase minisequencing. Available
samples from family members of carriers of the new DNA changes
were used to confirm segregation in families as well as
cosegregation with the apoB 3´VNTR. Identical DNA variants
detected in two or more unrelated SSCP-screened subjects were
suspected to represent apoB polymorphisms, in which case,
especially if family data suggested lipid effects, their
occurrence and allele frequencies were further assessed in
Finnish normo- and hyperlipidemic population samples.
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SSCP screening of the whole apoB gene coding area (exons 2 to
29) was carried out in a group of twenty-nine moderately
hypercholesterolemic probands selected from a sample of 92
hypercholesterolemic families identified in the Kuopio district
(Group 1a). In addition, apoB gene exons 26 to 29 were screened
in a group of thirty-nine patients with severe
hypercholesterolemia resembling FH, in whom both major Finnish
LDLR gene mutations and the apoB Arg3500SGln mutation had been
excluded (Group 2). By choosing exons 26 to 29 for screening in
this material, we aimed at covering apoB regions possibly
contributing to the LDL-LDLR interactions, including sites
located apart from the actual LDLR binding site, such as the
carboxyl-terminal region of apoB (185,197). In severely
hypertriglyceridemic patients (Group 3), SSCP screening was
carried out in apoB gene exons 2 to 16 and 21, containing the
apoB domain interacting specifically with LPL (240).
Since apoB is known to be a highly polymorphic protein, several
SSCP moving pattern shifts were anticipated. All previously
known common apoB genetic variants situated in the regions
included in our analyses were detected and could be easily
genotyped in the SSCP gels. The SSCP-based genotyping of these
apoB polymorphisms was verified through additional PCR-RFLP
analyses (ApaLI, AluI, XbaI, BfaI, MspI, and EcoRI). In
addition, twelve new apoB variants, located in exons 15, 18, 26,
27 and 29, were detected. In the following, these new apoB
variants will be presented according to their order in the 5´ to
3´ direction of the gene. All new apoB variants are also shown
in Table 4.
In the hypertriglyceridemic patients (Group 3), analysis of apoB
gene exon 15 revealed one subject with an SSCP-shift resulting
from a GSA change at cDNA nucleotide 2316, changing codon 703
from GTC to ATC, and generating a ValSIle change in the mature
apoB protein. Further studies in Kuopio district probands (Group
1) led to the identification of seven more carriers of this apoB
Val703SIle change. Family studies confirmed the segregation of
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this variant in each family, with the cosegregation of the 703
Ile allele with the apoB 3´VNTR allele 45. Allele frequency
analyses in the Kuopio district hypercholesterolemic patients
(Group 1, n=78), in the diet study participants (Group 4, n=69),
and in the random sample of healthy Finns (Group 5, n=83),
confirmed the polymorphic nature of the apoB Val703SIle change
with frequencies of the 703 Ile allele of 0.045, 0.036 and 0.048
in these populations, respectively (differences not
significant). Compared with the other studied groups, the 703
Ile allele in the hypertriglyceridemic patients (Group 3) was
slightly but not significantly underrepresentated (one carrier
in 76 patients, allele frequency 0.007). During the course of
this study, this Val703SIle variant has also been detected in a
family with hypobetalipoproteinemia, not however cosegregating
with the FHBL phenotype (719). (IV)
Three Kuopio district Group 1a probands showed a shift in the
SSCP analysis of apoB exon 18. In the families of these
probands, the shift cosegregated with apoB 3´ VNTR allele 49.
The DNA change producing this shift results from a CST change in
the third nucleotide of apoB codon 875 (AACSAAT), with no change
in the amino acid sequence of apoB (apoB Asn875SAsn), and with
no effect on the lipid phenotype in the studied families. No
further studies to determine its allele frequency in the Finnish
population were therefore carried out. During the course of this
study, this apoB polymorphism was also reported in a French
population of thirty-five apoB 3´VNTR allele 49 carriers, with
a rare allele frequency of 0.032 and a weak association with the
3´VNTR 49 allele (584). (Unpublished).
Exon 26 contains the region coding for all three FDB-producing
apoB mutations, the Arg3500SGln (14), Arg3500STrp (16), and
Arg3531SCys (15) mutation. With this in mind, this region was
especially carefully analyzed in both the moderately as well as
the severely hypercholesterolemic patient groups (Groups 1a and
2). In spite of the readily identified mobility shift in the DNA
sample from a known 3500 Gln carrier, no similar or other
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mobility shifts in this region were detected in our SSCP
analyses. Instead, four other apoB genetic variants were
detected in exon 26. Of these, the ASG changes at cDNA
nucleotides 5869 and 5896, leading to Asn1887SSer and
His1896SArg changes, respectively, are more thoroughly
characterized in connection with their association with the
newly described mAb D7.2 polymorphism later in this section. The
detection of a mobility shift between nucleotides 6506 and 7007
(the 3´ end of fragment 26b cut with EcoRI) in one Group 2
severely hypercholesterolemic proband led to the identification
of a new apoB mutation, a deletion of nucleotides 6766-6768.
This ATG deletion removes the second and third bases of codon
2186 (Asp) and the first of 2187 (Glu), leading to a frameshift
which generates a GAG codon, produces a Glu residue at the site
of the deletion, and deletes the Asp 2186. The segregation of
this apoB del Asp 2186 variant in family members was confirmed,
yet with no clear effects on the lipid phenotype. The fourth DNA
variant detected in exon 26 was a TSC change in the third base
of codon 2285 (GATSGAC) at cDNA nucleotide 7064, with no change
in the amino acid sequence of apoB (apoB Asp2285SAsp). This
T7064SC change is also detectable with MaeII (113). Genotyped
with SSCP, the apoB T7064SC polymorphism was shown to be closely
linked with the XbaI RFLP, with the 7064 C allele occurring in
conjunction with the XbaI- allele. The allele frequency of the
C allele was similar to the XbaI- allele in both hyper-
cholesterolemic patients (Group 1a) and a subgroup of 20 healthy
subjects from Group 5 (0.500 and 0.525, respectively). (I,II).
Exon 27 analysis revealed an ASG change at cDNA nucleotide
11961, leading to a Thr3918SAla (ACTSGCT) variation. This
variant was found in one hypercholesterolemic Group 2 patient.
Additional DNA was available from only the proband´s sister,
who, although severely hypercholesterolemic, had not inherited
this apoB mutation. Thus, this variant was considered unlikely
to be the cause of the FH-like hypercholesterolemia in this
family, and no further attempts to identify more carriers were
considered necessary. This apoB variant has also been documented
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in the French population 3´VNTR allele 49 carriers with an
allele frequency of the 3918 Ala allele of 0.006 and linkage
disequilibrium with the 3´VNTR 49 allele (584). No lipid data
from this study population have been reported. (II).
SSCP analysis of apoB exon 29 revealed three moving pattern
changes. A complex change in the 5´ end of fragment 29b was
shown to be the result of three closely located DNA changes at
nucleotides 12922, 12935, and 12937. The nucleotide 12922 TSC
substitution produces a Val4238SAla (GTASGCA) change. It was
detected in two normocholesterolemic subjects (control samples),
of which no family data was available, and was thus not further
characterized. The second change, a TSC substitution at
nucleotide 12935, is silent at the protein level (Tyr4242STyr,
TATSTAC), but produces a new RsaI cutting site at nucleotide
12933. The segregtion of this variant was followed in five
families (both hyper- and normocholesterolemic), with no clear
effects on the lipid phenotype, and no further attempts to
assess the allele frequency of the RsaI+ allele in other Finnish
populations were carried out. The third component of this
polymorphic area was a GSC change resulting in an Arg4243SThr
variation. Its segregation was followed in five hyper-
cholesterolemic families (Group 1a), in which the 4243 Thr
allele was shown to cosegregate with 3´VNTR alleles 47 or 49,
but again, no clear effects on the lipid phenotype were
detected. Studies in other Finnish populations (Groups 1, 4, 5,
and 6) revealed an allele frequency of the 4243 Thr allele of
0.017, 0.034, 0.028 and 0.047, respectively, with no
statistically significant differences between these populations.
Ag haplotyping analyses in Group 4 revealed no association of
the 4243 Thr allele with any common Ag haplotype. (II).
SSCP analysis in four Kuopio district Group 1a patients showed
a mobility shift in the 5´ half of segment 29c. It was produced
by a GSA change at nucleotide 13569 resulting in an Ala4454SThr
(GCCSACC) variation. Later on, its segregation was followed in
eight families, showing cosegregation of the 4454 Thr allele
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with 3´VNTR allele 35. In other Finnish population samples
(Groups 1, 4, 5 and 6), this polymorphism was detected with an
allele frequency of the 4454 Thr allele of 0.022, 0.020, 0.017
and 0.022, respectively (no differences between different
populations). Ag haplotyping and 3´VNTR analyses in Group 4
showed an association between the apoB Ag haplotype xa1gti and,
as in families, 3´VNTR allele 35. This same apoB variant has
been detected in the French population with an allele frequency
of the 4454 Thr allele of 0.039 (584). In the French subjects,
the 4454 Thr allele seems not to associate with the apoB 3´VNTR
49 allele. (II).
Two hypercholesterolemic Group 2 patients showed a SSCP shift in
the 3´ half of fragment 29c. This shift resides in the non-
coding area of exon 29, and it cannot affect the amino acid
sequence of apoB. While DNA changes in non-coding regions of
exons can have some effect on gene expression and are in
principle of interest, this SSCP shift did not seem to associate
with lipid parameters in the families of these probands and was
thus not further characterized. (II).
5.2. Identification and characterization of the apoB D7.2 Ag
polymorphism (III)
In connection with analyses of lipid and lipoprotein responses
to changes in diet in the apparently healthy diet study group
(Group 4), LDL samples were tested for apoB variants with a
panel of mAbs. In 18 of the 102 subjects tested, a marked shift
to the right of displacement curves against mAb D7.2 was
detected. In two individuals, this change in binding affinity
was clearly stronger than in the remaining 16. Some of the
family members of these subjects showed similar shifts in mAb
D7.2 displacement curves, suggesting a genetic basis for the
changes in binding affinity. However, the observed changes in
families were too complex to be the result of a common biallelic
apoB genetic variant.
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The epitope of mAb D7.2 lies between apoB amino acids 1878 and
2148 (201). The availability of the SSCP-based mutation
detection system covering the DNA region coding for the mAb D7.2
epitope offered us a possibility to explore the DNA change
causing the changes observed in the Ag binding assays. SSCP
analysis of the 5´ end of fragment 26b showed a complex mobility
shift suggesting either a three-allelic polymorphism or two
closely located mutations. DNA sequencing revealed two ASG
transitions at cDNA nucleotides 5869 and 5896, leading to
Asn1887SSer (AATSAGT) and His1896SArg (CATSCGT) changes. The two
subjects expressing the most marked shifts in their mAb D7.2
displacement curves were shown to be doubly heterozygous for
both DNA variants. Family data collected from relatives of these
two subjects confirmed the segregation of the DNA variants as
well as a relatioship between the DNA variation and the binding
affinity of LDL apoB with mAb D7.2.
Genotyping of other participants of the diet study (Group 4) was
carried out by the PCR-RFLP technique. The A5896SG change
removes a normal BsrDI cutting site at nucleotide 5863, whereas
the A5896SG change produces a new RsaI cutting site at
nucleotide 5897. Compared with binding assay data, subjects
homozygous for both common alleles of these polymorphisms
usually showed normal immunoreactivity with mAb D7.2. All
subjects heterozygous for the 1887 Ser allele showed reduced
binding irrespective of their apoB 1896 genotype. However, only
11 of the 18 subjects carrying the 1896 Arg allele and
homozygous for the 1887 Asn allele showed detectable shifts in
the displacement curves, suggesting a less severe effect of the
1896 His allele on the mAb D7.2 epitope. Since the displacement
curves from the compound heterozygotes were shifted even more to
the right than those from 1887 Ser heterozygotes alone, an
additive effect of both polymorphisms on the immunoreactivity of
LDL with mAb D7.2 is suggested. Genotyping data from Group 4
subjects showed no further association between the two
polymorphisms, and family data indicated that they were not
inherited in the same apoB allele. Ag phenotyping, 3´VNTR, and
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XbaI RFLP genotyping of the new polymorphisms showed association
of the 1896 Arg allele with the xa1gti-3´VNTR 35-X- (XbaI-
allele) haplotype in the diet study participants, and with the
3´VNTR 35-X- allele in families. With regard to the 1887 Ser
allele, no common haplotype was shared by the carriers. In
families, the 1887 Ser allele cosegregated with 3´VNTR alleles
33 and 37.
Allele frequency estimations carried out in Group 4 and other
Finnish population samples (Groups 1a, 2, 7, 8) after either
PCR-RFLP or solid-phase minisequencing genotyping showed similar
frequencies for the rare alleles of both polymorphisms. For the
Asn1887SSer polymorphism, an allele frequency of the Ser allele
in Groups 1a, 2, 4, 7 and 8 of 0.034, 0.013, 0.025, 0.035 and
0.011, respectively, was estimated. The observed allele
frequency differences were not statistically significant, nor
were differences between the allele frequencies detected in
Group 7 subjects irrespectively whether they had (0.037) or had
not (0.027) angiographically documented CAD. In accordance with
our studies in the Finnish population, similar allele
frequencies of the 1887 Ser allele have also been detected in
both a French population of apoB 3´VNTR allele 49 carriers
(0.032) (584), in French hypercholesterolemic subjects (0.053)
(720), and a Norwegian population of hypercholesterolemic
patients (0.024) (585). As for the His1896SArg polymorphism,
estimated Arg allele frequencies in Groups 1a, 2, 4, 7 and 8
were 0.034, 0.051, 0.110, 0.043 and 0.062, respectively. The
allele frequency differences between these groups were not
statistically significant except for the diet study (Group 4)
and coronary angiography subjects (Group 7), between which the
difference in observed allele frequencies became significant
(p=0.0014, Fisher's excact test). Further analysis of Group 7
showed that this allele frequency difference was confined to
patients with CAD (allele frequency 0.034, difference compared
with Group 4 significant, p=0.0006), whereas those with angio-
graphically normal coronary arteries had a 1896 Arg allele
frequency (0.058) similar to and not statistically significantly
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different from the other groups. In addition to the Finns, the
His1896SArg polymorphism has also been detected in Norwegian and
French hypercholesterolemics with an allele frequency of 0.024
in both populations (585,720).
5.3. Lipid and lipoprotein effects of the new apoB variants in
exons 26 to 29 in Finnish populations (II, III, unpublished)
Lipid and lipoprotein effects of the Asn1887SSer and His1896SArg
polymorphisms were assessed in the diet study participants
(Group 4), in the patients undergoing coronary angiography
(Group 7, unpublished results), and a group of healthy subjects
free of symptoms or signs of CAD (Group 8, unpublished results).
Due to the low number of 1887 Ser allele carriers in women of
all these groups, and in the healthy men (Group 8) statistical
calculations were restricted to Group 4 and 7 men only. As shown
in Tables 12 and 13, the Asn1887SSer polymorphism did not show
significant effects on baseline serum lipid and lipoprotein
levels or their responses to dietary change in these subjects.
Due to the low number of subjects heterozygous for the 1887 Ser
allele, a moderate effect of this allele on serum lipid or
lipoprotein concentrations cannot, however, be totally ruled
out.
Effects of the His1896SArg polymorphism on serum lipid and
lipoprotein levels were estimated in both male and female
subjects of Groups 4, 7 and 8. Results of these analyses are
summarized in Tables 14 to 17. In the diet study, no differences
in baseline or swithcback lipid or lipoprotein levels between
the apoB His1896SArg genotypes could be observed in either sex
(Tables 14 and 15). During the diet intervention, men carrying
the 1896 Arg allele tended to exhibit slightly higher serum
total (p=0.0792), LDL cholesterol (p=0.0494), and apoB levels
(p=0.0814), leading to smaller increases in total and LDL
cholesterol and apoB levels when changing back from the
intervention to the original diet. Higher serum total and LDL
cholesterol levels were also observed in carriers of the apoB
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1896 Arg allele when male Group 7 subjects with no signs of
angiographic CAD were studied (Table 16). No differences between
His1896SArg genotypes were observed in Group 7 men with CAD or
Group 8 healthy men. In Group 4, 7 and 8 women, no significant
differences between genotypes were detected (Table 17).
Lipid and lipoprotein effects of the apoB Arg4243SThr and
Ala4454SThr polymorphisms were assessed in the 89 Kuopio
district hypercholesterolemic subjects (Group 1), the diet study
subjects (Group 4), the healthy population sample (Group 5), and
in the drug intervention participants (Group 6). Results in
males and females were similar. Therefore, combined results for
both sexes are presented (Tables 18 and 19). Allele frequencies
of the rare Thr alleles of both polymorphisms were low, and in
general, no statistically significant effects on either baseline
lipid levels, diet responses or responses to drug intervention
could be detected. In Groups 4 and 5, initial analyses of the
lipid effects of the Ala4454SThr polymorphism seemed to show
significant differences. These differences were however towards
opposite directions, and lost significance after repeated
calculations. More precisely, in Group 5, 4454 Thr carriers
exhibited slightly higher LDL cholesterol levels compared to
4454 Ala homozygotes (Table 19). In this group, all 4454 Thr
carriers were men, and when calculations were repeated after
exclusion of women and after adjusting for BMI, this difference
was no longer significant (p=0.0679). Group 4 included only one
female 4454 Thr carrier. Analyses of the male subjects in this
group (three 4454 Thr carriers) suggested a baseline LDL
cholesterol lowering effect of the rare Thr allele (4.97±1.07
and 3.59±0.57 mmol/l for the Ala/Ala and Ala/Thr genotypes,
respectively, p=0.0335). In repeated calculations adjusted for
age and BMI, this difference between genotypes was no longer
statistically significant (p=0.0555). Based on these
calculations, our conclusion was that this polymorphism is not
likely to be a major determinant of LDL cholesterol levels. As
mentioned earlier, no associations with the lipid phenotype and
the carrier status for the apoB Arg4243SThr or Ala4454SVal
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variants in the small number of families available for study
were seen.
Of the other DNA variants in apoB exons 26 to 29, the del 2186
Asp, Thr3918SAla, Val4238SAla, the silent Tyr4242STyr mutation,
and the non-characterized apoB variant in the non-coding region
of exon 29, were either detected in normocholesterolemic
subjects or were not associated with the lipid phenotype in the
families of the mutation carriers. Thus, no further attempts to
characterize their possible lipid or lipoprotein effects at the
population level were carried out. In view of the close
connection of the new silent Asp2285SAsp polymorphism with the
well known and widely studied apoB XbaI polymorphism, no
additional information regarding its associations with lipids or
lipoproteins was anticipated. Therefore, no population studies
conserning the effects of this polymorphism were performed.
5.4. Lipid and lipoprotein effects of the apoB variants in the
amino-terminal region of apoB in Finnish populations (IV)
Since the Val703SIle change was originally detected in only one
severly hypertriglyceridemic Group 3 patient, an analysis of its
lipid or lipoprotein effects in this group was not possible.
Instead, the effects of the 703 Ile allele were assessed in
Kuopio district hypercholesterolemic probands (Group 1), the
diet study population (Group 4), and in the random sample of
healthy subjects (Group 5). A summary of these results is shown
in Table 20, both sexes combined. In Groups 1 and 4, no lipid
effects of the 703 Ile allele could be detected. In Group 5,
lipid and lipoprotein analyses showed an association between
lower serum Tg levels and the 703 Ile allele. This effect was
more pronounced in males (1.41±0.31 and 0.83±0.16 mmol/l for the
33 Val/Val homozygotes and the 4 Val/Ile heterozygotes,
respectively, p=0.0040); in females, the difference was not
significant (0.84±0.43 and 0.67±0.21 mmol/l, p=0.4837). Although
larger population samples would be needed to confirm this
finding, both the association detected in Group 5 and the slight
94
underrepresentation of the apoB 703 Ile allele in severely
hypertriglyceridemic Group 3 patients could point towards a
triglyceride-lowering effect of this allele.
With the recently proposed hypothesis of a specific function for
the globular apoB amino-terminal domain in the interactions
between LPL and lipoproteins (240), we were interested in
studying whether any lipid or lipoprotein effects of previously
known apoB polymorphisms situated in this region, the Thr71SIle
and Ala591SVal, could be seen in severely hypertriglyceridemic
patients. Since the apoB signal peptide ins/del polymorphism is
known to be in close linkage disequilibrium with the Thr71SIle
polymorphism (398), genotyping of the ins/del polymorphism was
included in the study of hypertriglyceridemic patients. For
comparison, lipid and lipoprotein effects of the Thr71SIle and
Ala591SVal polymorphisms were additionally analyzed in both the
diet study population (Group 4) and in subjects undergoing
coronary angiography (Group 7). A summary of these analyses is
shown in Tables 21 to 23, both sexes combined.
Results from the lipid and lipoprotein analyses in the
hypertriglyceridemic patients (Table 21) showed that the 591 Ala
allele was associated with higher serum apoB levels in both
sexes, remaining statistically significant even after adjusting
for age and BMI (p=0.0113, Figure 4.). The 71 Ile allele showed
a non-significant trend in the same direction, and a similar
trend was also detected for the signal peptide del allele. By
combining the subjects with at least one of both alleles
associated with elevated apoB levels, in other words, those
homozygous or heterozygous for both rare alleles (apoB 71 Ile +
and 591 Ala +; apoB 1.56 ± 0.44 mg/ml, n=35) and comparing them
with those homozygous for both common alleles (apoB 71 Thr/Thr
and 591 Val/Val; apoB 1.18 ± 0.46 mg/ml, n=20), results showed
significantly higher apoB levels in the group consisting of
carriers of the "apoB-elevating" alleles (p=0.0044 after
adjustment for age and BMI). To analyse the effects of these
"apoB-elevating" alleles in normolipidemic populations, similar
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comparisons were made in the diet study and the coronary
angiography populations (Groups 4 and 7). In Group 4, no
significant effects on baseline lipid and lipoprotein levels of
either polymorphism, whether alone or combined were detected
(Table 22). The slight triglyceride-lowering effect of the 71
Ile allele in this group did not remain statistically
significant when adjusted for age and BMI (p=0.0836 for the
whole group, p=0.3964 and 0.0904 for males and females,
respectively). Likewise, no differences in lipid and lipoprotein
levels between genotypes of either polymorphism in Group 7 were
detected (Table 23), regardless of whether the whole group or
subjects with or without CAD were studied (data not shown).
However, when hypertriglyceridemic (serum Tg A2.00 mmol/l) Group
7 subjects alone were analyzed, men with the 591 Ala/Ala
genotype showed significantly higher (p=0.0154 after age and BMI
adjustment) apoB concentrations (1.27 ± 0.20 mg/ml, n=9) when
compared with the 591 Val/Ala or Val/Val men (apoB 1.01 ± 0.17
mg/ml, n=11; apoB 1.07 ± 0.20, n=10, respectively). When divided
into hypertriglyceridemic men with or without CAD, this apoB-
elevating effect of the 591 Ala allele was still significant in
men with CAD (n=22, p=0.0464 after age and BMI adjustment). In
males with healthy coronary arteries, this trend was no longer
significant (n=8, p=0.1559). Unfortunately, the number of
subjects with serum Tg level A 2.00 mmol/l in Group 4 was too
low for meaningful comparisons. Nevertheless, the results
obtained in other groups could point towards an apoB-elevating
role of the 71 Ile and 591 Ala alleles (or their combination),
expressed only in context of hypertriglyceridemia.
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6. DISCUSSION
6.1. Evaluation of the mutation screening methodology
Of the mutation detection methods, both SSCP, DGGE (457,622),
TGGE (20) and HA (456,542) have been successfully used to screen
and detect apoB variants; most studies have applied SSCP
(490,561,584,585). Of the new apoB mutations associated with
defective binding of LDL apoB to the LDLR, the Arg3531SCys
variant was originally detected by SSCP (15), and the
Arg3500STrp by DGGE screening (16). A recent SSCP analysis-based
study (561) detected seven variations in the sequence
surrounding the putative receptor binding domain of apoB. When
DGGE, SSCP and HA were compared, DGGE was found to be the most
reliable and HA the simplest method of the three for the
detection and distinction between the three apoB FDB mutations
(623). Developments in technical equipments, with the arrival of
systems capable of casting both nondenaturing SSCP and the more
demanding DGGE gels will probably result in a shift of the apoB
mutation screening methods towards DGGE or a combination of
different techniques.
The SSCP technique was chosen for our apoB screening studies
because we wanted to screen large regions of the apoB gene in a
relatively easy and reproducible way within a reasonable time
scale. The ability to analyze several fragments at the same time
by the use of restriction endonucleases or the multiplex PCR
technique was regarded as an advantage. Some of the DNA
fragments in our SSCP analyses were much larger than currently
considered optimal. Thus, efforts were focussed on achievment of
maximal resolution of the fragments through analysis under
several differing SSCP conditions as well as repetition of the
SSCP analyses either after additional PCR reactions covering
smaller regions of the gene or after other restriction
endonuclease digestions when a mobility shift in the original
SSCP gels was suspected.
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With our SSCP protocol, all the previously known common apoB
variants situated in the exonic regions screened were easily
identifiable, as was the Arg3500SGln mutation in the FDB-
positive control sample. In addition, altogether twelve new
variants were detected, some of which resulted from complex DNA
variations located very close to each other and were still
distinguishable in the SSCP gels. In spite of this, the
existence of yet more DNA variations, in particular in the
largest fragments, not detected by us cannot be excluded.
6.2. Rationale for the apoB screening strategy
For long, the putative apoB LDLR binding domain was suggested to
be located between two short apoB segments that contain clusters
of positively charged amino acids and include amino acids 3147-
3157 and 3359-3367, with a disulphide bridge between cysteines
3167 and 3297 bringing these clusters close to each other (158).
Recent studies with transgenic mice expressing mutant forms of
apoB have delineated the actual receptor binding site to amino
acids 3359-3369 (197). Several lines of evidence indicate, that
other regions of apoB surrounding this "core domain" are also
involved in the receptor binding function of apoB. These studies
include work using anti-apoB mAbs wich block binding of LDL to
the LDLR, studies using chemically modified LDL, and studies
with naturally occurring truncated apoB variants. Thus, a domain
of apoB between amino acids 2285 and 4189 has been implicated to
be involved in LDLR binding (179,180). The carboxyl-terminal
domain of apoB has been suggested to play a negative regulatory
role in this function (185,197). Therefore, to cover the domains
of apoB possibly involved in either LDL binding to the LDLR or
in its regulation, practically the whole 3´ two-thirds of the
gene should be considered to be screened. The search for
hypercholesterolemia-producing apoB mutations has so far largely
concentrated on the LDLR binding region of apoB
(490,561,622,633), and only few studies have spanned the
screened area to other parts of the gene (457,584). In the
studies presented in this thesis, the screening system for apoB
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variants in hypercholesterolemic subjects was extended to exons
26 to 29 including amino acids 1384-4536.
The globular amino-terminal domain of apoB (amino acids 1-1000)
has recently been suggested to play several differing roles in
lipoprotein metabolism. Among these is an interaction between
LPL and apoB-containing lipoproteins, taking place either in the
circulation or at the vessel wall. In vitro data have shown that
LPL associates with LDL and VLDL through specific protein-
protein interactions involving the amino-terminal end of apoB
(240). A protein shownt to be comprised of the amino terminus of
apoB has been extracted from vascular endothelial cells and has
been shown to affect the binding of LPL to vascular endothelium
in vitro (237). ApoB expression has also been detected in
vascular endothelial cells (120). While the biological relevance
of these findings is still unknown, it is tempting to
hypothesize, that a defect in the binding of LPL to apoB-
containing lipoproteins, either in the circulation or in the
tissue vasculature, could affect the effectiveness of LPL
mediated Tg hydrolysis. In addition, expression of an apoB
terminal fragment in vascular endothelium, if confirmed in vivo,
could suggest a new function for the apoB protein in the
trapping of LPL to arterial vasculature and the development of
atherosclerosis not connected with the lipid carrier ability of
apoB. In this thesis, an attempt to test the first hypothesis
was made by looking for new variants and studying the effects of
already known variants in this region of apoB in severely
hypertriglyceridemic patients. The choice of exons (2 to 16 and
21) to be screened in this material was based on the original
findings delineating the LPL-associating domain of apoB (240).
Based on the above delineated apoB functional regions, three
different types of screening studies were carried out. Firstly,
DNA variants in the region coding for the LDLR binding domain of
apoB were looked for in hypercholesterolemic subjects. Two types
of results were aimed at: either the detection of a Finnish FDB-
producing mutation, most likely to be found in severely
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hypercholesterolemic patients (Group 2), or a common apoB
polymorphisms with a more moderate effect on lipid metabolism
detectable in subjects with moderate hyper-cholesterolemia
(Group 1a). Secondly, severely hyper-triglyceridemic subjects
(Group 3) were screened to detect variants in the amino-terminal
end of apoB, possibly affecting the apoB-LPL interaction. In
addition, screening of all apoB exons was carried out in
moderately hypercholesterolemic Group 1a subjects. To date, only
one other complete screening of the apoB gene coding area has
been reported (584). This French survey included 35 subjects
participating in an epidemiological study to look for possible
associations with CAD in subjects who were carriers the apoB
3´VNTR 49 allele, and did not report lipid data. To our
knowledge, the studies presented in this thesis comprise the
first attempt to screen for apoB variants in the whole gene in
hyperlipidemic subjects.
6.3. Limitations of the studied materials
With regard to the selection of the studied materials, two
questions arise: firstly, the probability of finding a lipid-
level changing mutation in the patient groups included, and
secondly, the power of the sample studied to detect lipid
effects of the new variants at the population level.
Compared with the many polymorphisms of apoB, real apoB
mutations are rare. After the description of the so far best
characterized and common apoB mutation (Arg3500SGln) (14), it
took several years to find other apoB variants associated with
moderate to severe hypercholesterolemia. These Arg3500STrp and
Arg3531SCys mutations (15,16) are even more rare than the
original FDB mutation and had not even been found until several
hundreds of hypercholesterolemic patients had been screened. In
view of this, our attempts to look for a new FDB-like mutation
in a small group of 68 patients is modest. The Finnish
population is however genetically uniquely homogenous. Although
the otherwise fairly common FDB mutation seems to be absent from
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this population (32), several Finnish LDLR mutations have been
detected and characterized in only a small group of
hypercholesterolemic patients (31). A subgroup (31 patients) of
the hypercholesterolemic subjects screened by us were highly
selected, lacking detectable LDLR defects. Thus, if a Finnish
FDB-producing mutation exists, it should have been found in a
patient material such as that studied here. Two mutations in
this group were in fact detected, both with no lipid effects in
studied families. As to the possible role of the amino terminus
of apoB in triglyceride metabolism, no previous reports of apoB
genetic screening in hypertriglyceridemia or apoB mutations
associated with it have been published. Hypertriglyceridemia is
a heterogeneous lipid disorder, often running in families, but
with a poorly understood genetic basis. Therefore, in order to
concentrate on DNA variants with major effects, only patients
with severe hypertriglyceridemia, although relatively widely and
arbitrarly selected, were included.
With respect to the new polymorphic variants of apoB detected by
these studies, no earlier knowledge of their frequency in the
Finnish population was available. When studying their effects at
the population level in the materials available for study, we
discovered that none of these polymorphic variants was frequent
enough to detect moderate effects on the genotypic variance on
lipid and lipoprotein levels. The problem of population sample
size has been common in all apoB association studies reported so
far (12). Also, the genetic heterogeneity of the studied
populations has been considered to be a drawback in these
studies (12). While the genetic homogeneity of the Finns is
likely to overcome the last drawback, clearly, larger population
samples in the range of hundreds to thousands of subjects would
be needed to confirm or exclude the suggestive findings of the
possible lipid effects of the new apoB variants.
When assessing the effects of any apoB polymorphism on lipid
metabolism, two additional aspects should be considered. The
first is the concept of a specific hyperlipidemia-producing apoB
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haplotype, referring to polymorphic variations in the same apoB
molecule producing the observed effect only in combination with
each other. Screening for unknown variants in carriers of such
specific hyperlipidemia-producing haplotypes has been suggested
to improve the possibility of identifying relevant apoB variants
(12). Another aspect not usually considered is the well known
influence of the apoE polymorphism on lipid levels (74,75). Most
apoB association or screening studies have not taken this effect
into account, which might have obscured the results obtained in
this study as well.
6.4. Detection of new variants of apo B and their
characterization
In genetic research, the detection of a new mutation or
polymorphism should be followed by mutation expression
experiments and a thorough characterization of the mutated
protein and its biological effects. The enormous size of apoB
and the special features of its biological behaviour have made
this task difficult. In vitro, apoB gene may be expressed in
hepatic or other cells capable of producing lipids as well,
leading to the production of lipoproteins, the characteristics
of which, including density, lipid composition, and size, can
then be analyzed. With regard to the biological functions of in
vitro expressed apoB, their LDLR binding capacity is reasonably
easily studied with either peripheral blood lymphocytes,
fibroblasts or other cells expressing the LDLR such as the
macrophage cell line U937 (44,721). However, in vitro apoB
expression studies are often hampered by the low level of gene
expression, and by the fact that recombinant LDL secreted by
cultured cells usually lacks normal receptor-binding activity
(197). Therefore, in order to analyze changes in lipoprotein
metabolism caused by apoB mutations, in vivo techniques are
needed. So far, the only practical approach to study in vivo
effects of apoB mutations has been based on the extraction of
lipoproteins from natural mutant carriers (preferrably
homozygotes) (533), and on the study of their behaviour in
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different in vivo kinetic study settings. With recent
developments in the research of genetically modified animals
such as mice, some of these difficulties of apoB mutation
studies have been overcome (722,723). So far, in most studies
identifying new apoB variants, including those presented in this
thesis, characterization of new variants has been restricted to
attempts to associate the DNA changes with serum lipid and
lipoprotein levels either in families or in groups of unrelated
subjects.
Altogether twelve new variants of apoB were detected by SSCP in
our study populations. Four of them were silent changes, of
which, the two variations at codons 875 and 2285 were easily
identified as polymorphisms, whereas the Tyr4242STyr variant in
exon 29, detected in three families, and the noncharacterized
DNA variant in the noncoding area in exon 29, detected in two
families, were considered mutations. Since no amino acid changes
were produced by these variants and no association between the
DNA change and the lipid phenotype in families was observed, no
further studies to characterize these silent changes were
considered necessary. Of the eight nonsense DNA changes, two
mutations were seen in only single hypercholesterolemic
families. Neither the del mutation at Asp 2186, nor the
Thr3918SAla mutation seemed to cosegregate with the severe
hypercholesterolemia present in the probands, and no further
studies to characterize their effects on lipid metabolism were
carried out. The third rare variant, Val4238SAla, was detected
in two control DNA samples from normocholesterolemic subjects
and thus considered not to be of sufficient interest for further
study. The remaining five nonsense DNA changes identified by us
were all shown to represent new apoB polymorphisms with rare
allele frequencies ranging from 0.02 (Asn1887SSer and
Ala4454SThr) to 0.11 (His1896SArg). In spite of the relative
rareness of the variant alleles, an attempt to study their
effects on lipid and lipoprotein levels in different study
settings was carried out.
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6.5. Lipid and lipoprotein effects of the new carboxyl-terminal
polymorphisms of apoB
Effects of the Asn1887SSer and His1896SArg variations, composing
the mAb D7.2 polymorphism were studied in healthy subjects
(Groups 4 and 8), and patients undergoing coronary angiography
(Group 7). While the effect on the reactivity against mAb D7.2
was more clear with the 1887 Ser allele compared with the 1896
Arg allele, only the latter seemed to exhibit effects on lipid
phenotype. Altogether, lipid data collected from the diet study
participants, patients undergoing coronary angiography, and the
healthy control group pointed towards a cholesterol- and apoB-
raising effect of the 1896 Arg allele. In the diet study
participants, this effect was observed in men and was detectable
only during a low-fat, low-cholesterol diet. In coronary
angiography patients, a slight total and LDL cholesterol
elevating effect of the 1896 Arg allele was obesereved in men
with no angiographically detectable vessel disease. This effect
was not observed in men with angiographic CAD. One explanation
for the fact that lipid effects were seen solely during diet
intervention in the diet study, but already at baseline in the
angiographically healthy males could be that subjects with
suspected CAD had changed their eating habits, and were
consuming a diet which in fact resembled the low-fat low
cholesterol diet of the North Karelia study. Why the same effect
was not observed in men with CAD is not known, but serum LDL
cholesterol levels in angiographically healthy males were than
thosw of the male CAD patients (3.04±0.94 and 3.71±1.00,
p=0.0001 in the non-CAD and CAD subjects, respectively), or
control males (data not shown). Thus, it might be proposed that
a lower overall LDL cholesterol level is required for the LDL
cholesterol-elevating effect of the 1896 Arg allele to be
detected. The possible mechanism through which the His1896SArg
change exerts its cholesterol- and apoB-raising effect is not
known. No signs of altered LDLR binding affinity of LDLs
extracted from the carriers of the 1896 Arg allele has been
detected (724), neither has mAb D7.2 been shown to inhibit the
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LDL-LDLR interaction (725). No lipid effects of the apoB 1896
Arg allele were detected in women. In all groups, women were
fewer in number, making a moderate effect of the 1896 Arg allele
more difficult to detect, and were also not matched for their
menstrual or menopausal status, which might have influenced the
results (65). In addition to differences in the effects of the
1896 allele on lipid levels between studied groups, the observed
1896 Arg allele frequencies were also different, with a higher
1896 allele frequency in the diet study participants, and a low
frequency in CAD subjects. While a low 1896 Arg allele frequency
might partly explain the missing lipid effects of this allele in
this group, it can also be suspected to relate to changes in CAD
risk. Therefore, the frequency of this allele was additionally
analyzed in another diet study population (228) collected from
the same area (228), showing similar allele frequencies and
similar statistical significances as Group 4 compared to other
groups (data not shown). Therefore, the allele frequency
difference was considered more likely to represent an enrichment
of the 1896 His allele in North Karelia, which is known to be a
genetic subisolate (726), than a sign of underrepresentation of
this allele in subjects with CAD.
With regard to the apoB Asn1887SSer polymorphism, no major lipid
effects in the studied materials were detected. However, so far,
only small numbers of 1887 Asn/Ser heterozygotes have been
analyzed, thus not outruling moderate effects of the 1887 Ser
allele on lipid levels not detectable with a small population.
As with the His1896SArg polymorphism, no changes in the LDLR
binding affinity have been detected in 1887 Ser allele carriers
(724). This polymorphism has been detected with an allele
frequency similar to the Finns at least in the French and
Norwegian populations (584,585,720). No data concerning the
lipid effects of the 1887 Ser allele in these samples are
available. Recently, LDL particles from 1887 Ser allele carriers
were reported to show increased electrophoretic mobility as a
sign of increased LDL electronegativity (720).
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Lipid and lipoprotein effects of the Arg4243SThr and Ala4454SThr
polymorphisms were analyzed both in normolipidemic Finnish
population samples (Groups 4 and 5) and in hypercholesterolemic
subjects (Groups 1 and 6). No differences between allele
frequencies, or significant lipid effects in the different
populations could be detected. Since frequencies of the rare
alleles of both polymorphisms were low, the number of observed
heterozygotes remained small, weakening the power of the
analyses to detect moderate lipid or lipoprotein effects. The
Ala4454SThr polymorphism was tested for its effects on LDLR
binding affinity and no detectable change was observed (724). To
date, only the Ala4454SThr polymorphism has been detected in
other Caucasian populations, with a slightly higher allele
frequency in the French (0.039) than in the Finnish population
(0.020) (584).
6.6. Lipid and lipoprotein effects of the amino-terminal
polymorphisms of apoB
The only new apoB polymorphism characterized in the amino-
terminal part of apoB, Val703SIle, was originally detected in a
sample of severely hypertriglyceridemic patients (Group 3).
Further studies involving both normolipidemic and hyper-
cholesterolemic subjects showed that this DNA variant was a
polymorphism and that it seemed to be underrepresented in the
hypertriglyceridemic patients. As to its lipid or lipoprotein
effects, a Tg-lowering effect was observed in normolipidemic
relatively young Finnish healthy subjects (Group 5). No effects
were observed either in the slightly older population of diet
study participants (Group 4) or hypercholesterolemic subjects
(Group 1). Again, the frequency of the rare apoB 703 Ile allele
was relatively low. It would clearly be of much interest to
study the effects of this apoB polymorphism in larger population
samples. The possible mechanism(s) of the Tg-lowering effect of
the Val703SIle polymorphism is not known; since it is located in
the apoB domain suggested to interact with LPL (240), one
explanation might be an accelerating effect on the LPL mediated
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hydrolysis of Tg-rich particles. So far, this apoB polymorphism
has not been detected in other populations.
Two previously characterized apoB polymorphims, Thr71SIle and
Ala591SVal, are situated in the proposed LPL-binding domain of
apoB. In earlier studies, the 71 Ile allele has been associated
with higher serum apoB concentrations in Finnish children (426)
and healthy adults (423), the 591 Val allele with larger
postprandial TGRLP responses after a fat load (410), and the 591
Ala allele with higher serum apoB concentrations in ischemic
stroke patients (434). In the hypertriglyceridemic patients
studied by us, a signifcant association between 591 Ala carrier
status and higher serum apoB concentrations was detected. The
same association was also observed when the 71 Ile and 591 Ala
alleles were combined. In normolipidemic populations, this
association could not be detected. Thus, these results would
point towards an apoB-raising effect of these amino-terminal
apoB polymorphisms, expressed only in the setting of
hypertriglyceridemia. These results are preliminary and need to
be confirmed in other studies. Also, the mechanism(s) through
which this kind of effect is brought about are not known.
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7. SUMMARY AND CONCLUSIONS
The main points and conclusions of the present study are:
1) SSCP is a technically easy, reproducible and effective
method offering the possibility of screening for mutations even
in large genes such as the apoB gene. In the studies presented
here, twelve new apoB variants were detected. All the previously
known apoB polymorphisms and the Arg3500SGln mutation were also
easily identifiable by SSCP.
2) The amino terminus of apoB seems to have some impact in Tg
and apoB metabolism, as suggested by the recent findings of an
LPL-binding amino-terminal apoB domain. A new polymorphism of
apoB, the Val703SIle variation, is associated with lower serum
Tg levels in healthy relatively young subjects and seems also to
be underrepresented in severely hypertriglyceridemic patients.
The Ala591SVal polymorphism, alone or in combination with the
apoB Thr71SIle polymorphism, is associated with higher serum
apoB levels in hypertriglyceridemic subjects.
3) The His1896SArg variation seems to have a tendency to
increase serum total and LDL cholesterol concentrations in
healthy men during a low-fat, low cholesterol diet. The
mechanism of this effect is not known. No direct changes in LDLR
binding affinity have been detected. Since this polymorphism can
be detected immunologically as well, some changes of the
configuration of apoB-containing lipoproteins are possible.
Kinetic studies would be needed to clarify the mechanisms of
this polymorphism on cholesterol metabolism in vivo.
4) The Asn1887SSer, Arg4246SThr, and Ala4454SThr polymorphisms
detected in this study have so far not been shown to affect any
lipid or lipoprotein parameters in different Finnish populations
and study settings. Allele frequencies have however been too low
for the detection of moderate effects. Larger population studies
would be needed.
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5) No FDB-like mutation characteristic to Finns seems to be
present in the highly selected severely hypercholesterolemic
study population screened for DNA changes in the 3´ two-thirds
of the apoB gene covering the whole LDLR binding region of apoB
and its surroundings.
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TABLES
TABLE 1. Characteristics of the major human plasma lipoproteins.
Lipo- Density Molecular Diameter Lipid composition Apolipoproteins
protein (g/dl) weight nm (% of lipids)
(kDa) Tg Chol Pl
CM < 0.95 400×103 75-1200 80-95 2-7 3-9 B-48, AI, AII,
AIV, CI-III, E
VLDL 0.95-1.006 10-80×103 30-80 55-80 5-15 10-20 B-100, CI-III, E
IDL 1.006-1.019 5-10×103 25-35 20-50 20-40 15-25 B-100, CI-III, E
LDL 1.019-1.063 2.3×103 18-25 5-15 40-50 20-25 B-100
HDL 1.063-1.210 1.7-3.6×102 5-12 5-10 15-25 20-30 AI-II, AIV, CI-III, E
Lp(a) 1.050-1.090 5×103 28 similar to LDL B-100, apo(a)
Data from Rudel et al. 1986, Durrington 1995, Ginsberg 1998 (10,38,727).
TABLE 2. Characteristics of the major apolipoprotein
____________________________________________________________________________________________________________________________________________________________________________________________
Name Chromo- Peptide Molecular Lipo- Functions
some length weight protein
(aa)* (kDa)
____________________________________________________________________________________________________________________________________________________________________________________________
A-I 11 243 28 HDL,CM structural (HDL),
LCAT activation,
receptor ligand
(SR-BI), promotes
cholesterol efflux
A-II 1 77 17 HDL,CM structural (HDL),
HL, LPL activation
LCAT modulator
A-IV 11 377 46 HDL,CM LCAT activator, LPL
modulator, function
in Tg transport?
(a) 6 4529 e 250-800 Lp(a) unknown
B-100 2 4536 540 VLDL, structural, LDLR
IDL,LDL ligand
B-48 2 2152 264 CM structural
C-I 19 57 6.6 CM,VLDL LRP and LDLR
IDL,HDL interaction
inhibitor,
LCAT activator
C-II 19 79 8.9 CM,VLDL LPL activator
IDL,HDL
C-III 11 79 8.8 CM,VLDL LPL inhibitor
IDL,HDL apoE-mediated
remnant removal
inhibitor
E 19 299 34 CM,VLDL receptor ligand,
IDL,HDL reverse cholesterol
transport, cell
growth and immune
response
regulation?
____________________________________________________________________________________________________________________________________________________________________________________________
* aa = amino acids.
e based on cDNA analysis of one apo(a) isoform; otherwise highly variable
(728).
Data from Patsch and Gotto 96, Tailleux and Fruchart 96, Ginsberg 98
(10,35,39).
TABLE 3. Effects of age, gender, obesity, diet and other lifestyle factors
on lipid and lipoprotein levels.
________________________________________________________________________
Chol Tg LDL- HDL- Reference
chol chol
________________________________________________________________________
Age U U U U (61-63)
Sex (male) U U U V (61)
Obesity U U U V (66-70)
Diet
Fatty acids (47,48,729)
Saturated U U U
PUFA* V V e V V
MUFA* V V U
Cholesterol U U U (48,50,51)
Carbohydrate # V U V V (53,730)
Fibre V V V
(54)
Protein (plant) V V U
(56,731-733)
Alcohol U V U (57)
High caloric U U (52)
intake
Smoking U U U V (58)
Physical activity V V U (59)
Stress U U U (60)
* PUFA = polyunsaturated fatty acid, MUFA = monounsaturated fatty acid.
Effects produced when substituted for saturated
fatty acids.
e Effect of omega-3 PUFA only.
# Low-fat, high-carbohydrate diet.
TABLE 4. ApoB genetic variants reported to date. Mutations associated with hypobeta-lipoproteinemia excluded.
Site* Mutation Outcome RFLP Ag Allele Number of Reference
ass e frequency # families
-4kb AvaII+/- 0.20 734
5'VNTR -3256bp (TG)n repeat, 7 alleles (TG)14 0.78 554,735
(TG)15 0.19
Reduc -1860/80 (A)n(TA)m repeat, 6 alleles 0.36,0.29 584
(2 smallest)
Prom -837 GSA 0.48 584,736
Prom -516 CST 0.31 584,736
Prom -265 CST MspI+/- 0.21 719,737
MscI-/+
Prom +14 CSG AluI-/+ 719
Ex 1 del162-170 del Leu-Ala-Leu -16-14 0.27 372
signal peptide 27S24 aa
Ex 1 ins CTGCTG 194/5 ins Leu-Leu -6/-5 0.03 377
signal peptide 27S29 aa
In 2 ASG +722 StyI+/- 0.01 634
In 3 GST +92 0.47 734
Ex 4 C421ST Thr71SIle ApaLI+/- g/c 0.26 416,417
Bsp12861+/-
MB19 2/1 418,419
BIP45, D2E1 420,421
In 4 CSA + 171 HincII-/+ 0.20 554,734,738
In 4 GSA -523 to ex 5 PvuII-/+ 0.04 554,734,738,739
In 5 CST -9 to ex 6 MnII+/- 719
Ex 14 C1981ST Ala591SVal AluI+/- d/a1 0.56 431
H11G3 421
Ex 15 G2316SA Val703SIle Alw26I+/- 0.04 719,740
BsmAI+/-
Ex 18 C2834ST Asn875SAsn 0.03 584
In 20 TTTA repeats and sequence variation 5' to the Alu element, 7 alleles 741,742
In 20 sequence variation in the Alu element, 12 alleles 742
In 20 ASG -146 to ex 21 BalI-/+ 0.50 734
Ex 26 C4439SG Phe1410SLeu 1 584
Ex 26 A5869SG Asn1887SSer BsrdI+/- D7.2 0.02 743
Ex 26 A5896SG His1896SArg RsaI-/+ D7.2 0.11 743
Ex 26 del6766-8 del Asp2186 1 744
Ex 26 T7064SC Asp2285SAsp MaeII-/+ 0.63 113,575,745
Ex 26 T7673SC Thr2488SThr XbaI+/- 0.63 113,373,374
Ex 26 G7824SA Glu2539SLys 0.009 584
Ex 26 C8344ST Pro2712SLeu MaeI-/+ y/x 0.29 371,455,456,458
BfaI-/+
Ex 26 G9489SA Ala3094SThr 1 584
Ex 26 A9963SG Ser3252SGly 7 561
Ex 26 C10083SG His3292SAsp 1 585
Ex 26 G10259SA Leu3350SLeu PstI +/- 0.01 20,561,588
Ex 26 C10321ST Ala3371SVal AluI +/- 1 588
Ex 26 G10397SA Val3396SMet 1 561
Ex 26 A10408SC Lys3400SThr 1 585
Ex 26 G10422SC Glu3405SGln 0.01 20,561,587
TABLE 4, continued.
Site Mutation Outcome RFLP Ag Allele Number of Reference
ass frequency families
Ex 26 C10574SA Ser3455SArg 1 561
Ex 26 G10648SC Arg3480SPro 565
Ex 26 C10707ST Arg3500STrp 15 16
Ex 26 G10708SA Arg3500SGln 0.001 14
Ex 26 T10760SG Leu3517SLeu 1 562
Ex 26 C10790ST Ala3527SAla 1 562
Ex 26 C10800ST Arg3531SCys NsiI-/+ 26 15
Ex 26 G10829ST Thr3540SThr 21
Ex 26 C10835ST Asn3542SAsn 21
Ex 26 C10865ST Thr3552SThr 21
Ex 26 G11041SA Arg3611SGln MspI+/- i/h 0.06 464,465
Ex 26 G11889SA Val3894SIle RsaI-/+ 1 585
Ex 27 A11961SG Thr3918SAla 0.01 1 584,744
In 27 GSC +50 - 0.20 584
Ex 29 C12264ST Arg4019STrp MspI+/- 1 586
Ex 29 G12510SA Val4101SMet 0.08 584
Ex 29 A12669SG Lys4154SGlu EcoRI-/+ z/t 0.84 113,479,480
Ex 29 T12922SC Val4238SAla 2 744
Ex 29 T12935SC Tyr4242STyr RsaI-/+ 3 744
Ex 29 G12937SC Arg4243SThr 0.03 457,744
Ex 29 A13141SG Asn4311SSer Eco57I-/+ y/x 0.29 456-458
Ex 29 G13569SA Ala4454SThr 0.02 584,744
3'VNTR 73 bp 3' to the 2. polyadenylation signal 26 alleles 375,376
22-57 repeats of 11-16 bp sequences
In addition, rare TaqI, EcoRV, StuI and RsaI polymorphisms have been reported. Their exact
location is currently not known (9).
* Reduc = reducer segment of the apoB gene, Prom = promoter, Ex = exon, In = intron.
e Antigenic association with either monoclonal (mAb) or alloantibodies (Ag).
# Bolded numbers denote allele frequencies reported in the Finns.
TABLE 5. Associations between alleles of the apoB XbaI polymorphism and
serum total cholesterol, triglycerides, apoB or CAD in population studies.
Study population XbaI association § Reference
High levels of
Source* Sample e n S# TC Tg apoB CAD
Norway h 56 B X+ 0 X+ - 746
USA (c) CAD+h 219 B 0 X- 0 0 484
USA (c) MI/h 84/84 B 0 0 0 X- 485
GB (c) ns 83 M X+ X+ 0 - 747
Italy h 79 B - 0 - - 748
GB (c) HL/h 133/62 B X+ X+ - - 486
Finland h 176 B X+ 0 0 - 427
Japan HL/h 53/54 B 0 0 0 0 749
France h 53 B X- - - - 429
GB (c) MI/h 100/62 M - - - 0 498
GB (c) HL/h 124/34 B 0 X+ - - 487
Norway HC 64 M 0 0 X+ - 750
GB ATH/h 205/139 B 0 0 0 X- 488
GB (c) CAD+h 290 M 0 0 0 X- 475
Finland FH 120 B X+ 0 - - 751
Sweden h 187 B 0 0 0 - 752
GB (c) CAD/h 124/146 M 0 0 0 X- 441
Sweden MI/h 52/52 M 0 X- 0 0 753
USA (c) CAD/h 111/128 M 0 0 0 0 478
Norway h 170 M 0 0 0 - 521
Austria CAD/h 106/118 M 0 0 0 0 491
Germany FCHL/h 321/107 B X+ 0 0 - 467
USA (c) >90-y 41 B 0 0 0 - 754
Italy h ch 209 B 0 0 0 - 468
Finland HL 221 M X+ 0 - - 447
Finland h ch 307 B X+ 0 - - 436
Italy h 82 M 0 - 0 - 755
Finland FH 51 B X+ 0 - - 756
GB (c) NIDDM 95 B 0 0 0 0 492
Sri Lan CAD/h 95/95 M 0 X+ - X- 472
Finland HL 211 B 0 0 - - 757
GB (a) CAD/h 46/107 M 0 0 - - 382
Denmark MI/h 50/39 M X+ 0 0 X- 493
USA (c) CAD/h 274/162 B X+ - X+ - 490
Italy HL/h 44/35 B - - - 0 758
Austral CAD/h 122/80 B 0 0 0 X- 435
Finland CAD/h 111/142 B X+ 0 0 0 759
Sweden MI/h 87/91 M X+ 0 0 0 404
China h 221 B 0 0 0 - 438
China CAD/h 139/149 B 0 0 0 0 406
Spain h 228 M X+ 0 X+ - 760
Norway MI/h 238/621 B X+ 0 X+ X- 761
Italy HL/h 76/79 B - - - 0 762
Italy CAD/h 39/40 M - - - 0 763
China h 148 M 0 0 0 - 514
Israel CAD off 525 B X+ 0 X+ - 764
Denmark h 464 M X+ 0 X+ - 390
TABLE 5, continued.
High levels of
Source Sample n S TC Tg apoB CAD
Singapo h 181 B X+ X+ 0 - 384
GB HC/h 280/265 B X+ - - - 476
Finland NIDDM 268 B X+ X+ - 0 499
Java h 231 B 0 X+ - - 385
Denmark FH 99 B 0 0 - - 765
Denmark HL+CAD 318 B X+ 0 - - 393
Finland 100-y 364 B 0 0 0 - 766
USA (c) CAD/h 444/404 B - - - 0 407
Finland CAD/h 82/50 M 0 0 - 0 767
China CAD/h 80/60 B 0 0 0 X+ 439
Finland h 52 M 0 0 - - 768
China CAD/h 148/153 B 0 0 0 - 437
Europe CAD/h off 682/312 B X+ 0 X+ - 381
China CAD/h 103/100 B 0 0 0 X+ 440
Nigeria h 1222 B 0 0 0 - 386
Italy CAD/h 45/118 F X+ 0 0 0 400
Europe FDB 205 B 0 0 - - 19
Japan h 1328 B 0 - - - 387
Chech hl/h ch 82/86 B 0 0 0 - 769
China ch 93 B X+ 0 0 - 770
Russia CAD/h 94/122 M 0 0 - 0 470
Asia HL/h 131/374 B 0 0 0 - 466
Norway hl+RR/h 108/64 B 0 0 0 0 477
Brazil(i)h 82 B 0 0 0 - 378
Finland HC 48 B X+ 0 X+ - 402
* Country of origin; c=caucasian, a=asian, i=indian.
e h, healthy, CAD, coronary artery disease, MI, myocardial
infarction, ns, not specified, HL, hyperlipidemic, HC,
hypercholesterolemic, ATH, atherosclerotic (both CAD and
peripheral), FH, familial hypercholesterolemia, FCHL,
familial combined hyperlipidemia, y, years, ch, children,
NIDDM, non-insulin-dependent diabetes mellitus, off,
offspring, FDB, familial defective apoB, RR, hypertensive
subjects.
# S, sex, M, male, F, female, B, both sexes.
§ TC, total cholesterol, Tg, triglycerides, X+, association with the XbaI+
allele, X-, the XbaI - allele, 0, no significant association detected, -,
not analyzed.
Significance level p<0.05 or less.
TABLE 6. Apolipoprotein B gene mutations associated with familial hypobetalipoproteinemia.
Name Site* Mutation e ApoB size Outcome § Reference
(aa) #
ApoB-2(4) in 5 GST, +1 to ex 5 152 splicing defect 575,719
no apoB in plasma
ApoB-9 ex 10 C1443ST 411 Arg412STer 575
no apoB in plasma
ApoB-25 deletion of 694 1085 Gly1014SVal-72aa-Ter1086 577
bp, from intron no apoB in plasma
20 to intron 21
ApoB-27.6 in 24 TSC, base +2 1282 Ser1254SArg-28aa-Ter1283 579,771
splice site disruption
activation of cryptic
splice site in intron 24
traces in plasma
ApoB-29 ex 25 C4125ST 1305 Arg1306STer 772
no apoB in plasma
ApoB-31 ex 26 del 4480 1425 Gly1424SVal-Tyr-Ter1426 773
ApoB-32 ex 26 C4557ST 1449 Gln1450STer 774
ApoB-32.5 ex 26 T4631SG 1473 Tyr1474STer 775
ApoB-37 ex 26 del 5391-4 1728 Asn1728SVal-Ter1729 776,777
ApoB-38.7 ex 26 C5472ST 1754 Gln1755STer 581
ApoB 38.9 ex 26 del 5444 1767 Asn1745SLys-4aa-Ter1768 778
ApoB 38.95 ex 26 del 5478-91 1767 Val1757SThr-10aa-Ter1768 779
ApoB-39 ex 26 del 5591 1799 His1795SMet-4aa-Ter1800 772
ApoB-40 ex 26 del 5694-5 1829 Val1829SCys-Ter1830 201,780
ApoB-43.7 ex 26 C6162ST 1984 Arg1985STer 568
ApoB-44.4 ex 26 ins 11 bp 2014 Ala2012SGlu-2aa-Ter2015 781
6243/4
ApoB-45.2 ex 26 T6368SA 2052 Tyr2053STer 580
ApoB-46 ex 26 C6381ST 2057 Arg2058STer 782
ApoB-48.4 ex 26 del 6686 2166 Lys2159SLys-7aa-Ter2167 783
ApoB-50 ex 26 C6963ST 2251 Gln2252STer 578
ApoB-52 ex 26 del 7279-83 2361 Val2357SAsp-4aa-Ter2362 784
ApoB-52.8 ex 26 del 7295 2395 Tyr2362STyr-33aa-Ter2396 775
ApoB-52.8 ex 26 del 7359 2395 Thr2364SHis-11aa-Ter2396 775
ApoB-54.8 ex 26 C7665ST 2485 Arg2486STer 785
ApoB-55 ex 26 C7692ST 2494 Arg2495STer 781,786,787
(independent
mutations)
ApoB-61 ex 26 del 8525-61 2784 Ser2772SSer-12aa-Ter2785 788
ApoB-67 ex 26 del 9327 3040 Lys3040SArg-Ter3041 789
ApoB-70.5 ex 26 ins A9754/60 3196 Asn3184SLys-12aa-Ter3197 790
ApoB-75 ex 26 del 10366 3386 Thr3386SMet-Ter3387 202
ApoB-82 ex 26 C11411SA 3733 Cys3734STer 775
ApoB-83 ex 26 C11458SA 3749 Ser3750STer 791
ApoB-86 ex 26 del 11840 3896/4536 Asn3877SLys-19aa-Ter3897 576
reading frame restoration
yields 10% of normal apoB-100
ApoB-87 ex 28 del 12032 3978 Glu3942SAsn-36aa-Ter3979 203
ApoB-89 ex 29 del 12309 4039 Glu4034SArg-5aa-Ter4040 201,780
* In = intron, ex = exon. e Del = deletion, ins = insertion.
# Aa = amino acids. § Ter = termination codon.
TABLE 7. Summary of the studied materials used in SSCP screening, allele frequency analyses and estimations of lipid
effects of newly detected DNA variants.
Group n M/F* Type of analysis e Description Reference
1 89 48/41 Allele frequency and Kuopio district subjects (696)
lipid effects of codon Primary hypercholesterolemia
703,4243,4454 pm:s Cholesterol A 8 mmol/l
ApoB Arg3500SGln excluded
Three subjects (2/1) with
FH excluded
1a 29 12/17 Exon 2-29 SSCP screening Kuopio district subjects (696)
Allele frequency of Subgroup based on family data
codon 1887,1896 pm:s
2 39 23/16 Exon 26-29 SSCP screening Non-FH hypercholesterolemia (31)
Allele frequency of codon Cholesterol A 8 mmol/l and
1887,1896 pm:s tendom xanthomas in the
proband and a first-degree
relative
LDLR defects and apoB
Arg3500SGln excluded
3 76 66/10 Exon 2-16 and 21 screening Severe hypertriglyceridemia (697)
Triglycerides > 6 mmol/l
4 102 48/54 Characterization of mAb North Karelia diet study (442)
D7.2 polymorphism Apparently healthy
Allele frequency and
lipid effects of codon 703,
1887,1896,4243,4454 pm:s
Lipid effects of Ag(c/g) and
Ag(a1/d) pm:s
5 88 41/47 Allele frequency and Random sample of Finns born (698)
lipid effects of codon in 1954
703,4243,4454 pm:s Apparently healthy
6 220 112/108 Allele frequency and Drug intervention study (32,699)
lipid effects of codon Cholesterol A 6.2 mmol/l
4243,4454 pm:s Triglycerides @ 4.0 mmol/l
FH not excluded
7 327 217/110 Allele frequency and Coronary angiography patients (700)
lipid effects of codon CAD 205 ( M/F 162/43)
1887,1896 pm:s Non-CAD 122 (55/67)
160 98/62 Lipid effects of Ag(c/g) Coronary angiography patients (700)
and Ag(a1/d) pm:s Ag(c/g) and Ag(a1/d) data
available
CAD 84 (64/20)
Non-CAD 76 (34/42)
8 72 45/27 Allele frequency and Normal voluntary controls (701)
lipid effects of codon No symptoms or signs of CAD
1887,1896 pm:s
* M = male, F = female.
e pm = polymorphism.
TABLE 8. Oligonucleotides used as primers in SSCP screening of exons 2 to 29 of the
apoB gene.
Primer Upstream (sense) Downstream (antisense)
Exon 2 5´ CTC ACA GAA TTT CTT TCT CC 5´ AGA TGC CTT ACT TGG ACA G
Exon 3 5´ TGT GGC TGA CGT ATT TCT C 5´ TCC CTC CTG CCT GCA TC
Exon 4 5´ AAC CTC AAT GCT CTG CTA CC 5´ TGC GTG TGC TCA TGT ACA AC
Exon 5 5´ ATT TCC GTG ACC ATC CTC TC 5´ ACT GCT ATC AGC TTT CTA AAT C
Exon 6 5´ GTG TTG AAT ACA TGT GGT TGC 5´ TAA TAA GAG GAT GCT CCT TGC
Exon 7 5´ GAT CAA AAT GCT CGT CTC C 5´ AGG GTT GCA TCA CAT GAC
Exon 8 5´ AAT AGT ATG TTC TGG CCA TC 5´ ATT TTC CAG CAA CTA TGT GG
Exon 9 5´ CAC TTT CCA TCT TCC AGG T 5´ AAG TTC AGT CAG TTA CCA TC
Exon 10 5´ TGA AGG TGG TCT GTA TAA CT 5´ AGA AAT ACA TGT GAA ACT CAC
Exon 11 5´ AAG TCC TGA CTC TCT TCT C 5´ AAA AGT GCT TCT GAA ATG ATG
Exon 12 5´ CCT GAT GGG TTC TTG TTT C 5´ AAC TTT CAC TTT CAG ACC TC
Exon 13 5´ GGA CAG TGA TAA CCA TCT CC 5´ AGT GGT ATA TGG GGT GAA TAG
Exon 14 5´ AAT AAC ATG GTG TGT CAG CTC 5´ CTA GAG AAC CTC AAA CTC TTC
Exon 15 5´ CCA TTT TCT TGT CTG ATT TTC 5´ CTT TCC TTA AGA AGA TAC TTC
Exon 16 5´ CTC ACT GGC CAT TTT ATT AC 5´ AAC CAA CTC TGG TCT CAT G
Exon 17 5´ TTA TTT GCT CTC CCT TGT TG 5´ CTA AGA AAT CAA AAG GCA AAC
Exon 18 5´ GAA TCT GAA TAG GTT GTT TTC 5´ GGC TGA AAG AAT TAC CCT C
Exon 19 5´ GAC TTG GCA ATA ACT CAG G 5´ GGA AGG TGA GAA AAT GCT G
Exon 20 5´ ACA TTA TGC ATG TCT TCA TTG 5´ ATG AGG CAG CTG TGT TTT G
Exon 21 5´ TAC CAC ACA TCT CTT GAT TC 5´ CAG TGC AGG TCA GAT GAC
Exon 22 5´ ATT GGT GCC AAC TGA TTT TC 5´ ACT TTG GAA GTG CTC ACA C
Exon 23 5´ AGT ACC ATT CAC AAC TAT TTC 5´ ATC CAT GTA TTT ATT GAC TGG
Exon 24 5´ TTA CCT TAA AAA TCT CCT GTC 5´ AAG AAG CCT TGC TGC TTT C
Exon 25 5´ TGA CTG TGG GGA TGT TAT C 5´ TGC ACC CTT TAC CTG AGC
Exon 26a 5´ ACA TAT GAC CAC AAG AAT ACG 5´ TGA ACC TTA GCA ACA CTG TC
Exon 26b 5´ ACA TCT ATG CCA TCT CTT CTG 5´ ATC AAT AGC CTC AAT GTG TTG
Exon 26c 5´ AAG AGA CAC ATA CAG AAT ATA G 5´ ACA AAG TCA ATT GTA AAG GAA G
Exon 26d 5´ GTT TTC CAC ACC AGA ATT TAC 5´ TAT ACT GAT TGA ACC TAG CAC
Exon 26e 5´ TAA CTA TGC ACT GTT TCT GAG 5´ GAG TAC AGC ATT GAA GAA TTG
Exon 26f 5´ AGT CAA AAC CTA CTG TCT CTT 5´ TCA TAT TCT AGG AAC TGT ACG
Exon 27 5´ ACA AAA TCT CTC CTA TAC AG 5´ TCA ATA AAA GCT CCA TAC TG
Exon 28 5´ TCT GTT TTT CTG CTT TCA GG 5´ CAT TAG GTG GTA TTT ACC TG
Exon 29a 5´ TCC TCT CCA GAT AAA AAA CTC 5´ TCT GAA CCA TTA TGG ACT TTC
Exon 29b 5´ ATG TTC ATA AGG GAG GTA GG 5´ TTC CTG AAT ATT TCT GTG CAG
Exon 29c 5´ TAC TTC CCA ACT CTC AAG TC 5´ TAT GAT ACA CAA TAA AGA CTC C
Sequence data from Ludwig et al. 1987 (118).
TABLE 9. Characteristics of PCR-amplified fragments of the apoB gene, restriction enzymes used, and sizes of
digestion products screened with SSCP.
Fragment* Nucleotide Amino Product Restriction Cutting Digestion
position in acids size enzymes sites product size
cDNA e (bp) # (cDNA) (bp)
2 211-249 1-14 80 - - -
3 250-365 14-52 170 - - -
4 366-511 53-101 207 - - -
5 512-665 101-152 211 - - -
6 666-821 153-204 244 - - -
7 822-946 205-246 180 - - -
8 947-1032 246-275 170 - - -
9 1033-1252 275-348 293 - - -
10 1253-1480 348-424 277 - - -
11 1481-1598 424-463 191 - - -
12 1599-1745 464-512 217 - - -
13 1746-1957 513-583 278 - - -
14 1958-2195 583-662 311 - - -
15 2196-2372 663-721 239 - - -
16 2373-2564 722-785 267 - - -
17 2565-2732 786-841 227 - - -
18 2733-2944 842-912 258 - - -
19 2945-3127 912-973 264 - - -
20 3128-3249 973-1014 183 - - -
21 3250-3460 1014-1084 283 - - -
22 3461-3636 1084-1143 243 - - -
23 3637-3824 1143-1205 259 - - -
24 3825-3970 1206-1254 205 - - -
25 3971-4344 1254-1379 437 - - -
26a 4359-5707 1384-1833 1348 BanI 4713 354 + 579 + 417
HincII 5291
26b 5641-7007 1811-2266 1366 BanI 6063 422 + 443 + 501
EcoRI 6506
26c 6936-8125 2243-2639 1190 HindIII 7335 400 + 577 + 213
AvaII 7912
26d 8060-9417 2617-3070 1358 AseI 8584 524 + 398 + 436
EcoO109I 8982
26e 9344-10540 3045-3444 1197 EcoO109I 9859 515 + 402 + 280
PstI 10261
26f 10474-11908 3422-3900 1435 EcoO109I 10850 377 + 541 + 518
BglII 11390
27 11916-12031 3903-3941 153 - - -
28 12032-12215 3941-4003 220 - - -
29a 12216-12847 4003-4213 632 PstI 12454 239 + 393
29b 12783-13478 4192-4423 696 EcoO109I 13028 246 + 450
29c 13424-14121 4405-4536 698 DraI 13826 403 + 295
* Fragment numbering refers to apoB gene exons.
e Nucleotide numbering according to Knott et al., 1986 (116).
# Exons 2 to 25, 27 and 28 amplified with intronic primers flanking the exons (118).
TABLE 10. Oligonucleotides used as primers in solid-phase sequencing and minisequencing reactions, and in apoB
ins/del and 3´VNTR genotyping.
Fragment Upstream (sense) Downstream (antisense)
15 5´ CCA TTT TCT TGT CTG ATT TTC 5´ CTT TCC TTA AGA AGA TAC TTC (b)*
18 5´ GAA TCT GAA TAG GTT GTT TTC 5´ GGC TGA AAG AAT TAC CCT C (b)
26b/422 e 5´ CCT ACC AAA ATA ATG AAA TAA AAC (b) 5´ TCT TGA GTT TCC AGG TGC CT
26b/1887/1896 # 5´ TGC ATT TCA GCA ATG TCT TCC (b) 5´ TGG AGC CTT TGT AAT CAT GTG
1887 D § 5´ CCC AGA GAG CGA GTT TCC CA
1896 D 5 TGC TAT ACA GCT GCC CAG TA
26b/501 5´ GGA AAA CTC CCA CAG CAA G 5´ ATC AAT AGC CTC AAT GTG TTG (b)
26c/400 5´ AAG AGA CAC ATA CAG AAT ATA G 5´ TCT TGA CAG CAT CAT CAA TAA A (b)
27 5´ ACA AAA TCT CTC CTA TAC AG (b) 5´ TCA ATA AAA GCT CCA TAC TG
29b/246 5´ ATG TTC ATA AGG GAG GTA GG 5´ TCT ATT AGT TGG AAA ATG AAT TG (b)
29b/4243 # 5´ CTA GGG AGG AAC TTT GCA C (b) 5´ TCT ATT AGT TGG AAA ATG AAT TG
4243D 5´ GAT AAA TCT TTC AAC AGT TCC
29c/403 5´ ATA TTG TCA GTG CCT CTA AC 5´ GTG AAA GTT CAA TTG GAA AAG (b)
29c/4454 # 5´ ATA TTG TCA GTG CCT CTA AC (b) 5´ TGG TCT GAA AAA TCT TGC AG
4454D 5´ TAT TTT CTT CGT CGC AAT GG
ins/del 5´ CAG CTG GCG ATG GAC CCG CCG A 5´ ACC GGC CCT GGC GCC CGC CAG CA
3´VNTR 5´ ATG GAA ACG GAG AAA TTA TG 5´ CCT TCT CAC TTG GCA ATA AC
Sequence data from Ludwig et al. 1987 (118).
* b = biotinylated.
e 26b/422 denotes the 422 bp digestion product of fragment 26b.
# Primers used to produce template for minisequencing of the apoB 1887, 1896, 4243 and 4454
polymorphisms.
§ D = detection step primer.
TABLE 11. PCR-RFLP analyses of apoB polymorphisms studied.
ApoB SSCP Nucleotide Product Restriction Cutting Digestion product
polymorphism fragment position size enzyme site sizes when site
in cDNA* (bp) e (cDNA) present (bp) #
Thr71SIle 4 366-511 207 ApaLI 416 82 + 124
Ala591SVal 14 1958-2195 311 AluI 1980 49 + 201 + 43
Val703SIle 15 2196-2372 239 Alw26I 2321 155 + 84
Asn1887SSer 26b 5641-6081 441 BsrDI 5873 173 + 60 + 208
His1896SArg 26b 5641-6081 441 RsaI 5897 256 + 185
Thr2488SThr 26c 6936-8125 1190 XbaI 7682 747 + 443
Pro2712SLeu 26d 8060-9417 1358 BfaI 8343 176 + 108 + 488 + 570
Arg3611SGln 26f 10474-11908 1435 MspI 11039 566 + 869
Lys4154SGlu 29a 12216-12847 632 EcoRI 12669 453 + 178
* Nucleotide numbering according to Knott et. al. 1986 (116).
e Exons 4, 14 and 15 amplified with intronic primers flanking the exons.
# Amplified segment contains both variant and invariant cutting sites. Bolded figures denote
digestion products involved in the polymorphic variation.
TABLE 12. Serum lipid and lipoprotein levels in Group 4 men with and
without the apoB Asn1887SSer DNA change during dietary intervention.
Asn/Asn Asn/Ser P
(n=44) (n=3)
Tot-chol (mmol/l)
B 6.57 ± 1.22 6.19 ± 0.80 0.5924
I 5.20 ± 0.85 5.29 ± 0.30 0.8608
S 6.30 ± 0.96 5.98 ± 1.39 0.5931
LDL-chol (mmol/l)
B 4.90 ± 1.14 4.68 ± 0.64 0.7371
I 3.80 ± 0.81 3.94 ± 0.17 0.7728
S 4.64 ± 0.95 4.47 ± 1.25 0.7772
Tot-tg (mmol/l)
B 1.43 ± 1.10 1.30 ± 0.38 0.8345
I 1.25 ± 0.64 1.14 ± 0.16 0.7742
S 1.30 ± 0.81 0.97 ± 0.22 0.4876
HDL-chol (mmol/l)
B 1.38 ± 0.34 1.25 ± 0.31 0.5093
I 1.16 ± 0.26 1.13 ± 0.25 0.8601
S 1.40 ± 0.31 1.32 ± 0.30 0.6479
ApoB (mg/ml)
B 1.25 ± 0.27 1.34 ± 0.03 0.5457
I 1.09 ± 0.26 1.25 ± 0.21 0.3064
S 1.28 ± 0.26 1.36 ± 0.21 0.6010
B=baseline, I=intervention, S=switchback period.
Values expressed as mean ± S.D.
TABLE 13. Serum lipid levels in Group 7 men with angiographically detected CAD or with normal coronary arteries with
or without the apoB Asn1887SSer change.
CAD Non-CAD
Asn/Asn Asn/Ser P Asn/Asn Asn/Ser P
(n=150) (n=10) (n=52) (n=3)
Tot-chol 5.74 5.12 0.0861 5.09 5.17 0.8868
(mmol/l) (±1.12) (±0.89) (±0.91) (±1.64)
LDL-chol 3.74 3.16 0.0767 3.04 3.01 0.9599
(mmol/l) (±1.00) (±0.78) (±0.94) (±1.23)
Tot-tg 1.89 1.67 0.4689 1.66 0.93 0.2055
(mmol/l) (±0.95) (±0.59) (±0.94) (±0.26)
HDL-chol 1.13 1.20 0.4805 1.30 1.73 0.0638
(mmol/l) (±0.28) (±0.24) (±0.38) (±0.49)
ApoB 1.01 0.90 0.0658 0.89 0.89 0.9630
(mg/ml) (±0.20) (±0.11) (±0.21) (±0.15)
Values expressed as mean ± S.D.
TABLE 14. Serum lipid and lipoprotein levels in Group 4 men with and
without the apoB His1896SArg DNA change during dietary intervention.
His/His His/Arg P
(n=37) (n=10)
Tot-chol (mmol/l)
B 6.52 ± 1.23 6.67 ± 1.10 0.7141
I 5.10 ± 0.77 5.62 ± 0.95 0.0792
S 6.31 ± 0.98 6.16 ± 1.00 0.6723
LDL-chol (mmol/l)
B 4.84 ± 1.14 5.08 ± 1.02 0.5392
I 3.69 ± 0.74 4.24 ± 0.82 0.0494
S 4.64 ± 0.98 4.58 ± 0.95 0.8807
Tot-tg (mmol/l)
B 1.42 ± 1.14 1.45 ± 0.80 0.9292
I 1.19 ± 0.57 1.44 ± 0.77 0.2604
S 1.26 ± 0.81 1.37 ± 0.74 0.6969
HDL-chol (mmol/l)
B 1.40 ± 0.37 1.30 ± 0.18 0.4378
I 1.17 ± 0.28 1.09 ± 0.12 0.3857
S 1.43 ± 0.34 1.30 ± 0.16 0.2777
ApoB (mg/ml)
B 1.13 ± 0.27 1.34 ± 0.24 0.2226
I 1.06 ± 0.26 1.22 ± 0.21 0.0814
S 1.29 ± 0.28 1.27 ± 0.19 0.8364
B=baseline, I=intervention, S=switchback period. Values
expressed as mean ± S.D.
TABLE 15. Serum lipid and lipoprotein levels in Group 4 women with and
without the apoB His1896SArg DNA change during dietary intervention.
His/His His/Arg P
(n=43) (n=10)
Tot-chol (mmol/l)
B 5.89 ± 1.12 5.78 ± 0.45 0.7527
I 4.88 ± 1.03 4.61 ± 0.84 0.4512
S 5.79 ± 1.20 5.65 ± 0.84 0.6945
LDL-chol (mmol/l)
B 4.20 ± 1.05 4.04 ± 0.43 0.6195
I 3.41 ± 0.91 3.12 ± 0.74 0.3455
S 4.04 ± 1.05 3.90 ± 0.78 0.9398
Tot-tg (mmol/l)
B 0.94 ± 0.27 0.90 ± 0.30 0.7308
I 0.98 ± 0.38 0.91 ± 0.38 0.5829
S 0.99 ± 0.44 0.98 ± 0.45 0.9398
HDL-chol (mmol/l)
B 1.50 ± 0.34 1.56 ± 0.17 0.5965
I 1.27 ± 0.32 1.31 ± 0.13 0.6864
S 1.55 ± 0.32 1.55 ± 0.14 0.9710
ApoB (mg/ml)
B 1.11 ± 0.30 1.11 ± 0.27 0.8132
I 0.95 ± 0.26 0.94 ± 0.38 0.9686
S 1.12 ± 0.29 1.07 ± 0.22 0.6056
B=baseline, I=intervention, S=switchback period. Values
expressed as mean ± S.D.
TABLE 16. Serum lipid levels in Group 7 men with angiographically detected CAD or with normal coronary arteries, and
in healthy control men (Group 8) with or without the apoB His1896SArg change.
CAD Non-CAD Controls
His/His His/Arg P His/His His/Arg P His/His His/Arg P
(n=151) (n=11) (n=48) (n=7) (n=40) (n=5)
Tot-chol 5.73 5.46 0.4385 5.00 5.71 0.0610 5.88 6.21 0.4258
(mmol/l) (±1.13) (±0.88) (±0.91) (±0.98) (±0.93) (±0.27)
LDL-chol 3.73 3.43 0.3600 2.94 3.72 0.0400 4.04 4.41 0.3522
mmol/l) (±1.01) (±0.92) (±0.89) (±1.10) (±0.87) (±0.41)
Tot-tg 1.85 2.18 0.2622 1.62 1.40 0.5471 1.12 1.21 0.6405
(mmol/l) (±0.90) (±1.21) (±0.97) (±0.56) (±0.36) (±0.37)
HDL-chol 1.13 1.17 0.6876 1.32 1.36 0.7583 1.54 1.58 0.8328
(mmol/l) (±0.28) (±0.31) (±0.37) (±0.52) (±0.40) (±0.42)
ApoB 1.01 0.99 0.7117 0.88 0.96 0.3420 0.97 1.01 0.6294
(mg/100ml) (±0.19) (±0.31) (±0.20) (±0.24) (±0.20) (±0.12)
Values expressed as mean ± S.D.
TABLE 17. Serum lipid levels in Group 7 women with angiographically detected CAD or with normal coronary arteries,
and in healthy control women (Group 8) with or without the apoB His1896SArg change.
CAD Non-CAD Controls
His/His His/Arg P His/His His/Arg P His/His His/Arg P
(n=40) (n=3) (n=58) (n=7) (n=23) (n=4)
Tot-chol 6.03 5.49 0.4927 5.15 5.36 0.6157 5.85 5.70 0.8318
(mmol/l) (±1.32) (±0.58) (±1.07) (±0.80) (±1.20) (±1.35)
LDL-chol 3.94 3.42 0.5010 3.06 3.13 0.8390 3.93 3.85 0.8911
(mmol/l) (±1.29) (±0.59) (±0.96) (±0.78) (±1.15) (±1.04)
Tot-tg 1.95 1.78 0.7450 1.33 1.48 0.4961 1.16 1.02 0.4547
(mmol/l) (±0.91) (±0.75) (±0.53) (±0.77) (±0.34) (±0.30)
HDL-chol 1.20 1.26 0.7519 1.47 1.55 0.6457 1.68 1.70 0.8862
(mmol/l) (±0.31) (±0.31) (±0.44) (±0.28) (±0.30) (±0.46)
ApoB 1.10 0.95 0.5094 0.85 0.84 0.8006 0.93 0.84 0.4896
(mg/ml) (±0.38) (±0.10) (±0.18) (±0.19) (±0.22) (±0.23)
Values expressed as mean ± S.D.
TABLE 18. Serum lipid and lipoprotein levels in Group 4 subjects with and without the apoB Arg4243SThr or
Ala4454SThr DNA changes during dietary intervention.
4243 Arg/Arg 4243 Arg/Thr P 4454 Ala/Ala 4454 Ala/Thr P
(n=95) (n=7) (n=98) (n=4)
Tot-chol (mmol/l)
B 6.16 ± 1.12 6.72 ± 1.58 0.2411 6.20 ± 1.15 5.97 ± 1.31 0.6941
I 5.00 ± 0.92 5.26 ± 1.13 0.5010 5.01 ± 0.93 4.98 ± 0.97 0.9435
S 6.02 ± 1.09 6.03 ± 1.14 0.9815 6.02 ± 1.09 6.03 ± 1.02 0.9799
LDL-chol (mmol/l)
B 4.47 ± 1.05 5.09 ± 1.46 0.1771 4.52 ± 1.07 4.30 ± 1.50 0.6918
I 3.55 ± 0.85 3.88 ± 1.05 0.3661 3.57 ± 0.86 3.55 ± 1.03 0.9605
S 4.31 ± 1.02 4.36 ± 1.08 0.8860 4.31 ± 1.02 4.26 ± 1.19 0.9278
Tot-tg (mmol/l)*
B 1.15 ± 0.77 1.42 ± 1.22 0.5858 1.18 ± 0.80 0.77 ± 0.34 0.1891
I 1.08 ± 0.51 1.34 ± 0.72 0.2826 1.11 ± 0.52 0.72 ± 0.34 0.1030
S 1.11 ± 0.60 1.32 ± 1.09 0.6366 1.14 ± 0.65 0.80 ± 0.37 0.2631
HDL-chol (mmol/l)
B 1.45 ± 0.33 1.35 ± 0.41 0.4629 1.44 ± 0.33 1.52 ± 0.30 0.6714
I 1.23 ± 0.28 1.11 ± 0.26 0.3251 1.22 ± 0.28 1.29 ± 0.15 0.6374
S 1.49 ± 0.31 1.40 ± 0.34 0.4643 1.48 ± 0.31 1.60 ± 0.34 0.4136
ApoB (mg/ml)
B 1.16 ± 0.29 1.25 ± 0.26 0.4490 1.17 ± 0.28 1.07 ± 0.46 0.5069
I 1.01 ± 0.28 1.08 ± 0.32 0.5436 1.02 ± 0.28 0.95 ± 0.28 0.6022
S 1.19 ± 0.28 1.20 ± 0.28 0.9391 1.20 ± 0.28 1.16 ± 0.34 0.8186
B=baseline, I=intervention, S=switchback period. Values expressed as mean ± S.D.
* Statistical calculations were made using log-normalized values.
TABLE 19. Serum lipid and lipoprotein levels in Kuopio district
hyperlipidemics (Group 1), the random sample of healthy subjects (Group 5),
and drug intervention participants (Group 6, baseline levels) with and
without the apoB Arg4243SThr or Ala4454SThr changes.
Geno- Kuopio Random sample Drug inter-
type (n) (n) vention (n)
Tot- Arg/Arg 8.32±1.07 (81) 5.10±0.90 (83) 9.0±1.7 (192)
chol Arg/Thr 7.82±0.56 (3) 5.43±1.00 (5) 9.4±1.9 (19)
P=0.4293 P=0.4374 P=0.2938
Ala/Ala 8.27±1.07 (83) 5.09±0.90 (85) 9.0±1.7 (211)
Ala/Thr 8.78±0.43 (4) 5.94±0.56 (3) 9.1±1.9 (9)
P=0.3467 P=0.1104 P=0.7774
LDL- Arg/Arg 5.82±0.94 (81) 2.84±0.88 (83) 6.8±1.7 (192)
chol Arg/Thr 5.48±0.88 (3) 3.16±1.03 (5) 7.2±2.1 (19)
P=0.5349 P=0.4382 P=0.2979
Ala/Ala 5.79±0.94 (83) 2.82±0.87 (85) 6.8±1.8 (211)
Ala/Thr 6.27±0.31 (4) 3.99±0.66 (3) 7.0±2.0 (9)
P=0.3184 P=0.0227 P=0.7140
Tot- Arg/Arg 2.40±1.72 (81) 1.02±0.64 (83) 2.08±1.09 (192)
tg* Arg/Thr 2.62±0.83 (3) 1.67±1.03 (5) 1.93±0.79 (19)
P=0.5765 P=0.2062 e P=0.5676
Ala/Ala 2.42±1.70 (83) 1.05±0.68 (85) 2.07±1.06 (211)
Ala/Thr 1.70±1.05 (4) 1.35±0.60 (3) 1.79±0.65 (9)
P=0.3459 P=0.3478 P=0.4127
HDL- Arg/Arg 1.41±0.48 (81) 1.78±0.50 (83) 1.26±0.30 (192)
chol Arg/Thr 1.17±0.26 (3) 1.52±0.37 (5) 1.31±0.39 (19)
P=0.3817 P=0.2400 P=0.4904
Ala/Ala 1.39±0.46 (83) 1.78±0.49 (85) 1.27±0.31 (211)
Ala/Thr 1.74±0.62 (4) 1.34±0.38 (3) 1.33±0.52 (9)
P=0.1444 P=0.1261 P=0.5509
ApoB Arg/Arg 1.56±0.34 (81) 1.03±0.23 (83) 1.74±0.37 (192)
Arg/Thr 1.53±0.20 (3) 1.34±0.65 (5) 1.78±0.44 (19)
P=0.9084 P=0.3499 e P=0.6824
Ala/Ala 1.55±0.33 (83) 1.04±0.27 (85) 1.74±0.39 (211)
Ala/Thr 1.66±0.39 (4) 1.24±0.04 (3) 1.70±0.39 (9)
P=0.5063 P=0.2291 P=0.7690
Values expressed as mean ± S.D. Tot-chol, LDL-Chol, Tot-tg, and HDL-chol,
mmol/l; and apoB, mg/ml.
* Statistical calculations were made using log-normalized values.
e Welch and Brown-Forsythe statistics.
TABLE 20. Effects of the apoB Val703SIle polymorphism on serum lipid and lipoprotein concentrations in the
hypercholesterolemic Kuopio district patients (Group 1), random sample of healthy subjects (Group 5), and diet study
participants (Group 4, baseline levels).
Hypercholesterolemic Normolipidemic groups
Genotype Kuopio n Random healthy n Diet study n
Tot-chol Val/Val 8.27 ± 1.08 69 5.14 ± 0.95 75 6.23 ± 1.12 64
(mmol/l) Val/Ile 8.73 ± 1.14 6 4.92 ± 0.64 8 5.52 ± 1.04 5
P=0.3249 P=0.5332 P=0.1771
LDL-chol Val/Val 5.76 ± 0.91 69 2.86 ± 0.92 75 4.53 ± 1.07 64
(mmol/l) Val/Ile 6.46 ± 0.97 6 2.79 ± 0.45 8 3.94 ± 1.05 5
P=0.0768 P=0.7075 e 0.2324
Tot-tg* Val/Val 2.32 ± 1.76 69 1.09 ± 0.70 75 1.18 ± 0.87 64
(mmol/l) Val/Ile 2.36 ± 0.59 6 0.75 ± 0.19 8 0.91 ± 0.42 5
P=0.5687 P=0.0140 e P=0.4106
HDL-chol Val/Val 1.46 ± 0.50 69 1.76 ± 0.49 75 1.46 ± 0.32 64
(mmol/l) Val/Ile 1.20 ± 0.17 6 1.79 ± 0.32 8 1.40 ± 0.25 5
P=0.2146 P=0.8810 P=0.6959
ApoB Val/Val 1.51 ± 0.33 69 1.06 ± 0.28 75 1.19 ± 0.28 64
(mg/ml) Val/Ile 1.73 ± 0.27 6 0.94 ± 0.26 8 1.01 ± 0.30 5
p=0.1444 p=0.2669 p=0.1550
Values expressed as mean ± SD.
* Statistical calculations were made using log-normalized values.
e Welch and Brown-Forsythe statistics.
TABLE 21. Effects of the apoB ins/del, Thr71SIle, and Ala591SVal polymorphisms on lipid and lipoprotein levels in
severely hypertriglyceridemic subjects (Group 3).
Ins/Ins Ins/Del Del/Del Thr/Thr Thr/Ile Ile/Ile Val/Val Val/Ala Ala/Ala
(n=40) (n=29) (n=5) (n=39) (n=32) (n=5) (n=22) (n=37) (n=17)
Tot-chol 7.41 7.72 7.57 7.43 7.54 8.03 7.17 7.57 7.86
(mmol/l) (±1.92) (±2.79) (±1.78) (±1.94) (±2.70) (±1.52) (±1.40) (±2.20) (±3.17)
P=0.8511 P=0.8553 P=0.6330
LDL-chol 3.02 3.19 2.98 2.99 3.24 2.53 2.84 3.11 3.26
mmol/l (±1.32) (±1.26) (±1.05) (±1.32) (±1.22) (±0.92) (±1.31) (±1.29) (±1.14)
P=0.8448 P=0.4423 P=0.5609
Tot-tg 8.34 7.59 8.28 8.47 7.15 9.92 8.06 8.23 7.47
(mmol/l)* (±7.36) (±6.20) (±7.13) (±7.41) (±6.03) (±6.28) (±6.49) (±7.22) (±6.39)
P=0.9552 P=0.4792 P=0.9369
HDL-chol 0.97 0.92 1.05 0.97 0.90 1.05 0.98 0.90 1.01
(mmol/l) (±0.36) (±0.25) (±0.21) (±0.36) (±0.24) (±0.21) (±0.44) (±0.25) (±0.19)
P=0.6050 P=0.4535 P=0.3576
ApoB 1.37 1.47 1.71 1.37 1.47 1.73 1.20 1.54 1.51
(mg/ml) (±0.56) (±0.46) (±0.33) (±0.57) (±0.44) (±0.30) (±0.44) (±0.57) (±0.33)
P=0.3399 P=0.2911 P=0.0372
Values expressed as mean ± S.D.
* Statistical calculations were made using log-normalized values.
TABLE 22. Effects of the apoB Thr71SIle and Ala591SVal polymorphisms, alone or combined, on baseline lipid and
lipoprotein levels in the diet study participants (Group 4).
Thr/Thr Thr/Ile Ile/Ile Val/Val Val/Ala Ala/Ala Val/Val Ala+/Ile+
(n=57) (n=45) (n=5) (n=32) (n=54) (n=21) Thr/Thr
(n=27) (n=45)
Tot-chol 6.29 6.04 6.60 6.11 6.18 6.38 6.16 6.12
(mmol/l) (±1.05) (±1.24) (±1.44) (±1.00) (±1.19) (±1.28) (±1.03) (±1.30)
P=0.4083 P=0.6942 P=0.9076
LDL-chol 4.59 4.40 4.77 4.46 4.49 4.68 4.50 4.46
(mmol/l) (±1.10) (±1.09) (±0.96) (±1.02) (±1.14) (±1.08) (±1.05) (±1.10)
P=0.5830 P=0.7445 P=0.8595
Tot-tg 1.35 0.98 0.79 1.17 1.18 1.12 1.25 0.99
(mmol/l)* (±0.98) (±0.42) (±0.24) (±0.74) (±0.90) (±0.59) (±0.77) (±0.42)
P=0.0209 e P=0.9856 P=0.0771
HDL-chol 1.43 1.45 1.67 1.42 1.46 1.48 1.41 1.47
(mmol/l) (±0.32) (±0.31) (±0.54) (±0.25) (±0.34) (±0.40) (±0.26) (±0.35)
P=0.2737 P=0.7751 P=0.4122
ApoB 1.22 1.09 1.20 1.15 1.17 1.18 1.17 1.12
(mg/ml) (±0.29) (±0.27) (±0.26) (±0.27) (±0.31) (±0.25) (±0.26) (±0.27)
P=0.0759 P=0.8856 P=0.3853
Values expressed as mean ± S.D.
* Statistical calculations were made using log-normalized values.
e Welch and Brown-Forsythe statistics.
TABLE 23. Effects of the apoB Thr71SIle and Ala591SVal polymorphisms, alone or combined, on lipid and lipoprotein
levels in subjects undergoing coronary angiography (Group 7).
Thr/Thr Thr/Ile Ile/Ile Val/Val Val/Ala Ala/Ala Val/Val Ala+/Ile+
(n=73) (n=73) (n=14) (n=38) (n=74) (n=41) Thr/Thr
(n=33) (n=76)
Tot-chol 5.22 5.38 5.63 5.24 5.31 5.41 5.16 5.36
(mmol/l) (±1.09) (±0.91) (±1.11) (±0.92) (±1.05) (±1.05) (±0.91) (±0.96)
P=0.3134 P=0.7477 P=0.2910
LDL-chol 3.18 3.32 3.60 3.20 3.28 3.34 3.12 3.31
(mmol/l) (±0.99) (±0.88) (±0.98) (±0.90) (±0.97) (±0.95) (±0.83) (±0.88)
P=0.2846 P=0.8107 P=0.2963
Tot-tg 1.87 1.60 1.79 1.95 1.63 1.74 2.04 1.67
(mmol/l)* (±1.14) (±0.84) (±0.82) (±1.19) (±0.93) (±0.89) (±1.25) (±0.88)
P=0.2910 P=0.2583 P=0.0957
HDL-chol 1.21 1.32 1.22 1.21 1.29 1.29 1.16 1.30
(mmol/l) (±0.37) (±0.41) (±0.24) (±0.35) (±0.38) (±0.42) (±0.30) (±0.39)
P=0.1851 P=0.5500 P=0.0814
ApoB 0.94 0.94 0.99 0.94 0.93 0.97 0.95 0.95
(mg/ml) (±0.20) (±0.22) (±0.32) (±0.20) (±0.19) (±0.30) (±0.20) (±0.25)
P=0.6873 P=0.6714 P=0.9549
Values expressed as mean ± S.D.
* Statistical calculations were made using log-normalized values.
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Figure 1. Schematic illustration of lipoprotein metabolism: endogenous and exogenous pathways:
See chapter 2.1.3. for details.
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Figure 2. Schematic representation of the apoB gene and localization of its regulatory motifs.
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Figure 3. (a) Schematic illustration of the ribbon-and-bow model for the organization of apoB on
lipoprotein particles. (b) Schematic diagram of the five-domain structure of apoB. a 1, amphipathic
helix cluster 1, ß1 and ß2, amphipathic ß-sheet clusters 1 and 2 (irreversible lipid binding domains),
a 2 and a 3, amphipathic helix clusters 2 and 3  (reversible lipid binding domains).
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Figure 4. Effects of the apoB Val591     Ala polymorphism alone, and the apoB Thr71    Ile
and Val591     Ala polymorphisms combined on serum apoB levels in severely hypertriglyceridemic
Group 3 patients.
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